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Chapter 1
Parkinson’s disease (PD) is one of the major neurodegenerative disorders of middle and old 
age (Pickel et al. 1992; Zhang, Roman, 1993). At presence the incidence of the disease is 0.15 
%. However, due to the increasing life expectancy, the number of people suffering from this 
disease is enlarging. The disorder is characterized by the preferential degeneration of 
dopaminergic neurons in the substantia nigra, pars compacta (SNc; Lewis, 1971), although 
also other midbrain dopamine neurons are lost (Braak et al., 1995). Patients primarily suffer 
from a triad of motor symptoms, namely tremor, rigidity and hypokinesia. In addition, autonomic 
nervous system dysfunctions including hypotension, seborrhea, mood disturbances and cognitive 
disturbances (Cools et al., 1984) may occur. Almost 30 years after its clinical introduction, 
levodopa (L-DOPA) remains the standard of care for the treatment of PD (Cotzias et al., 
1969), but has important disadvantages.
The aim of the present study was to increase the insight into the therapeutic potential of 
some new pharmaco-therapies for the treatment of PD, using thereby animal models of the 
disease.
The present introduction deals with the following issues:
1) The normal function of the central dopamine transmitter system and the consequences of its 
dysfunction at the level of the midbrain. This includes: a) the dopamine receptor subtypes and 
signal transduction systems involved in the transmission of the dopaminergic signal, and b) the 
brain areas that are functionally linked to the midbrain dopamine neurons and that are critically 
involved in the regulation of motor behavior.
2) The pathological processes hypothesized to underlie the degeneration of dopamine neurons 
in PD.
3) The currently available treatment strategies for PD and their disadvantages.
4) The treatment strategies currently under investigation, with special emphasis on the treatments 
examined in the present study.
5) The animal models used to study these new treatments.
6) The aim and outline of the present study.
1. The dopaminergic transmitter system
1.1 Dopamine receptors
Only a decade ago the effects of dopamine were attributed to activation of two receptor 
subtypes, namely dopamine D1 and D2 receptors (Garau et al., 1978; Kebabian, Calne, 1979). 
However, in the early nineties, DNA cloning techniques led to novel, previously uncharacterized 
dopamine D3 (Sokoloff et al., 1990), D4 (Van Tol et al., 1991) and D5 (Tiberi et al., 1991; 
Sunahara et al., 1991) receptors. These receptors were not previously detected by 
pharmacological investigations and, today, the relevance of such diversity is subject of 
speculation. However, due to the similarities in structure, gene organization, signaling systems 
and pharmacology between the dopamine D1 and D5 subtypes and between the dopamine D2, 
D3, and D4 subtypes the dopamine receptors are still classified as D1-like and D2-like receptor 
subfamilies.
1.1a Dopamine D1-like receptor subfamily
The dopamine D1 and D5 receptor both consist of seven very similar membrane-spanning 
domains (Seeman, Van Tol, 1994; Lachowicz, Sibley, 1997). These domains are thought to
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play an important role in the pharmacological binding profiles of the receptors and indeed the 
dopamine D1 and D5 receptor display a very similar profile (Gingrich, Caron, 1993). Gene 
transcripts of the dopamine D1 receptor are abundant in the brain; the highest densities of 
dopamine D1 receptors are found in the projection areas of the SNc and the ventral tegmental 
area (VTA), namely in the caudate putamen (CP), the nucleus accumbens (ACC) and the olfactory 
tubercle (OT), but significant amounts are also present in the neocortex, the pallidum and the 
amygdala (Boyson et al., 1986; Richfield et al., 1989; Mansour et al., 1990). Dopamine D5 
receptors are less abundantly present in the brain; however, relatively high densities are found 
in the hippocampus, the hypothalamus and the parafascicular nucleus of the thalamus (Tiberi 
et al. 1991; Meador-Woodruff et al. 1992; Bergson et al. 1995).
1.1b Dopamine D2-like receptor subfamily
The dopamine D2, D3 and D4 receptor have somewhat more variety in the organization of 
their trans-membrane domains, which may contribute to considerable differences in binding 
characteristics of dopamine D2 receptor subtypes (Gingrich, Caron, 1993).
A short and a long isoform of the dopamine D2 receptor, produced by alternative splicing 
of the same gene, exists (Dal Toso et al., 1989; Giros et al., 1989). Like the dopamine D1 
receptor, the dopamine D2 receptor is abundantly present and shows some similarities in 
distribution. High densities are present in the CP, the ACC, the OT and the SNc, while 
intermediate densities are found in the central nucleus of the amygdala, the lateral septum, the 
entorhinal cortex, the superior colliculus and the hippocampus (Boyson et al., 1986; Richfield 
et al., 1989; Mansour et al., 1990). The D3 receptor is predominantly found in the OT and the 
shell of the ACC (Sokoloff et al., 1990). The density of dopamine D4 receptors is very low; 
however, moderate levels are present in the frontal cortex, the amygdala and, to a lesser extent, 
the striatum (Defagot, Antonelli, 1997).
1.2 Signal transduction mechanisms of dopamine
Figure 1 gives a schematic representation of the signal transduction processes of the dopamine 
transmitter system. After the binding of dopamine to postsynaptic receptors, the coupling with 
G proteins leads to the transmission of the extra-cellular signal to intra-cellular sites. This intra­
cellular site may be either a second messenger or an ion channel.
The majority of dopamine D1 receptors is coupled the adenylate cyclase (AC) second 
messenger system. Activation of the dopamine D1 receptor induces stimulation of the Gs protein 
that then stimulates AC to convert adenosine tri-phosphate (ATP) into cyclic adenosine mono­
phosphate (cAMP), in the presence of Mg2+ ions (Stoof, Kebabian, 1981; Zhou et al., 1990). 
The resulting increase in cAMP stimulates protein kinase A (PKA), which in turn stimulates 
the phosphorylation of a large variety of proteins, including Na+ channels, Ca2+ channels, various 
receptors, Na/K ATP-ase, B adrenoceptors and tyrosine hydroxylase (Walsh, Van Patten, 1994). 
Thus, the AC-coupled dopamine D1 receptor is intimately involved in ion fluxes, neurotransmitter 
release and gene transcription.
However, also other second messenger systems have been identified; among others, evidence 
is increasing that dopamine D1 receptors can activate the phosphoinositide second messenger 
system (Undie et al., 1994; Wang et al., 1995). Stimulation of these receptors activates a G 
protein coupled to phospholipase C (PLC) that in turn hydrolyses the membrane-associated 
phosphatidylinositol 4,5-bisphosphate (PIP2). PIP2 is converted into two second messengers, 
namely diacyl glycerol (DAG) and inositol triphosphate (IP3). DAG remains in the membrane 
and stimulates protein kinase C (PKC), while IP3 diffuses into the cytoplasm where it releases
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Ca2+ from the endoplasmatic reticulum, and activates Ca2+ dependent functions including the 
stimulation of PKC (Worley et al., 1987; Berridge, Irvine, 1989). Many neuronal proteins are 
substrate to PKC, including Na+ channels, Ca2+ channels K+ channels, GAP 43 and GABA-A, 
nicotinic and NMDA receptors.
Various second messenger systems participate in dopamine D2 receptor signal transduction, 
among which the AC transduction system. In the striatum, dopamine D2 receptor stimulation 
inhibits a Gi protein that inhibits AC to convert ATP into cAMP, and, thus, the coupling of 
dopamine D1 and dopamine D2 receptor to this transduction system is opposed (Stoof, Kebabian, 
1981). Moreover, dopamine D2 receptors affect the release of arachidonic acid from 
phospholipids (Piomelli et al., 1991; Tang et al., 1994) and influence ion channels; they 
increase the efflux of K+ that results in the hyperpolarization of neurons (Lacey et al., 1987; 
Freedman, Weight, 1988). In addition, the influx of Ca2+ is reduced by dopamine D2 receptor 
stimulation (Vallar, Meldolesi, 1989).
Bl-UKE D2-LIKE
1.3 Connections of the midbrain dopamine neurons with brain areas involved in motor control 
The fast majority of dopamine containing nerve cells is found in the midbrain. Several 
different forebrain projections from the midbrain dopaminergic cell groups are distinguished, 
including the mesostriatal, mesocortical and mesolimbic projections (Tulloch et al., 1978; 
Loughlin, Fallon, 1984). The nigrostriatal projection comprises the dorsal component of the 
mesostriatal system, which originates primarily from the dopamine cells of the SNc and, to a 
lesser extent, from the dopamine cells of the retrorubral area and the VTA (Tulloch et al., 
1978; Beckstead et al., 1979). It ascends via the medial forebrain bundle and the internal 
capsule to innervate the CP and the globus pallidus (GP). Through this connection the SNc is 
functionally linked to a collection of brain areas, the basal ganglia. These areas are believed to 
have a predominant role in motor control. Moreover, studies in our institute have shown that 
the basal ganglia play a definite role in cognitive behavior (Cools et al., 1984). The degeneration
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of this projection leads to a deficiency in dopamine in the CP, viz. the primate analogue of the 
rodent dorsal striatum, and is critically involved in the pathology of PD. The type of motor and 
cognitive symptoms present in patients with Parkinson’s disease can be modeled by manipulating 
the dopamine function of the basal ganglia brain structures in rats, felines and non-human 
primates (Vrijmoed-de Vries, Cools, 1985; Jaspers et al., 1989; Ploeger, Spruijt, et al., 1992; 
van Oosten et al., 1998; Arts, Cools, 1999) which underlines the important role of these areas 
in the pathophysiology of PD. A simplified version of the conceptual framework of the anatomical 
and functional organization of the basal ganglia is given below (Alexander, Crutcher, 1990; 
Parent, Hazrati, 1995a; Parent, Hazrati, 1995b; Graybiel, 1995; Smith et al., 1998). The basal 
ganglia consist of five closely interlinked structures: the CP, the internal and external segment 
of the GP (GPi and GPe), the subthalamic nucleus (STN) and the substantia nigra, pars reticulata 
(SNr). Dopaminergic neurons from the SNc project onto GABA-ergic medium spiny neurons 
of the striatum. These neurons also receive massive glutamatergic input from the neocortex via 
the cortico-striatal pathway and from the cerebellum via the intralaminar nuclei of the thalamus. 
Within the basal ganglia, the information is processed via pathways from the medium spiny 
neurons of the striatum to the output structures of the basal ganglia, the SNr and the GPi. When 
movements are absent, the neurons in the SNr and GPi are tonically active, and their constant 
release of GABA produces a powerful inhibition of target cells in the ventral thalamic nuclei, 
superior colliculus and pendunculo pontine nucleus. The medium spiny neurons affect the activity 
of the SNr and GPi neurons through two pathways: a subclass of medium spiny neurons projects 
directly to the SNr and GPi whereas another subgroup projects to the output nuclei through an 
indirect route that includes the GPe and the STN. All medium spiny neurons form inhibitory 
synapses with the GPi and SNr that release GABA. Execution of movements involves an 
increased activity of the corticostriatal pathway exciting the medium spiny neurons, which 
leads to a rapid silencing of the inhibitory GPi and SNr neurons through the direct pathway. 
Consequently the thalamic, collicular and pontine neurons than exhibit a burst of activity. The 
glutamatergic stimulation of striatal neurons projecting to the indirect pathway tends to oppose 
this action: the striatum suppresses the activity of neurons in the GPe which releases the STN 
from inhibition and in turn excites the GPi and SNr. It has been proposed that the inhibitory 
effect of this subclass of striatal neurons serves a “smoothing” function on motor excitation.
The nigrostriatal dopamine projection exerts a net excitatory influence on striatal output 
neurons of the direct pathway, but a net inhibitory effect on the neurons giving rise to the 
indirect pathway. The excitatory effect is thought to be mediated by the stimulation of dopamine 
D1 receptors that are located primarily on the direct pathway neurons while the inhibitory 
effects are likely to be mediated through the stimulation of dopamine D2 receptors located 
mainly on the indirect pathway neurons. As a net result, the innervation of spiny neurons by 
nigral dopamine fibers releases the thalamic and brainstem nuclei from the tonic suppressing 
effects of the GPe and SNr. The increased activity of the latter nuclei increases their glutamatergic 
output to the various cortical areas involved in motor control. Thus, a loop exists between the 
cortex and the basal ganglia through the ventral thalamic nuclei, suggesting that the basal ganglia 
influence the output of the cortex to lower brainstem regions to execute movements. However, 
the direct projection of the SNr to brain stem areas, including the superior colliculus (Beckstead 
et al., 1979b) and the pedunculo-pontine nucleus (Spann, Grofova, 1991) shows that the basal 
ganglia exert direct effects on motor control as well (Jaspers et al., 1989).
1. Conclusions
Despite the characterization of five dopamine receptor subtypes, dopamine receptors are
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still classified according to their signaling system and pharmacology into D1-like receptors 
and D2-like receptors. Moreover, the majority of the dopamine receptors in the CP complex 
that has lost its dopaminergic input in the parkinsonian brain, belong to either the dopamine D1 
or the dopamine D2 subtype. The most important transduction system is the AC second messenger 
system, which is stimulated by dopamine D1 receptor stimulation through a Gs protein and 
inhibited by dopamine D2 receptor stimulation through a Gi protein. Dopamine plays a 
facilitating role in motor behavior at the level of the striatum. It modulates the regulatory role 
of cortical areas involved in motor behavior through the indirect and direct pathways in the 
basal ganglia and, in addition, exerts a direct regulatory role by directly innervating brain stem 
areas.
2. Etiology and pathogenesis of PD
At present, it is not clear what causes the degeneration of dopaminergic neurons to ultimately 
induce PD. The hereditary factor in PD is suggested to be small; most studies indicate a two­
fold increase in the risk of developing PD in first-degree relatives (Plante-Bordeneuve et al., 
1995; Gasser, 1998). Recently, mutations in single genes have been shown to be able to cause 
PD (Polymeropoulos et al., 1997; Parsian et al., 1998), however, these are likely to account 
only for a very small number of cases. Alternatively, there is some evidence that environmental 
factors play a role in the majority of cases of sporadic PD (Veldman et al., 1998; Checkoway, 
Nelson, 1999). Especially, the discovery of neurotoxins that are able to induce Parkinsonism 
supported this idea. Most likely genetic factors predispose patients to develop PD, if combined 
with environmental factors.
Whatever initiates PD, there are several mechanisms indicated to be involved in the 
progressive degeneration of the dopamine neurons in the midbrain. In recent years attention 
has been focused on several conceptually distinct mechanisms (oxidative stress, mitochondrial 
dysfunction, excitotoxicity, calcium imbalance, inflammatory changes), which may all interact 
and amplify each other. The factors currently supported by substantial evidence are discussed 
below.
The first factor, focused on by many researchers, is the process of damage caused by free 
radicals (Olanow, Arendash, 1994; Jenner, Olanow, 1996). Free radicals are molecules with an 
unpaired electron that are extremely reactive with other molecules and can therefore cause 
extensive damage through mechanisms of lipid peroxidation causing membrane disruption, 
oxidation of proteins and injury to nucleic acids. Usually, free radicals are maintained at a low 
level through the action of cellular anti-oxidants such as Vitamin E and C, and enzymes such as 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX). If the formation 
of free radicals is increased and/or their removal is decreased, the affected cells are considered 
to be under oxidative stress. In dopaminergic cells there are many sources of free radical 
formation. Dopamine itself is a source of free radicals: its deamination by mono-amine oxidase 
(MAO) leads to the formation of hydrogen peroxide (H2O2) from which hydroxyl radicals 
(OH) are easily formed. Dopamine can also undergo auto-oxidation that gives rise to free 
radicals as by-product. Several lines of evidence suggest that nigral dopaminergic neurons are 
under oxidative stress in PD. In these neurons lipid peroxidation reactions (Dexter et al., 
1994), reduced gluthatione concentrations (Sofic et al., 1992) and increased iron levels (Dexter 
et al., 1989; Jenner, 1993), which catalyze the formation of OH- from H2O2, are found.
A second factor that is likely to be involved in the degeneration of dopaminergic neurons, is 
impaired energy metabolism induced by a dysfunction of mitochondrial complex I (NADH
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CoQ1 reductase) and/or the reduction of the enzyme a keto gluterate dehydrogenase (Schapira 
et al., 1990; Mizuno et al., 1994). Intriguingly, recent studies suggest a key role for the so- 
called mitochondrial mega channel in the mechanism of cell death induced by minor damage to 
mitochondria. Mitochondrial dysfunction causes the leakage of electrons from the electron 
transport chain, which in turn triggers the opening of this channel. The final consequence of 
this is calcium influx, the activation of caspases and further damage to the mitochondria. The 
impairment in energy supply may lead to neuronal depolarization, activation of N-methyl-D- 
aspartate excitatory amino acid receptors, and increases in intra-cellular calcium (Beal, 1998). 
Moreover, a rise in extra-cellular calcium activates nitric oxide synthase (NOS). This generates 
nitric oxide (NO) that, in turn, promotes the formation of the hydroxyl radicals (Schulz et al., 
1995; Doble, 1999). The fact that mitochondrial dysfunction can elicit oxidative stress together 
with the fact that oxidative stress further damages the mitochondria, indicates that these two 
processes both play an important, interconnected role.
The final consequence of all these events is the death of nigral dopaminergic neurons. 
Although questioned earlier, evidence is now accumulating that this death involves an apoptotic 
process (Mochizuki et al., 1996; Anglade et al., 1997; Tompkins et al., 1997; Tatton et al.,
1998). Apoptotic cell death has been detected in the brain tissue of patients: in situ end labeling 
techniques and ultrastructural analyses have demonstrated nuclear condensation, chromatin 
fragmentation and formation of apoptotic-like bodies in parkinsonian brains. There are a large 
variety of enzymes, genes and receptors involved in the process of apoptosis (Michel et al.,
1999). Interestingly, evidence is increasing that both mitochondrial dysfunction (Zamzami et 
al., 1997) and oxidative stress can precipitate and participate in apoptosis.
2. Conclusions
The initial factors causing PD are unknown. However, both oxidative stress and a reduction 
in the energy supply are likely to be involved in the breakdown of dopamine cells in the midbrain. 
Today, this breakdown is thought to be apoptotic rather than necrotic.
3. Current medical treatments
Already since the early sixties, the precursor of dopamine, levodopa (L-DOPA), is most 
frequently applied in the treatment of PD (Cotzias et al., 1967). During the first three to five 
years, L-DOPA is very effective in reducing parkinsonian symptoms (Blunt et al., 1991). 
However, thereafter, various response complications develop in the fast majority of patients 
(Marsden, 1994). The therapeutic efficacy of L-DOPA is reduced by: a) a shortening in the 
duration of the therapeutic effect, known as the wearing off effect (Marsden, Parkes, 1976) and 
b) fluctuations in the drug response, known as on-off effects (Fabbrini et al. 1988; Roos et al. 
1990). In addition, various undesired side-effects develop. Among these, dyskinesia is the 
most disabling side-effect. It develops in 60 to 80 % of patients (Barbeau, 1969) and is 
characterized by chaotic, uncontrolled movements of mouth, cheeks, face and limbs (Miller, 
Chouinard, 1993).
Although disease progression may contribute to the development of response complications, 
several lines of evidence indicate that the adverse effects are related to dose and duration of the 
L-DOPA treatment (Marsden, Parkes, 1976; Lesser et al., 1979; Quinn et al., 1987; Miller, 
Chouinard, 1993). The clinical deficiencies of L-DOPA have spurred the development of 
alternative treatments for PD: dopamine D2 receptor agonists, the MAO-B inhibitor deprenyl 
and a variety of surgical treatments being the most important.
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Dopamine D2 receptor agonists were introduced in the early eighties and replenish dopamine 
function through stimulation of postsynaptic dopamine D2 receptors. Although dopamine D2 
receptor agonists have been reported to exert less undesired effects as compared to L-DOPA, 
the initial therapeutic effects are also less. Thus, D2 agonists are principally prescribed as 
adjunct therapy to L-DOPA treatment. Classical dopamine D2 agonists are bromocriptine (Parkes 
et al., 1976; Lieberman et al., 1984), lisuride (Lieberman et al., 1985; Baronti et al., 1992) 
and pergolide (Lieberman et al., 1985) whereas, more recently, ropinirole (Sethi et al., 1998) 
and cabergoline (Steiger et al., 1996) were approved for the treatment of PD.
Deprenyl was one of the first drugs that was suggested to increase not only the dopaminergic 
signal, but also to inhibit the progression of PD (Birkmayer et al., 1985). Deprenyl inhibits the 
breakdown of dopamine through its inhibitory effect on MAO-B (Squires, Lassen, 1975; Gerlach 
et al., 1996). This leads to an increased amount of dopamine in the synaptic cleft inducing 
symptomatic effects. In addition, it results in a reduced formation of free radicals, which may 
slow down the progression of the degenerative process (Gerlach et al., 1996). Evidence is now 
accumulating that deprenyl has anti-apoptotic actions that appear to be independent of the 
inhibition of MAO-B. In 1987 the deprenyl and tocopherol (vitamin E) anti-oxidative therapy 
of Parkinsonism (DATATOP) was initiated to examine the benefits of deprenyl in slowing the 
progression of PD (Parkinson Study Group, 1989). The initial results showed that deprenyl 
significantly delayed the onset of disability that would require L-DOPA (Parkinson Study Group, 
1993). However, the mortality rate of deprenyl-treated patients did not differ from that of L- 
DOPA-treated patients (Parkinson Study Group, 1998). It is still vigorously debated whether 
deprenyl exerts solely symptomatic or also protective effects. This issue may be confounded by 
the metabolism of deprenyl: its neuroprotective properties are believed to be due to its 
desmethylated metabolite, that is only detected in limited amounts in the brain after oral intake 
of deprenyl (Gerlach et al., 1992). In addition, other main metabolites such as amphetamine 
and methamphetamine have been found to antagonize the neuroprotective effects of deprenyl 
(Tatton et al., 1996). Today, deprenyl is used in early patients and as adjunct therapy.
New surgical techniques with low morbidity have emerged as a viable alternative for carefully 
selected patients. Pallidotomy may reduce contralateral dyskinesia and improve bradykinesia 
and rigidity (Ghika et al. 1998), and thalamotomy may improve tremor (Speelman et al.
1998). Deep brain stimulation of the GP or STN may substantially improve contralateral 
symptoms including tremor (Benabid et al. 1998; Brown et al. 1999). Fetal nigral implants, 
containing dopamine-producing cells, improve the symptoms of PD considerably (Date, Ohmoto,
1999). Despite its benefits, the application of surgery in treating PD is limited: procedures 
carry risk of injury, the costs are very high, and long-term effects are unknown.
3. Conclusions
Despite the introduction of dopamine D2 receptor agonists, deprenyl and surgical treatments, 
L- DOPA is still the most commonly used treatment for PD. L-DOPA has at least two serious 
limitations. Firstly, severe response complications develop in the long run and, secondly, the 
progression of the disease is not significantly inhibited. These limitations urge the development 
of new treatments.
4. New treatment strategies for PD
The current treatment of PD can be improved in two ways. The first approach is to focus on 
the response complications induced by the currently used therapies by developing symptomatic
10
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therapies that: a) temporarily replenish the lost dopamine function, but that, unlike L-DOPA, 
do not induce response complications, or, b) are able to suppress the response complications 
induced by L-DOPA and are given as adjunct therapy to L-DOPA.
The second approach is to focus on the progressive character of the disease. Neuroprotective 
therapies such as compounds that “revive” cells that had already been injured, and compounds 
that prevent healthy cells from dying, could be valuable tools in this respect.
Both approaches are important. The development of compounds according to the 
“symptomatic” approach is needed for the large group of patients that is in a later stage of the 
disease: the majority of these patients suffer from severe side-effects due to long term L-DOPA 
treatment. Given the fact that in these patients only a very small percentage (< 10 %) of dopamine 
neurons is left, this group will not greatly benefit from neuroprotective treatments. Naturally, 
the subgroup of patients that is in the early phase of the disease, would benefit greatly for 
therapies that are able to inhibit or, even, stop the progression of the disease.
In the present study we examined the effectiveness of three putative therapies for PD. In the 
first part, two symptomatic therapies were examined: in this part we studied the therapeutic and 
undesired effects of two compounds that may replenish the dopamine function through their 
interaction with the dopamine D1 receptor. In the second part, a neuroprotective therapy was 
studied: we examined the ability of a putative anti-apoptotic compound, the propargylamine 
CGP 3466B, to inhibit dopaminergic degeneration.
The next paragraph will describe the state of the art concerning the research on the putative 
anti-parkinsonian effects of compounds with affinity for the dopamine D1 receptor and puts 
forward the possible reasons for the unanimous results of these studies. Moreover, the state of 
the art concerning research on the protective effects of anti-apoptotic compounds is described. 
Finally, the animal models used to study such new treatment strategies are described and 
discussed.
4.1 Symptomatic treatments: dopamine D1 receptor manipulation
During the last 10 years the possible role of dopamine D1 receptor agonists in relieving the 
symptoms present in PD has been subject of intense study. Primarily, the primate model of the 
disease, the MPTP-treated monkey, is used to study the therapeutic effects and undesired effects 
of dopamine D1 receptor agonists (Cohen, Spina, 1989; DeNinno et al., 1991; Gnanalingham 
et al., 1995a; Shiosaki et al., 1996; Pearce et al., 1999). However, the results of these studies 
are unanimous; it is still not clear whether these compounds can improve the treatment of 
patients with PD. Table 1 gives an overview of the therapeutic and undesired effects of three 
dopamine D1 receptor agonists. As illustrated by this Table, at least three factors may contribute 
to the unanimous results. Firstly, it remains to be established whether the current behavioral 
analyses used to predict the clinical effectiveness of symptomatic therapies are adequate; many 
of these analyses do not offer a clear distinction between drug-induced therapeutic- and drug- 
induced undesired effects. Furthermore, in some studies, the undesired effects of these therapies 
are completely neglected. Secondly, a large variety of animal models is used. Thirdly, there is 
much variation in the treatment regimen of the compound under study: while early studies only 
evaluated the acute effects of putative anti-parkinsonian drugs, more recently, the importance 
of studying their chronic effects has been acknowledged. Moreover, the pre-treatment history 
of the animals varies.
In sum, the conflicting results concerning the clinical efficacy of D1 receptor agonist may 
be largely due to the behavioral analyses, animal models and treatment regimens applied for 
evaluating the therapeutic and undesired effects of dopamine D1 receptor agonists.
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Table I
Dopamine 
D l agonist
Primate model D uraiionof
treatment
Pretreatment
history
Behavioral
analysis
Thera
peutic
effects
Urtdesired
effects
SKF 81297 
(Domino, 
Sheng, 1993)
Macaca nemistra 
unilateral, intracarotid 
administration, 0.6 
mg/kg
Iday L-DOPA and 
various dopamine 
agonists
Rotational
behavior
No Not
reported
SKF 81297 
(Vermeulen 
etaJ. 1993)
Macacca mulatta 
unilateral, intracarotid 
administration, 2.5 
mg
1 day L-DOPA and 
various dopamine 
agonists
Limb
movements
Rotational
behavior
Yes Not
reported
SKF 82958 
(Gnanalingham
etal. 1995b)
Callitrhix jacchus 
5 -7 * 2  mg/kg, sc.
1 day Various dopamine 
D2 and dopamine 
Dl agonists
Rating
scale,
Locomotor
activity
No Dyskinesia 
not reported 
oral activity
SKF 82958 
(Goulet etal. 
1996)
Macaca Fascicularis 
2 mg/day s.c. Until 
stable parkinsonism 
was reached
29days Naive Locomotor
activity
Yes Dyskinesia
SKF 82958 
(Domino, 
Sheng, 1993)
Macaca nemistra 
unilateral, intracarotid 
administration, 0.6 
mg/kg
1 day L-DOPA and 
various dopamine 
agonists
Rotational
behavior
Yes Not
reported
SKF 82958 
(Blanchet et 
al. 1993)
Macaca Fascicularis 
2mg/days.c. Until 
stable parkinsonism 
was readied
1 day L-DOPA, various 
dopamine D2 and 
dopamine Dl 
agonists
Rating
scale.
Locomotor
activity
Yes Very mild 
dyskinesia
A 77636 
(Pearce et al. 
1999b)
Callilrhix jacchus 
5*2mg/kgs.c.
lOdays L-DOPA and a 
dopamine Dl 
agonist
Rating scales: 
therapeutic and 
undesired effects 
Locomotor 
activity
Yes Yes
A 77636 
(Kebabian et 
al. 1992)
Callitrhix jacchus, 5 * 
10/mg/kg MPTP s.c.
1 day Yes? Rating
scalc,
Locomotor
activity
Yes Not
reported but 
epileptoid 
insults in 
rats
mentioned
A 77636 
(Blanche! et 
al. 1993)
Macaca Fascicularis 
2 mg /day s.c. until 
stable parkinsonism 
was readied
1 day L-DOPA, Various 
dopamine D2 and 
dopamine Dl 
agonists
Rating
scale,
Locomotor
activity
Yes 0.5 mg no 
dyskinesia 
1.0 very 
mild
dyskinesia
Interestingly, not only full dopamine D1 receptor agonists, but also some compounds that 
act as a partial agonist or, even, antagonist to dopamine D1 receptors coupled to the AC 
transduction system are suggested to exert therapeutic effects in animal models of PD (Deveney, 
Waddington, 1995; Gnanalingham et al., 1995b). The apparent lack of correlation between 
the effects of compounds with affinity for the dopamine D1 receptor on motor behavior in 
primate models of PD and their ability to stimulate AC in rats is illustrated by Table 2. The 
most remarkable drug in this respect is benzazepine SKF 83959; this compound potently inhibits 
rat AC-coupled dopamine D1 receptors (Arnt et al., 1992), but has been reported to exert 
therapeutic effects in a primate model of PD after acute administration (Gnanalingham et al., 
1995b). Not only is it completely unclear which mechanism of action underlies these therapeutic 
effects of SKF 83959 in models of PD, also the in vitro effects of this drug on primate dopamine 
D1 receptor are unknown. Moreover, it also remains to be established to what extent this 
compounds induces therapeutic and undesired effects after long term treatment.
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Table 2
Dopamine D I agonist Therapeutic efficacy 
(monkey)
Intrinsic Activity 
(rat)
SKF 38393 +/_
SKF 82958 +L +
SKF 83959 + + __
SKF 80723 +/_ +
A 77636 + + ++
CY 208-243 + +/_
References:(Amt etal. 1988;0'Boyle et al. 1989; Kebabian etal. 1992; O'Boyle,
1992;Nomoto etal. 1988; Temlett etal. 1988; Gnanalingham etal. 1995c).
4.2 Neuroprotective treatments: propargylamines
The increased knowledge concerning the large variety of biochemical processes underlying 
dopaminergic cell death together with the finding that this death is likely to be programmed and 
thus requires multiple steps, had led to a large number of potential targets for the neuroprotective 
therapy in PD. Compounds such as free radical scavengers, glutathione-enhancing agents, iron 
chelators, NOS inhibitors, glutamate antagonists, calcium antagonists and anti-apoptotic 
compounds are now examined for their protective effects, primarily in in vitro and in rodent 
models of PD (Kanthasamy et al. 1997; Olanow, 1997; Ciccone, 1998; Koller, 1998; Marsden, 
Olanow, 1998; Michel et al., 1999). A large body of evidence supports the anti-apoptotic 
action of especially one subclass of compounds: the propargylamines (Yu et al. 1992). Some 
of these propargylamines have been found to rescue dopamine nigrostriatal neurons after either 
trophic withdrawal (Roy, Bedard, 1993), MPP+ treatment (Koutsilieri et al., 1996) or DSP-4 
treatment (Zhang et al., 1996) and to reduce neuronal death in a variety of insults, including 
axotomy (Salo, Tatton, 1992; Oh et al., 1994), ischemia (Barber et al., 1993; Zhang et al., 
1996) and aging (Amenta et al., 1994). These data suggest that, although the majority of 
propargylamines has MAO-B inhibiting properties, these compounds exert many other actions 
as well, which may be largely responsible for their neuroprotective effects (Tatton, Greenwood, 
1991; Iwasaki et al., 1996; Koutsilieri et al., 1996; Gelowitz, Paterson, 1999). This is further 
underlined by the fact that the propargylamine CGP 3466B does not inhibit MAO-B, but is 
very effective in protecting cells from neuronal apoptosis in vitro (Kragten et al., 1998). In 
vivo studies on this propargylamine are limited, but promising: it increases not only the life 
span of mice mutant with motoneuron degeneration (Kato et al., 1996), but also the survival of 
CA1 pyramidal neurons in an animal model of ischemia (Paterson et. al., 1998c). Moreover, 
both deprenyl and CGP 3466B inhibit apoptosis induced by glyceraldehyde-3-phosphate over­
expression (Kragten et al., 1998). Apart from this, some propargylamines have been shown to 
alter the expression of a number of mRNAs and proteins (Li et al., 1992), among which the 
onco-proteins BCL2 and BAX (Tatton et al. 1996) and the scavengers SOD 1 and 2 (Carrillo 
et al., 1992).
The limited clinical effect of deprenyl is possibly confounded by its metabolism: its 
neuroprotective properties are believed to be due to its desmethylated metabolite (Mytilineou
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et al., 1997), which is only present in low concentration in the brain after the oral administration 
of deprenyl. Moreover, its other metabolites, amphetamine and methamphetamine, were found 
to antagonize the neuroprotective effects. Some propargylamines including CGP 3466B are 
not metabolized into amphetamine and methamphetamine and easily cross the blood brain 
barrier. Such compounds may offer a better tool for neuroprotection.
4. Conclusions
Taken together, information about the therapeutic and undesired effects of dopamine D1 
receptor agonists and antagonists is too limited to predict the effects of these compounds in 
patients with PD, and these compounds need to be studied in validated animal models of PD. 
Propargylamines such as CGP 3466B that are, in contrast to deprenyl, not metabolized into 
amphetamine and methamphetamine, need to be studied for their neuroprotective effects in 
vivo animal models of PD.
5. Animal models of PD
5.1 6-hydroxydopamine
6-hydroxydopamine (6-OHDA) is a toxin that is widely applied in rats to introduce 
degeneration in dopaminergic cells. 6-OHDA is proposed to mediate its cell death through an 
increase in free radical formation (Jenner, Olanow, 1996) and an inhibition of mitochondrial 
complex I and IV (Glinka et al. 1996), that reduces the energy supply. Moreover, evidence is 
increasing that low doses 6-OHDA induce apoptosis (Walkinshaw, Waters, 1994). Thus, the 
processes of 6-OHDA-induced degeneration are very similar to the processes thought to play 
an important role in the degenerative process underlying PD. Since 6-OHDA destructs both 
dopaminergic and noradrenergic neurons (Breese, Traylor, 1971), the compound is given in 
combination with a noradrenergic transporter blocker, which inhibits the uptake of 6-OHDA in 
the latter cells. 6-OHDA does not pass the blood-brain barrier and is equally toxic to nigrostriatal, 
mesolimbic and mesocortical dopaminergic neurons. In the majority of studies rats are used for 
injecting 6-OHDA into the medial forebrain bundle resulting in the degeneration of dopamine 
neurons in the whole midbrain (Ungerstedt et al. 1974; Zigmond, Stricker 1989; Schwarting, 
Huston, 1997; Zigmond, Stricker, 1989). Moreover, 6-OHDA is most frequently injected 
unilaterally, because the bilateral injection of high concentrations of 6-OHDA induces severe 
motor deficits including akinesia and aphagia (Ungerstedt, 1971). Both L-DOPA and dopamine 
receptor agonists induce contralateral rotational behavior in these animals (Koller, Herbster, 
1987; Ungerstedt, Arbuthnott, 1970), which is used as a behavioral parameter to predict their 
therapeutic efficacy. However, given the fact that both place and size of the lesion as well as 
the behavioral effects induced by such a lesion are very different from the pathology and 
symptoms in patients with PD, the validity of this model may be questioned.
Recently, the 6-OHDA model has been updated (Van Oosten et al., 1998, see also: Zigmond 
et al. 1984; Whishaw, Dunnett, 1985; Wolf et al., 1989; Fornaguera et al. 1993; Sakai, Gash, 
1994; Schwarting, Huston, 1997). First, low amounts of 6-OHDA are injected bilaterally into 
the substantia nigra. This induces a lesion that is largely restricted to the substantia nigra and 
that elicits parkinson-like and striatal-specific motor deficits such as hypokinesia, deficits in 
sensimotor coordination as well as cognitive deficits. Second, more reliable test-batteries that 
include more aspects of the 6-OHDA-induced motor and cognitive deficits have been developed 
in order to evaluate the therapeutic effects of new therapies in a more sophisticated manner.
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5.2 MPTP
Currently, the MPTP model is extensively used in various mammalian species, but primarily 
in monkeys and mice. The parkinsonian syndrome is produced by the dopaminergic neurotoxin 
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). The fact that MPTP can induce 
Parkinsonism was originally suggested by Kopin and coworkers (Davis et al., 1979). They 
were confronted by a student who wanted to make the hard drug MPPP; however, by mistake 
he synthesized MPTP and became extremely akinetic. A few years later Langston and his 
colleagues showed the neurotoxic effects of MPTP in monkeys (Langston et al., 1983). The 
theory of the mechanism of MPTP neurotoxicity is presented in Figure 2. MPTP is a liphophilic 
molecule that therefore easily passes the blood brain barrier (Tipton et al., 1993). It is oxidized 
to MPDP+ and further oxidized to MPP+ by MAO-B (Langston et al., 1984). This is believed 
to occur in non-dopaminergic MAO-B rich cells (Di Monte et al. , 1992). In contrast to MPTP, 
MPP+ is a good substrate for the plasma membrane dopamine transporter, which mediates the 
uptake of the toxin (Javitch, Snyder, 1984). There, MPP+ accumulates by binding to 
neuromelanin (D’Amato et al., 1986).
Figure 2
MPP+ inhibits the activity of 
complex I in the mitochondrial 
respiratory chain (Ramsay et al., 
1986; Gerlach et al., 1991; Villa 
et al., 1992), which is believed 
to decrease the formation of ATP 
and to increase the formation of 
free radicals, primarily 
superoxide (Przedborski et al., 
1992). The lack of ATP may 
impair vital energy-dependent 
processes in the cell. Moreover, 
superoxide has found to react with 
NO. This induces highly reactive 
species, which in turn damage 
DNA, lipids and proteins 
(Przedborski et al., 1996). 
Subsequently, energy failure and 
oxidative stress decrease the cell’s 
ability to maintain its intra­
cellular potential and may reach 
the threshold of NMDA 
ionophore channels and trigger an excitotoxic insult (Turski et al., 1991). If the injury is very 
severe, the cell may die by necrosis (Jackson-Lewis et al., 1995), however, in most cases, the 
cell dies from apoptosis (Tatton, Kish, 1997; Spooren et al., 1998). Thus, degenerative processes 
induced by MPTP are thought to closely resemble the processes underlying the dopaminergic 
cell death in PD.
Early studies have suggested that MPTP induces a marked loss of dopaminergic neurons in 
the SNc and a loss of dopaminergic fibers, especially in the putamen and, to a lesser extent, in
ASTROCYTE NEURON
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the caudate nucleus (Burns et al., 1983). Later, studies have shown that also other dopaminergic 
areas, including the mesolimbic and mesocortical area dopamine pathways, are damaged 
(Mitchell et al., 1985; Elsworth et al., 1990). In addition, the adrenergic system is affected as 
well: especially the locus coeruleus is damaged by MPTP (Elsworth et al., 1990). Thus, the 
cell groups vulnerable to MPTP closely correspond with those degenerating from the pathological 
process underlying PD.
Taken all available animal models into account, the MPTP-treated primate most closely 
resembles the pathophysiology and symptoms of PD. Both the similarities between the effects 
of MPTP and the neurodegenerative process underlying PD and the great similarities between 
the brain and behavior of monkey and men play a definite role in this respect (Langston, Ballard, 
1984). Not only akinesia, rigidity and postural instability are induced, but also more subtle 
signs, including masked face, freezing episodes, sensory neglect and increasing seborrhea become 
apparent. However, the characteristic resting tremor is rarely seen.
Unfortunately, there is much variation in the MPTP-treatment regimen and the primate 
species used to study new drug treatments for PD. Therefore, the type and severity of the 
behavioral symptoms varies across distinct studies. Moreover, the drug treatment regimen and 
the evaluation of the drug-induced therapeutic and undesired effects show much variation. 
Therefore, it remains to be established to what extent these models are adequate for studying 
the therapeutic efficacy of new treatments for PD.
5.3 Use of the 6-OHDA-treated rat and MPTP-treatedprimate as experimental models ofPD
The 6-OHDA-treated rat and the MPTP-treated primate are both models that are valuable
for increasing the insight into new treatment strategies for PD. However, the selection of the 
most adequate model is dependent on the research question that is addressed.
The 6-OHDA-treated rat typically illustrates the motor and cognitive defects induced by 
striatal dopamine depletion in the mammalian brain. It offers a valid tool for evaluating the 
efficacy of new treatment strategies to temporally inhibit (symptomatic treatments) or to prevent 
(neuroprotective treatments) such defects.
The MPTP-treated monkey illustrates motor and cognitive defects that are even more 
characteristic for PD. It offers a valuable tool for evaluating the efficacy of compounds to 
inhibit or prevent parkinsonian symptoms. Moreover, the undesired side-effects induced by 
these compounds in the clinic can be adequately predicted, when this model is used. However, 
ethical, methodological and economical reasons limit the actual use of the MPTP-treated primate. 
Thus, only those new treatment strategies that have been found to be effective in rodent models 
of PD, should be evaluated with this model.
5.4 Use of  the 6-OHDA-treated rat and MPTP-treated primate in the present study
Given the fact that the effects of the putative neuroprotective compound CGP 3466B on 
dopaminergic degeneration in vivo are completely unknown, we decided to study the protective 
effects of this compound in the 6-OHDA-treated rat. Because the effects of dopamine D1 receptor 
stimulation have been extensively studied in various rodent models of PD, the therapeutic and 
undesired effects of these compounds were studied in the MPTP-treated primate. In fact, two 
primate models were evaluated, and the model with the greatest predictive validity was used 
for studying the effects of dopamine D1 receptor stimulation.
5. Conclusions
Both the 6-OHDA rat and the MPTP-treated monkey offer valuable tools for increasing our
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knowledge about new treatment strategies for PD. The 6-OHDA-treated rat offers a good model 
for evaluating the efficacy of new compounds to inhibit the motor and cognitive consequences 
of striatal dopamine depletion. When proven effective in the latter model, compounds should 
be evaluated in MPTP-treated primates, predicting the anti-parkinsonian and the undesired 
effects of these compounds in the clinic.
Aim and outiine of the present thesis
Available literature shows that the current medical treatment of PD, which still mainly consists 
of L-DOPA treatment, is far from ideal: these treatments induce severe response complications 
after long term administration. Moreover, none of these compounds significantly inhibits the 
progression of the disease.
The aim of the present study is to increase the insight into the potential of some new pharmaco­
therapies to improve the treatment of patients with PD, using thereby animal models of the 
disease.
In MPTP-treated primates, the therapeutic and undesired effects of compounds with affinity 
for the dopamine D1 receptor vary largely across studies, which can be attributed to variations 
in drug-treatmenthistory, primate species, mode of MPTP application, behavioral analysis and, 
subsequently, variations in the predictive validity of the models. In Chapter 2, we present a 
study on the predictive validity of the unilaterally MPTP-treated monkey. The monkeys had 
been previously primed with dopaminergic agents since the new symptomatic treatments are 
especially evaluated in those patients no longer responding to their long term L-DOPA treatment. 
A detailed behavioral analysis allowing a clear separation between drug-induced therapeutic 
and undesired effects was used. This study revealed that this model has a low predictive validity, 
which is believed to be due to the pre-treatment regimen of the monkeys and/or the unilaterality 
of the lesion. In Chapter 3, therefore, we present a study on the predictive validity of the bilaterally 
drug-naive MPTP-treated monkey, using the same behavioral analysis. This model was found 
to have a good predictive validity. The therapeutic and undesired effects of a symptomatic 
therapy, namely the dopamine D1 receptor agonist SKF 82958, were studied in naive bilaterally 
MPTP-treated monkeys and compared to the effects of this compound in L-DOPA pre-treated 
animals.
Not only full dopamine D1 receptor agonists having high intrinsic activity for the AC- 
coupled dopamine D1 receptor stimulate motor behavior in MPTP primates, but also some 
compounds with very limited intrinsic activity for this receptor have this effect. The most striking 
example in this respect is the dopamine D1 antagonist SKF 83959: this compound does not 
stimulate rat striatal AC-coupled receptors, but potently stimulates motor behavior after acute 
administration in MPTP-treated marmosets. This discrepancy may be due to species differences 
in the coupling of dopamine D1 receptors with SKF 83959. Moreover, it interaction with other 
aminergic receptors may contribute to the effects of SKF 83959 in monkeys. In Chapter 4, we 
present a study on the effects of SKF 83959 on human and primate dopamine D1 receptors as 
well as its functional interaction with others aminergic receptors. It was found that SKF 83959 
is a potent in vitro antagonist of primate dopamine D1 receptors.
Only one single study in which only the acute therapeutic effects of SKF 83959 have been 
evaluated, has led to the suggestion that this compound has anti-parkinson effects. In Chapter
5, we present our studies on both the therapeutic and undesired effects of this compound after 
chronic treatment in the bilaterally MPTP-treated monkey. It was found that this drug has clear- 
cut therapeutic effects and very limited side-effects that wore off after chronic administration.
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The mechanism underlying the anti-parkinsonian effects of SKF 83959 remains largely unknown. 
Given the fact that SKF 83959 interacts with both dopamine D1 receptors and a2 adrenoceptors 
together with the fact that extra-striatal receptors at the level of the ACC and prefrontal cortex 
regulate the release of striatal dopamine, these receptor are putative target sites in mediating 
the anti-parkinsonian effects of the compound. In Chapter 6, therefore, we present a study on 
the ability of SKF 83959 to interact with these receptors.
In Chapter 7, we present a study on the efficacy of a new putative neuroprotective treatment 
strategy. In this Chapter, the protective effects of the propargylamine CGP 3466B were examined, 
using a rodent model of PD, namely the bilaterally 6-OHDA-treated rat.
Finally, Chapter 8 gives an overview of the results and provides a general discussion.
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Abstract
The goal of this study was to evaluate the validity of the pre-treated, unilaterally MPTP- 
treated monkey as an animal model of Parkinson’s disease (PD). For that purpose, a detailed 
ethogram was developed and assessed in four male rhesus monkeys that had received MPTP 
(2.5 mg) in the carotid artery contralateral to the dominant limb. Subsequently, the behavioral 
effects of the dopamine D2 receptor agonist LY 171555 and the dopamine D1 receptor agonist 
SKF 81297 were studied.
The ethogram was found to allow a clear-cut and objective separation of drug-induced 
behavioral items into therapeutic and undesired effects in the MPTP-treated monkeys. Saline- 
treated monkeys predominantly displayed ipsilateral goal-directed forelimb movements and 
distinct types of ipsilaterally directed rotations. Although LY 171555 and SKF 81297 increased 
motor behaviors such as body displacement, contralateral forelimb movements and contralateral 
rotational behaviors, assessment of the new detailed ethogram revealed that this increase was 
completely due to the activation of abnormal, non-goal-directed behaviors, such as dyskinetic 
forelimb movements, pivoting and shuffling. Moreover, the new ethogram made clear that the 
drug treatments did not only induce dyskinesia, dystonia, but also epileptoid behavior, which 
was confirmed by EEG analysis. In sum, this detailed behavioral analysis showed that this 
model does not adequately predict the clinical effects of the dopamine D2 receptor agonist. It 
is concluded that the pre-treated, unilaterally MPTP-treated monkey is not a valid model to 
predict the therapeutic and undesired effects of dopaminergic drugs in humans.
Introduction
Since the early sixties the treatment of Parkinson’s disease (PD) has been based on the 
suppletion of the dopamine loss by administering its precursor, L-DOPA (Barbeau, 1969; Calne 
et al., 1969). Other therapies such as dopamine D2 receptor agonists (Parker et al., 1976; 
Goldstein et al., 1980; Braun et al., 1987) and MAO-B inhibitors (Birkmayer et al., 1975; 
Elizan et al., 1990; LeWitt et al., 1997) cannot completely replace L-DOPA therapy. Whereas 
L-DOPA relieves parkinsonian symptoms at the beginning of the therapy, complications including 
wearing off effects (Marsden, Parkes, 1976) and response fluctuations (Mouradian, Chase, 
1988; Roos et al., 1989) eventually develop in the majority of patients (Nutt, 1990).
Because L-DOPA results in the stimulation of both dopamine D1 and dopamine D2 receptors, 
the clinical efficacy of dopamine D1 receptor agonists has been investigated in primate models 
for PD, the unilaterally or bilaterally MPTP-treated monkey. Unfortunately, the majority of 
these studies have focused on the anti-parkinsonian effects (Nomoto et al., 1988; Rouillard et 
al., 1990; DeNinno et al., 1991; Kebabian et al., 1992; Loschmann et al., 1992; Domino, 
Sheng, 1993; Watts et al., 1993; Gnanalingham et al., 1995ab; Johnson et al., 1995; Shiosaki et 
al., 1996; Asin et al., 1997; Domino, 1997ab). Fewer studies have considered the undesired 
effects of dopamine D1 and D2 receptor agonists (Gomez-Mancilla, Bedard, 1991; Gomez- 
Mancilla, Bedard, 1992; Luquin et al., 1992; Blanchet et al., 1993).
Rotational behavior, body displacement and disability scores, as measured by rating scales, 
have been used as parameters to study the anti-parkinsonian effects of dopamine receptor 
agonists. Dopamine D2 agonists, such as LY 171555 and pergolide, and the majority of dopamine 
D1 agonists, including SKF 82958 and A 77636, stimulate body displacement and reduce 
disability scores (Kebabian et al., 1990; Rouillard et al., 1990; Loschmann et al., 1992; Arai et
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al., 1995; Gnanalingham et al., 1995ab; Domino, 1997ab). Dopamine D2 receptor agonists are 
suggested to be more potent in this respect than dopamine D1 receptor agonists (Domino, 
Sheng, 1993).
Data on the undesired (side)-effects of dopamine D2 and dopamine D1 receptor agonists 
are much more controversial. The dopamine D2 agonists LY 171555 and bromocriptine re­
initiate dyskinesia (Gomez-Mancilla and Bedard, 1991; Luquin et al., 1992; Blanchet et al., 
1993), but are also claimed to induce co-ordinated movements (Bedard et al., 1986; 
Gnanalingham et al., 1995b). In addition, the dopamine D1 agonist SKF 82958 induces only a 
mild re-initiation of L-DOPA-induced dyskinesia (Blanchet et al., 1993), whereas other studies 
report the induction of unco-ordinated behaviors by SKF 82958 (Gnanalingham et al., 1995ab). 
Thus, the effects of dopamine D2 and dopamine D1 receptor agonists on the induction and the 
re-initiation of dyskinesia appear to vary not only between the receptor agonists, but also between 
different reports on the same agonist. Finally, dopamine D1 agonists have sometimes been 
reported to induce convulsions (Kebabian et al., 1990; DeNinno et al., 1991; Gnanalingham et 
al., 1995ab).
There are several explanations for the reported differences. For instance, the discrepancies 
might be due to differences in treatment history of the monkeys. More importantly, no unified 
definition of therapeutic and undesired behavioral effects exists, resulting in different 
interpretations. It is unclear whether the currently used parameters such as rotation and body 
displacement really reflect the restoration of functional motor behavior.
Rotational behaviors are especially used in unilaterally MPTP-treated monkeys to evaluate 
the therapeutic effects of dopamine agonists (Vermeulen et al., 1993; Asin et al., 1997; Domino, 
1997ab). However, this parameter has two disadvantages. The drug-induced stimulation of 
rotational behaviors may not reflect the attenuation of MPTP-induced defects, but rather reflect 
the disbalance in dopaminergic activity between the hemispheres upon dopamine receptor 
stimulation (Glick et al., 1988). Thus, the amount of rotational behavior is not only dependent 
on the dopamine agonist studied, but also related to the size of the unilateral lesion (Carman et 
al., 1991). Moreover, many reports claim that rotational behaviors become conditioned to the 
exteroceptive stimuli of the test environment (Richards et al., 1990; Carey et al., 1991; Hudson 
et al., 1994).
Body displacement is a parameter that is very frequently used to study anti-parkinsonian 
effects of dopamine receptor agonists (Kebabian et al., 1990; Gnanalingham et al., 1995ab; 
Goulet et al., 1996; Shiosaki et al., 1996). However, body displacement incorporates both 
therapeutic (functional body displacement) and undesired (hyperkinesia, dyskinesia) effects. 
This is also true for the parameter limb movements: no distinction is made between functional, 
goal-directed movements and dyskinetic movements.
Taken together, knowledge about the predictive validity of the MPTP-treated primate as 
model of PD is rather limited, since a detailed behavioral analysis, allowing the splitting of 
therapeutic and undesired effects is lacking. Therefore, a detailed ethogram was developed in 
order to discriminate therapeutic and undesired effects of putative anti-parkinsonian drugs in 
primate models for PD. Using this ethogram, the validity of the unilaterally MPTP-treated 
monkey was evaluated by studying the effects of two typical examples of dopamine agonists, 
the dopamine D2 agonist LY 171555 and the D1 agonist SKF 81297.
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Materials and Methods
Animals
Four male rhesus monkeys (Macaca Mulatta) aged 15, 16, 23 and 27 years and weighing between 6.0­
10.8 kg were used. All monkeys had been used for prior studies, in which L-DOPA and low doses of 
dopamine agonists were given. The animals were individually housed in cages of 80x80x80 cm in which 
a piece of wood and a ball were placed. They were given lab chow at 9.00 h and 17.00 h and fruit and 
bread at 15.30 h; water was available ad libitum. The room temperature was kept at 22o C., and a 12-hour 
light-dark cycle was maintained (lights on: 7.00 a.m. - 7.00 p.m.). The study was carried out in 
accordance with the declaration of Helsinki and institutional guidelines.
MPTP-treatment
MPTP-HCl (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-hydrochloride, Research Biochemicals 
Incorporated, Natick, USA) was dissolved in 60 ml 0.9% NaCl with 100E heparin (Tromboliquine) and 
filtered through a 22 mm pore filter (Millex, Millipore) prior to use. The MPTP solution (2.5 mg) was 
infused into the common carotid artery, while the external branch was temporarily clamped. One animal 
received a second dose of MPTP (2 mg), since no motor deficits were induced by the first bolus. See 
Wolters et al., (1991), for a detailed description of the lesion procedure. Our previous SPECT study 
revealed that striatal accumulation of the dopamine transporter ligand FP-CIT was significantly reduced 
at the side of the MPTP treatment in all four animals (Booij et al., 1997).
Prior to the MPTP lesion, the animals were offered pieces of fruit to test which forelimb was 
dominantly used. As this turned out to be the right forelimb in all monkeys, the MPTP solution was 
always infused into the left artery. In the remainder of this article, the left and right extremities will be 
referred to as ipsilateral and contralateral extremities (towards the lesion), respectively.
Drugs
A 0.9 % NaCl solution was used as control injection. LY 171555 (trans-(-)-4aR,-4,4a,5,6,7,8,8a,9- 
octahydro-5-propyl-1H-3pyrazolo[3,4-g] quinoline mono-hydrochloride, Research Biochemicals Inc., 
Natick, USA) and SKF 81297 (2,3,4,5,-tetrahydro-6-chloro-7,8-dihydroxy-phenyl-1H-3-benzazepine, 
generous gift of Dr. J. Weinstock, SmithKline Beecham, USA) were dissolved in a total volume of 0.2 ml/ 
kg saline and administered in the doses 0.01 and 0.1, and 0.05, 0.1 and 0.3 mg/kg. In a previous study 
(Vermeulen et al., 1994) 0.01 mg/kg LY 171555 and 0.3 mg/kg SKF 81297 appeared to be the lowest 
effective doses. In the present study, the effects of these dosages were therefore analyzed in more detail. 
The drugs were filtered through a 0.22 mm pore filter prior to use. Injections were given i.m. at 10.00 
a.m., while the animals were seated in their home cages. The interval between the MPTP treatment and 
the drug administration was at least eight weeks.
Scoring procedure
Directly after the drug injection, behavior was recorded on videotape for 90 consecutive minutes and was 
later analyzed with an event recording computer program (Observer 3.0) which allowed both a time and 
frequency analysis of the behavior. The analyzer of the tapes was unaware of the given treatment.
Behavioral analysis 
In general, the drugs elicited three classes of effects:
A. Changes in behavioral items that were also present in saline-treated MPTP monkeys;
B. Behavioral items that were never seen in saline-treated MPTP monkeys; and
C. Epileptoid behavior.
The following levels of description were chosen to delineate and describe specific behavioral items 
(Cools, 1981).
1. Motor elements: motor synergies, responsible for observable changes in contractions, c.q. relaxation 
of muscle groups.
2. Motor components: motor synergies, responsible for observable changes in spatio-temporal
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relationships between parts of extremities and/or face.
3. Motor complexes: motor synergies, responsible for observable changes in spatio-temporal 
relationships between various body parts.
4. Motor patterns: motor synergies, responsible for observable changes in spatio-temporal relationships 
between the body and its surroundings.
The levels 1 to 4 form a hierarchical structure, in which each hierarchically higher-order level 
incorporates motor synergies of the hierarchically lower-order levels.
The behavioral analysis of the data was performed in four steps (step I-IV, which are shown in the 
Results section). First, a qualitative description of the behavioral items displayed by saline- and/or drug- 
treated MPTP monkeys was made. Second, these behavioral items were quantitatively analyzed in terms 
of frequency and/or duration. Third, a qualitative description of the epileptoid behavior was made.
Finally, this behavior was quantitatively analyzed in terms of frequency and/or duration.
EEG registration
The epileptoid behavior was verified by registration of the EEG pattern after saline, SKF 81297 and LY 
171555 treatment in one of the MPTP-treated animals. The conscious monkey was placed in a restraining 
chair, and electrodes were fixated on the skull (2 frontal, 2 temporal, 2 occipital, 3 central and 1 reference 
electrode). After 30 minutes of habituation, saline was administered i.m. and the EEG pattern was 
monitored. After 45 minutes, either 81297 (0.3 mg/kg) or LY 171555 (0.01 mg/kg) was injected. The 
effects of SKF 81297 and LY 171555 on the EEG pattern were monitored in two distinct sessions with a 
washout period of three weeks.
Statistical analysis
All values are expressed as mean ± S.E.M. Behavioral items of classes A and B that were present during 
saline injection, were analyzed using a two-way ANOVA including the factors time (four periods of 15 
minutes) and treatment (saline, SKF 81297 and LY 171555). Data in class A and B that were only present 
after drug-treatment (saline value of 0) were analyzed using a one-tailed, one sample t-test. The epileptoid 
behavior (class C) was analyzed in six 15-minutes periods. The latter data were subjected to a MANOVA, 
followed by a Mann Whitney U test. The accepted level of significance was p<0.05 for all data
Results
I. Qualitative description o f behavioral items
Since the MPTP monkeys infrequently displayed behaviors that normally occur in unoperated 
monkeys, the description given below is limited to behaviors that were pathognomic for saline- 
and drug-treated MPTP monkeys.
Motor components:
1a. Dyskinesia. This class of movements encompasses two types of movements:
1a.a. Athetoid movements being defined as non goal-directed, spontaneous limb movements 
while the monkey is standing, sitting or lying on its side: the whole pattern is purposeless, non­
adaptive and compulsive in character. The movements begin slowly: the limb is lifted from the 
floor and the lower arm, hand and/or fingers undergo alternating hyperextension and flexion 
movements. The movements occur independently of the ongoing activity of the monkey. The 
monkey itself has no visual interest in the induced limb movements. This item occurred only in 
drug-treated monkeys.
1a.b. Choreiform movements being defined as rapid, jerky shaking-off movements involving 
lower arm, wrist and/or fingers and occurring only when the monkey is standing or sitting. The 
movements are repeated several times and are violent in nature and the monkey has continuous 
visual interest in these movements. This item occurred only in drug-treated monkeys.
Since the type of dyskinetic movements displayed varied between the monkeys, both athetoid
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and choreiform movements were lumped together and labeled as dyskinetic movements.
1b. Dystonia being defined as a contorted and twisted posture marked by the presence of the 
total, or a part, of the following behavior elements: torticollis, a shrugged shoulder, an abducted 
upper-arm, flexion of the elbow, pronation of the wrist with abducted digits, abducted thigh 
with flexion of the knee-joint and pronation of the ankle with abducted toes at one side of the 
motionless animal. During such a dystonic period the hand and foot at the other side of the 
body are often pressed against a nearby object such as the bars of the cage or the feeding- 
trough. This item occurred only in drug-treated monkeys.
Motor complexes:
2a. Goal-directed forelimb movements being defined as normal hand movements directed either 
at the body itself or at objects such as bars, ball and feeding-trough. Thus, items such as self­
grooming, masturbating, caressing, grasping, etc. are clustered into this class. This item occurred 
in saline- and drug-treated monkeys.
2b. Dyskinetic forelimb movements being defined as hand movements that are choreiform in 
nature. These movements are ultimately incorporated in grasping either parts of the body or 
objects such as bars, ball and feeding-trough. This item occurred only in drug-treated monkeys. 
Motor patterns:
3A. Body displacement being defined as any displacement of (parts of) the animal over a 
minimum distance of 50 cm. Apart from walking straight forwards, climbing etc. this item also 
includes the items 4b to 4d. This item occurred in saline- and drug-treated monkeys.
3b. Turning being defined as rotating in circles with a diameter of about 70 cm, while walking 
on all four limbs: the stepping pattern consists of the sequential occurrence of an opening and 
a closing step of the forelimbs and two forward steps of the hind-limbs (Cools et al., 1989). 
This item occurred in saline- and drug-treated monkeys, although it was limited to turning 
toward the ipsilateral side in saline-treated animals.
3c. Dragging being identical to “turning” with the exception that the dorsum of the outer hindlimb 
is dragged over the floor of the cage before it is lifted and correctly placed on the floor. This 
item occurred in saline- and drug-treated monkeys and was limited to dragging toward the 
ipsilateral side in both cases.
3d. Pivoting being defined as rotating around the axis of the inner hind-limb in circles with a 
diameter of about 40 cm. The movements are initiated from the head and torso. The inner 
hindlimb is carrying the weight, making small correcting steps during the rotation. The passively 
moved outer limb swings around the inner limb, before being placed on the floor. This item 
occurred in saline- and drug-treated monkeys, although it was more or less limited to pivoting 
toward the ipsilateral side in saline-treated animals.
3e. Shuffling being defined as rotations around the axis of the trunk in circles with a diameter of 
about 40 cm, while the monkey is sitting on its bottom. Meanwhile, various lifting and placing 
movements with the forelimbs as well as small opening and closing steps with the hindlimbs 
are made. This item occurred mainly in drug-treated monkeys and was limited to shuffling 
towards the contralateral side.
II. Quantitative analysis o f drug-induced changes in behavioral items 
1a. Dyskinesia
Under control conditions dyskinesia was absent, whereas both drug treatments induced 
dyskinesia (Table 1). No significant difference in the duration of dyskinesia was found between 
LY 171555 and SKF 81297.
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1b. Dystonia
Under control conditions dystonia was absent. Both drug treatments induced dystonia during 
the whole observation period (Table 1). No significant difference in the duration of dystonia 
was found between either treatment.
Control LY 171555 SKF 81297
Body displacement 33.3 ±4.1 56 ±2.25* 33.2 ±5.8
Dyskinesia 0 7.03 ± 2.48 * 7.31 ± 2.12 *
Dystonia 0 15.28 ±9.17* 5.57 ±'1.86*
Table 1. Effects of intramuscular injection of SKF 81297 (0.3 mg/kg) and LY 171555 (0.01 mg/kg) on 
body displacement, dyskinesia and dystonia. Values express the mean duration + S.E.M. calculated in 
percent of 60 min. Dyskinesia: LY 171555 t(3)=2,84 * p <0.05. SKF 81297: t(3)=3,0 * p <0.05. Dystonia: 
LY 171555 t(3)=3,45 * p <0.05. SKF 81297: no significant effect. Body displacement: LY 171555 vs. 
saline F(1,24)=26,17 * p <0.05 treatment effect. SKF 81297 vs. saline: no significant effect.
2a. Goal-directed forelimb movements
Under saline conditions, the duration of goal-directed forelimb movements was significantly 
longer in the ipsilateral forelimb as compared to the contralateral forelimb (Fig. 1A). Both 
drug-treatments decreased the duration of goal-directed movements at the ipsilateral side.
None of the dopaminergic treatments altered the performance of goal-directed movements 
in the contralateral forelimb.
2b. Dyskinetic forelimb movements
Saline administration did not induce dyskinetic movements in either forelimb, whereas LY 
171555 and SKF 81297 produced dyskinetic forelimb movements in both limbs to the same 
amount (Fig. 1B).
1A 1B
GOAL-DIRKCTEl) FORE-LIMB MOVEMENTS DYSKINETIC FORE-LIM B MOVEMENTS
ipsilateral c o n tra la te ra l Ipsilateral contralateral
□  SALINE ÌH L Y m 5 5 S  H  SKF81297 
0.01mg/kg 0.3mg/kg
Fig. 1. Effects of intramuscular injection of SKF 81297 (0.3 mg/kg) and LY 171555 (0.01 mg/kg) on 
goal-directed (Fig. 1A) and dyskinetic (Fig. 1B) forelimb movements. Values express the mean duration 
+ S.E.M. calculated in percent of 60 min. Fig. 1A: Control condition; ipsilateral limb vs. contralateral 
limb: F(2,37) = 5,6, p <0.05.Ipsilateral limb: LY 171555 vs. saline F(1,24)=8.90 * p <0.05, treatment 
effect. SKF 81297 vs. saline: F(1,24) = 4,96 * p <0.05, treatment effect.Contralateral limb: no significant 
effects. Fig. 1B: Ipsilateral limb: LY 171555: t(3) = 2.4 * p <0.05. SKF 81297: t(3) = 3,3 * p <0.05.
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contralateral limb: LY171555: t(3) = 2.5 * p <0.05. SKF 81297: t(3) = 3,1 * p <0.05.
3a. Body displacement
LY 171555 increased body displacement (Table 1). SKF 81297, instead, had no effect on 
body displacement.
3b. Turning
Under saline conditions, the frequency of ipsilateral turning was low, whereas contralateral 
turning was absent (Fig. 2A). Neither treatment significantly increased ipsilateral or contralateral 
turning behavior.
3c. Dragging
In the control situation, dragging was performed in the ipsilateral direction (Fig. 2B). Both 
drug-treatments reduced its frequency significantly. Contralateral directed dragging was never 
elicited.
3d. Pivoting
During saline treatment, pivoting was performed in the ipsilateral direction, whereas 
contralateral pivoting was absent (Fig. 2C). SKF 81297, but not LY 171555, significantly 
decreased ipsilateral pivoting. Both drug-treatments generated contralateral pivoting, however 
this did not reach statistical significance.
3e. Shuffling
Ipsilateral shuffling was not observed under any treatment (Fig. 2D). Under saline conditions, 
contralateral shuffling was only occasionally performed. Both LY 171555 and SKF 81297 
greatly increased its frequency.
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Fig. 2. Effects of intramuscular injection of SKF 8Í297 (0.3 mg/kg) and LY Í7Í555 (0.0Í mg/kg) on 
turning (Fig. 2A), dragging (Fig. 2B), pivoting (Fig. 2C) and shuffling (Fig. 2D). Values express the 
mean frequency + S.E.M. calculated in percent of 60 min.Fig. 2A. Ipsilateral and contralateral turning: 
no significant effects. Fig. 2B:Ipsilateral dragging LY Í7Í555 vs. saline F(í,24) = Í4,23 * p <0.05
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treatment effect. SKF 81297 vs.saline: F(1,24) = 4,68 * p <0.05, treatment effect. Fig. 2C: ipsilateral 
pivoting LY 171555 vs. saline no significance. SKF 81297 vs.saline: F(1,24)=5,0 * p <0.05, treatment 
effect. Contralateral pivoting: no significant effects. Fig. 2D. contralateral shuffling: LY 171555 vs. 
saline F(1,24)=15,10 * p <0.05 treatment effect. SKF 81297 vs.saline: F(1,24)=7,8 * p <0.05, treatment 
effect.
III. Qualitative description o f an epileptoid attack
Using the various levels of description shown in the Methods, it became clear that, during 
an epileptoid attack, the affected animal went through a series of successive phases. During the 
initial four phases, the so-called warming-up of the attack, the behavioral items belonging to 
level 1 to 4 were successively displayed. Then, the animal suddenly became motionless. 
Dependent on the severity of the attack, all phases, or only a part, were displayed.
Some of the behavioral items categorized in class A or B, for instance shuffling and turning, 
were also included in the analysis of the epileptoid behavior.
In practice, the following phases were delineated:
Phase 1: rapid opening and closing of the eyelids (motor elements).
Phase 2: brief muscular contractions and relaxation of muscle groups in the ears, small 
sections of the face and mouth (motor elements). This was followed by purposeless, oral 
movements such as jaw movements and tongue protrusions (motor components).
Phase 3: rapid flexion and extensions of arm resulting in abrupt, staccato-like forelimb 
movements as well as abrupt, unco-ordinated movements of the torso (motor complexes).
Phase 4: contralateral turning of the eyeballs, followed by abrupt, contralateral rotations of 
the head followed by the appearance of jerky, contralateral rotations with the whole body. 
While the sitting animal was apparently forced to rotate, it still displayed the forelimb movements 
mentioned under phase 3 (motor patterns). At the end of this stage of the attack, the monkey 
often incorporated the unco-ordinated forelimb movement into a goal-directed, grasping 
movement of which the involuntary movement forms the initial phase: when this resulted in 
clasping the ball, feeding-trough or bars of the cage, the involuntary movements disappeared 
and the attack came to an end.
Phase 5: ptosis.
Phase 6 : overall muscle relaxation resulting in atonia: the monkey lay down on the floor 
and remained motionless for a variable amount of time.
IV. Quantitative analysis o f epileptoid attacks
Fig. 3 shows the total time spent on epileptoid behavior (right Y axes) and its different 
phases (left Y axes). Under control conditions, none of the animals suffered from epileptoid 
behavior. Both LY 171555 and SKF 81297 induced epileptoid attacks. However, their effect 
differed in time. LY 171555 induced a gradual increase of epileptoid behavior in time, reaching 
its highest effect at t= 15 to 45 minutes (Fig. 3A). SKF 81297 reached its peak level at t= 0 to 
15 minutes. Thereafter, time spent on epileptoid behavior rapidly decreased (Fig. 3B).
Different phases of epileptoid behavior were predominantly performed after each treatment. 
During its peak effect, LY 171555 induced a predominant display of phase 4 (“whole body”). 
SKF 81297 instead, especially induced the display of phase 3 (“extremities and trunk”) during 
its peak effect.
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Fig. 3AB. Effects of intramuscular injection of LY 171555 (0.01 mg/kg, Fig. 3A) and SKF 81297 (0.3 
mg/kg, Fig. 3B) on total epileptoid behavior (right Y axes) and its different phases (left Y axes). Values 
express the mean duration + S.E.M. calculated in percent of 15 min over a total period of 90 min. Total 
epileptoid behavior: treatment x time: F(6) = 7.78, p< 0.05, comparing the different drug treatments: 
MANOVA. LY 171555 at t = 15-45 minutes: * p <0.05 phase 4 vs. other phases: posteriori Mann Witney 
U test. SKF 81297 at t = 0-30: * p< 0.01 phase 3 vs. other phases: posteriori Mann Witney U test.
EEG Registration
Fig. 4A and B show the EEG pattem after saline and SKF 81297 treatment. Saline 
administration induced no abnormalities in EEG patterns. In contrast, seven and three minutes 
after LY 171555 and SKF 81297 administration respectively, clusters with high voltage (75 
^V), sharp, fast theta activity (7 Hz) were recorded from the FP1 lead (Fig. 4B). The FP1 lead 
is ipsilateral to the side of the MPTP injection.
4A
51
c o n t r o l  
52 53 54
O]
02
T1
T2
00
-Ws,
■mA
27
S K F  81297 
28 29
4B
30
FI
F2
Cl 
C2 I
01
02 .
Mp iWiW
unit
Ê
¿yiBwyWr’'-“
«'“ IlillllrtflW'''
- , —
11$www#**** '/‘kinpititmw"'"'
38
The validity ofthe unilaterally MPTP-treated monkey as a model o f Parkinson's disease
Fig. 4. EEG recording from electrodes that were fixated on the skull at the level of the frontal pole (F1, 
F2), temporal pole (T1, T2), occipital pole (O1, O2), central pole (C0, C1, C2) and one reference electrode.
1 = left hemisphere (ipsilateral to the MPTP lesion), 2 = right hemisphere (contralateral to the MPTP 
lesion).Fig. 4A: EEG, recorded 3 minutes after saline injection. Fig. 4B: EEG recorded after 3 minutes 
SKF 81297 administration (0.3 mg/kg, i.m.).
Discussion
General discussion
In the present study a detailed ethogram was used to study the validity of the pre-treated, 
unilaterally MPTP-treated monkey. The results revealed that the predictive validity of the 
unilaterally MPTP-treated monkey as an animal model of Parkinson’s disease (PD) is much 
less than has previously been believed.
Table 2 gives an overview of all the behavioral changes induced by the dopamine D2 agonist 
quinpirole and the dopamine D1 agonist SKF 81297 and clearly illustrates that assessment of a 
carefully designed ethogram allows the separation of drug-induced (changes in) behavioral 
items into “therapeutic” and “undesired” effects. Below these items will be discussed separately.
Predictive validity o f the unilaterally MPTP-treated monkey for the therapeutic effects o f 
dopamine agonists
In line with other reports, both LY 171555 and SKF 81297 increased gross motor activity in 
our monkeys; LY 171555 increased body displacement, whereas both drugs increased the display 
of contralateral forelimb movements and several types of contralaterally directed rotational 
behaviors (Domino, 1993; Vermeulen et al., 1993, 1994; Gnanalingham et al., 1995ab). However, 
assessment of the presented ethogram revealed that the effects LY 171555 and SKF 81297 on 
these different types of motor behaviors were not therapeutic effects but, instead, undesired 
effects.
Firstly, the drugs worsened the quality of the contralateral rotations: the monkeys displayed 
pivoting and, especially, shuffling. In contrast to turning, the latter types of rotation are 
characterized by an abnormal stepping pattern of the hindlimb (pivoting: contralateral limb, 
shuffling: both limbs). Secondly, and more importantly, the drugs did not stimulate goal-directed 
limb movements, which is, to our opinion, the most adequate parameter to predict therapeutic 
effects of dopaminergic drugs. In fact, the increase in contralateral forelimb movements was 
completely due to an increase in dyskinetic movements. Surprisingly, the drugs also elicited 
dyskinetic movements in the ipsilateral forelimb.
Taken together, neither LY 171555 nor SKF 81297 attenuated the MPTP-induced behavioral 
deficits in this experimental setting, but rather worsened the motor behavior of the monkeys. 
These data imply that the animal model used in this study has no predictive validity because 
dopamine D2 agonists such as LY 171555 have clear anti-parkinsonian effects in patients with 
PD (Parker et al., 1976; Goldstein et al., 1980; Braun et al., 1987).
Predictive validity ofthe unilaterally MPTP-treated monkey for the undesired effects ofdopamine 
agonists
As claimed by others, LY 171555 induced dyskinetic movements and dystonic postures. 
Moreover, our data show that SKF 81297 also induced these behaviors. However, assessment 
of the new ethogram revealed that both the dopamine D1 receptor agonist and the dopamine 
D2 receptor agonist generated epileptoid behavior. This was confirmed by sharp wave bursts in 
the EEG pattern ipsilateral to the lesion, which is similar to what is known from frontal lobe
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epilepsy in humans (Wieser, Hajek, 1995). Taken together, it is concluded that the animal 
model that was used in the present study had a limited predictive validity for drug-induced 
side-effects in the clinic since dopamine D2 receptor agonists such as LY 171555 are known to 
elicit dyskinetic and dystonic, but not epileptoid effects in patients with PD.
Lack o f predictive validity o f the pre-treated, unilaterally MPTP-treated monkey: possible 
explanations
The unilaterally MPTP-treated monkey is a commonly used model to evaluate putative 
anti-parkinsonian drugs. Unilateral intracarotid administration of 2.5 mg MPTP induces a severe, 
unilateral decrease in striatal dopamine levels (Guttman et al., 1990) and in vivo dopamine 
transporter binding (Booij et al., 1997). In contrast to many bilateral MPTP treatment procedures, 
the unilateral procedure results in animals that remain self-maintaining. We used relatively old 
monkeys, since these are more susceptible to MPTP as compared to younger monkeys, and are 
therefore suggested to be a more valid model for PD (Ovadia et al., 1995).
As mentioned in the materials and methods section, we carefully selected the dosages of the 
drugs on the basis of previous studies. It is important to underline that the dosages used elicited 
undesired effects without inducing therapeutic effects. Thus, it is unlikely that the effects seen 
were due to an inappropriate dose. However, there are at least three explanations for the lack of 
predictive validity of the pre-treated unilateral MPTP-treated monkey.
Firstly, the drug treatment history may have influenced the behavioral effects induced by 
LY 171555 and SKF 81297, since previous stimulation of dopamine receptor is known to 
enhance the behavioral response upon the next stimulation (Morelli, Di Chiara, 1987). For 
instance, priming by dopamine D1 receptor agonists might have facilitated the display of 
dopamine D2 receptor agonist-induced epileptoid behavior. This explanation is supported by 
the fact that LY 171555 and SKF 81297 had virtually the same effect on the majority ofbehavioral 
items studied. Because repeated administration of differential dopaminergic receptor agonists 
may have led to the introduction of both conditioning (rotational behaviors) and priming 
phenomena, care needs to be taken with the interpretation of dopamine agonist-induced 
behavioral effects in pre-treated monkeys.
Secondly, as shown by others, a unilateral MPTP-treatment does not induce the full repertoire 
of symptoms characteristic for PD (Riederer, Youdim, 1987; Schneider et al., 1992). Parkinsonian 
symptoms such as gait or balance disturbances and resting tremor were not present in our 
monkeys.
Finally, a large interhemispheric disbalance in dopamine levels might have been induced 
and, accordingly, differentially altered the susceptibility of the various dopamine receptors to 
the dopaminergic drugs (Guttman et al., 1990). All these factors might have contributed to the 
finding that the predictive validity of the animal model assessed in the present study is rather 
limited.
General conclusion
In sum, it is concluded that the predictive validity of the pre-treated unilaterally MPTP- 
treated monkey is far less than expected on the basis of the available literature. Both the pre­
treatment regimen and the unilateral infusion of MPTP may contribute to this. Therefore, this 
study was followed by a re-evaluation of the validity of bilaterally MPTP-treated monkeys as 
animal model of PD.
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Table 2. Effects of LY 171555 and SKF 81297 on motor behaviors
Saline LY 171555 SKF 81297
Motor components:
Motor complexes:
Motor patterns:
- Dystonia a t t t t
- Dyskinesia a t t t t
- Goal-directed forelimb
movements, ipsilateral P 44 U
- Goal-directed forelimb
movements, contralateral (P) = =
- Dyskinetic forelimb
movements, ipsilateral a t t
- Dyskinetic forelimb
movements, contralateral a t t t t
- Dragging, ipsilateral P 4- 4-
- Turning, ipsilateral P = =
- Turning, contralateral a = =
- Pivoting, ipsilateral P ; I
- Pivoting, contralateral a t t
- Shuffling, contralateral (P) t t t t
- Body displacement P t =
- Epileptoid behaviors a t t t t
p: present; (p): present in 1 (out of 4) monkey; a: absent; t : induction/increase; 4-: decrease; =: no 
change
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ofParkinson’s disease: effects ofL-DOPA and the dopamine D1 agonist SKF82958.
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Abstract
The aim of this study was twofold: 1) to study the predictive validity of the drug-naive, 
bilaterally MPTP-treated monkey as an animal model of Parkinson’s disease (PD) and 2) to 
investigate the therapeutic and undesired effects of the dopamine D1 receptor agonist SKF 
82958 as compared to L-DOPA treatment, both in drug-naive and L-DOPA pre-treated monkeys. 
A detailed ethogram was used, allowing the separation of therapeutic and undesired effects. 
Eight weeks after bilateral intracarotid MPTP administration, SKF 82958 (1 mg/kg, n = 4) or 
methyl-L-DOPA + carbi-dopa (10 + 2.5 mg/kg, n = 4) was administered i.m. for 22 days. After 
a drug-free period of eight weeks, the L-DOPA group was treated with SKF 82958 for 22 days. 
All drug treatments increased the parameters used classically to evaluate dopaminergic drugs, 
namely body displacement, dyskinesia and dystonia. However, the new detailed analysis revealed 
that L-DOPA, but not SKF 82958, had therapeutic effects, reflected by an increase in goal- 
directed forelimb use. SKF 82958, but not L-DOPA, induced additional undesired effects; it 
induced epileptoid behaviors in both drug-naive and drug-pre-treated monkeys. In one L- 
DOPA-unresponsive monkey, SKF 82958 did induce minor therapeutic effects as well as 
undesired effects. Although the effects of SKF 82958 on forelimb movements, rotational 
behaviors and body displacement were comparable in the naive and pre-treated group, SKF 
82958 re-initiated undesired effects in the L-DOPA pre-treated group from day one. It is 
concluded that the bilaterally MPTP-treated monkey is an animal model with predictive validity 
for PD: it adequately predicts the therapeutic effects and undesired effects of L-DOPA. 
Furthermore, it is concluded that SKF 82958 is less effective than L-DOPA in the treatment of 
PD, because it did not induce therapeutic effects but instead elicited several undesired effects.
Introduction
The role of dopamine D1 receptor agonists in the treatment of Parkinson’s disease (PD) is 
under investigation, both in preliminary clinical studies and in primate models of PD, the 
unilaterally and bilaterally 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated 
monkey. In primate studies, attention has been focused on the acute anti-parkinsonian effects 
of dopamine D1 receptor agonists in MPTP-treated monkeys that have been pre-treated with 
dopaminergic drugs (Nomoto et al., 1988; Rouillard et al., 1990; DeNinno et al., 1991; Kebabian 
et al., 1991; Löschmann et al., 1992; Watts et al., 1993; Gnalalingham et al., 1995ab; Johnson 
et al., 1995; Shiosaki et al., 1996; Domino et al., 1997ab). Although the majority of these 
reports suggest a therapeutic effect of dopamine D1 agonists, data are not completely consistent. 
The dopamine D1 receptor agonist SKF 82958 has been reported to increase several classically 
evaluated parameters such as body displacement and rotational behaviors and reduce disability 
scores, as measured with parkinsonian rating scales. SKF 82958 has therefore been suggested 
to exert anti-parkinsonian effects (Akai et al., 1995; Blanchet et al., 1996; Kuno et al., 1997). 
However, others have suggested that SKF 82958 has limited therapeutic effects (Gnanalingham 
et al., 1995ab). Knowledge of the undesired effects induced by dopamine D1 agonists is also 
inconsistent. Blanchet et al., reported that SKF 82958 induced dyskinesia in drug-naive animals 
(Blanchet et al., 1996), whereas it only mildly re-initiated L-DOPA-induced dyskinesia (Blanchet 
et al., 1993).
Taken together, information about the therapeutic and undesired effects of dopamine D1 
receptor agonists are too limited to predict the effects of these compounds in patients with PD. 
Several factors might have contributed to this. Firstly, only limited attention has been paid to
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the undesired effects of dopamine D1 agonists, which are especially manifested after chronic 
treatment. Secondly, most of the studies have been performed in monkeys that have been 
treated previously with dopaminergic drugs, which may have consequences for the behavioral 
outcome of the drug tested (see Andringa et al., 1999b). Thirdly, the validity of the animal 
models used may be limited. Our previous study, in which a detailed ethogram was assessed, 
has shown that the pre-treated, unilaterally MPTP-treated monkey has very limited validity 
(Andringa et al., 1999b). This may be partly due to the unilaterality of the lesion and partly due 
to the drug treatment history of these monkeys.
The first goal of the present study was to evaluate the validity of the drug-naive, bilaterally 
MPTP-treated primate as an animal model of PD, using an ethogram that allows the separation 
of behavioral items into undesired and therapeutic effects. Because the data revealed that the 
bilaterally MPTP-treated monkey is a valid model to predict the behavioral effects of L-DOPA, 
the second aim was to study the chronic behavioral effects of the dopamine D1 agonist SKF 
82958 in both pre-treated and drug-naive bilaterally MPTP-treated monkeys. In order to obtain 
a complete insight into the effects of SKF 82958, the behavioral effects of SKF 82958 in drug- 
naive monkeys were directly compared to the effects of L-DOPA in drug-naive animals. In 
addition, the influence of L-DOPA pre-treatment on the behavioral effects of SKF 82958 was 
analyzed.
Materials and Methods
Animals
Eight male rhesus monkeys (Macaca Mulatta) aged 7, 13, 14, 16, 16, 18, 24 and 24 years and 
weighing between 4.0-12 kg were used in this study. Housing and nursing condition were identical to the 
previous experiment (see Andringa et al., 1999b) with one exception, due to changed institutional 
guidelines. This time, the animals were housed in cages of 90x180x200 cm in which a 60x60x70 “squeeze 
cage”, a bar connected to the wall 1 meter above the floor, and toys were present. The study was carried 
out in accordance with the declaration of Helsinki and institutional guidelines.
MPTP treatment
The method of Smith et al., (1993) was used to produce a bilateral MPTP lesion. 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine-hydrochloride (MPTP-HCL, Research Biochemicals Incorporated, Natick, 
USA) was given with an interval of six weeks in the left (first treatment, 2.5 mg) and right (second 
treatment, 1.25 mg) carotid artery. The first 2.5 mg MPTP solution was always infused into the left artery 
since the right forelimb was most commonly used by all monkeys. See Andringa et al., (1999b) and 
Wolters et al., (1991) for the operation procedure, see Andringa et al., (1999b) for the selection of the 
dominant limb.
Drugs
A 0.9 % NaCl solution was used as control injection. Methyl-L-DOPA (L-3,4,-dihdroxyphenylalanine 
methyl ester, Sigma: 10 mg/kg) and benserazide-HCl (Sigma: 2.5 mg/kg) or SKF 82958 (2,3,4,5,- 
tetrahydro-6-chloro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine hydrobromide, Research Biochemical 
International, Natick, USA: 1 mg/kg) was administered in a total volume of 0.2 ml/kg saline. Since the 
oral route is not suitable for chronic administration, all drugs, including L-DOPA, were given i.m., between
13.00 and 17.00 p.m., in the home cage. SKF 82958 or L-DOPA was given for 22 consecutive days in 
these drug-naive animals (SKF 82958,N group (n=4) and L-DOPA group (n=4)), starting eight weeks 
after the second MPTP treatment. After a drug-free period of 8 weeks the L-DOPA-treated animals were 
given SKF 82958 (SKF 82958,P) for 22 consecutive days. Two days prior to and two days after the 
treatment regime saline injections were given. Since the effects of these injections did not significantly 
differ from each other in any behavioral item in any group, the two sets of results were combined.
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Scoring procedure
During saline treatment and on day 1, 8, 15 and 22 of the drug treatment period, directly after the 
drug injection, behavior was recorded on videotape for 60 consecutive minutes and, was later analyzed 
with an event recording computer program (Observer 3.0) which allowed both a time and frequency 
analysis of the behavior.
Behavioral analysis
In general, the drugs elicited two classes of effects:
A. Changes in behavioral items that were also present in saline-treated MPTP monkeys.
B. Behavioral items that were never seen in saline-treated MPTP monkeys.
A qualitative description of all behavioral items displayed by saline- and/or drug-treated MPTP monkeys 
is given in part A: Andringa et al., (1999b). In this study, the analysis was limited to the behavioral items 
giving insight in therapeutic and undesired effects of dopaminergic drugs, and for comparison, some of 
the classically used parameters.
Statistical analysis
All values are expressed as mean ± S.E.M. The data were analyzed using a two-way ANOVA, including 
the factors treatment (SKF 82958,N vs. SKF 82958,P and SKF 82958,N vs. L-DOPA) and time, performing 
repeated measurements for time (saline 1, day 1, 8, 15, 22 and saline 2). The ANOVA was followed by 
paired samples t-tests were appropriate. The accepted level of significance was p<0.05.
Results
I. Quantitative analysis o f drug-induced changes in behavioral items
Since one of the animals did not respond to the L-DOPA treatment, this animal was excluded 
from the L-DOPA group. Surprisingly, this monkey showed very clear behavioral responses to 
SKF 82958 and, therefore, remained included in the SKF 82958,P group.
1a. Dyskinesia
Under saline conditions, dyskinesia was absent (Fig. 1A). In the L-DOPA responsive animals, 
L-DOPA firstly induced dyskinesia at day 4, 8, and 12, respectively (Table I). SKF 82958 
induced dyskinesia from day 1 in 2 (out of 4) of the drug-naive animals; in the other two drug- 
naive monkeys dyskinesia started at day 4 and 15. In this group, dyskinesia was highest at day 
8 reaching statistical significance. In the L-DOPA pre-treated animals, SKF 82958 re-induced 
dyskinesia in all L-DOPA-responsive animals and initiated dyskinesia in the L-DOPA- 
unresponsive animal at day 4. At day 1 and 8 dyskinesia was significantly different from saline. 
The effects of L-DOPA and SKF 82958 in drug naive animals were significantly different with 
time; whereas L-DOPA increased dyskinesia through the treatment period, in the SKF 82958,N 
group dyskinesia was maximal at day 8. In addition SKF 82958 exerted different effects with 
time in the drug-naive and pre-treated group; the amount of dyskinesia elicited with time in the 
pre-treated group was more constant.
1b. Dystonia
Dystonia was absent during saline treatments (Fig. 1B). All drug treatments induced dystonia 
from the first day on. Dystonia was significantly increased from saline at day 22 in the SKF 
82958,N group and at day 1, 8 and 15 in the SKF 82958,P group. There were no significant 
differences between the three treatments.
1cd. Goal-directed forelimb movements
Under saline conditions the duration of goal-directed forelimb movements was low in both 
limbs, although all monkeys preferred the left forelimb (Fig. 1CD). The duration ofleft forelimb
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movements was not affected by the drug treatments in any treatment group. L-DOPA greatly 
increased goal-directed movements of the right forelimb, which became significantly different 
from saline treatment at day 15 and 22. In contrast, none of the SKF 82958 treatments affected 
goal-directed movements of the right forelimb. The SKF 82958-induced effects with time differed 
significantly from those of the L-DOPA treatment.
Fig. 1. Effects of daily intramuscular injection of L-DOPA (10.0 mg/kg) in drug-naive animals and SKF 
82958 (1.0 mg/kg) in pre-treated and drug-naive animals, on dyskinesia (Fig. 1A), dystonia (Fig. 1B) left 
goal-directed forelimb movements (Fig. 1C) and right goal-directed forelimb movements (Fig. 1D). Saline 
treatments: values show the mean duration + S.E.M calculated in percent of 60 min of two control 
experiments per animal. These control experiments were performed two days before and after the drug 
treatment period. Drug treatments: values express the mean duration + S.E.M. calculated in percent of 60 
min, at day 1, 8, 15 and 22 of the drug treatment period. Fig. 1A. In the drug-naive groups, the effects of 
SKF 82958 and L-DOPA were significantly different in time:(1,5)=13,02, p<0.05. The SKF 82958,N 
and SKF 82958, P group were significantly different in time: F(1,6)=15,6, p<0.05, and time x treatment 
F(1,6)=17,46, p<0.05. Moreover, dyskinesia was significantly increased from saline in the SKF 82958,N 
group at day 8 (t(3)=3,12, *p<0.05, and in the SKF 82958,P group at day 1 t(3)=5,3 *p<0,05 and 8 
t(3)=2,83, *p<0,05: paired samples t-test. Fig. 1B. There were no significant different time or treatment 
effects between the groups. At day 22 dystonia was significantly different from saline treatment in the 
SKF 82958,N group t(3)=2,44 *p<0.05. Moreover, at day 1,8 and 15 the duration of dystonia in the SKF 
82958,P group was different from saline treatment; t(3)=3,11, t(3)=2,6 and t(3)=4,2, * p<0.05 : paired 
samples t-test.
Fig. 1C: no significant effects were seen in the duration of left goal-directed limb movements. Fig. 1D.
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The duration of goal-directed right forelimb movements was significantly higher in the L-DOPA as 
compared to the SKF 82958,N group; F(1,5)=10,64, p<0,05 for treatment and F(1,5)=7,1, p<0,05 time x 
treatment. Moreover, the duration of goal-directed limb movements in the L-DOPA group was different 
from saline treatment at day 15 t(3)=2,9, *p<0,05 and 22 t(3)=3,2, *p<0,05: paired samples t-test. In the 
SKF 82958 groups, goal-directed right limb movements were not increased.
2a. Body displacement
Under control conditions, all groups displayed similar amounts of body displacement (Fig. 
2A). In the SKF 82958,N group, body displacement was significantly increased from saline 
treatment at day 1 and day 8 and in both the SKF 82958,P and the L-DOPA group at day 1. 
There were no significant effects between the groups.
2b. Turning
Under saline conditions, turning was absent in the L-DOPA and SKF 82958,N group and 
low in the SKF 82958, P group (Fig. 2B). All drug treatments induced turning behavior, however, 
this did not reach statistical significance.
2c. Pivoting
Under saline conditions, pivoting was absent in the L-DOPA and SKF 82958,N group and 
very low in the SKF 82958,P group (Fig. 2C). L-DOPA induced a very low frequency of pivoting 
behavior throughout the course of the experiment, however, no significance was reached.
2d. Shuffling
Shuffling was not performed under saline treatment in any group (Fig. 2D). All drug 
treatments induced shuffling, although this did not become significant.
MOTOR PATTERNS
BODY DISPLACEMENT
15 22
Fig. 2. Effects of daily intramuscular injection of L-DOPA (10.0 mg/kg) on drug-naive animals and SKF 
82958 (1.0 mg/kg) on drug-naive and pre-treated animals, on body displacement (Fig. 2A), turning (Fig. 
2B), pivoting (Fig. 2C) and shuffling (Fig. 2D). Saline treatments: values express the mean + S.E.M 
calculated in percent per 60 min of two control experiments per animal. These control experiments were 
performed two days before and after the drug treatment period. Drug treatments: values express the mean
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duration + S.E.M. calculated in percent of 60 min, at day 1, 8, 15 and 22 of the drug treatment period. 
Fig. 2A. Body displacement was significantly increased as compared to saline in the SKF 82958,N group 
at day 1 t(3)=3,1 and 8 t(3)=3,3, *p<0,05 in the L-DOPA group at day 1 t(2)=4,3 and the SKF 82958,P 
group at days 1 t(3)=3,22, * p < 0.05: paired samples t-test. This behavior was not significantly increased 
in the other groups. Fig. 2BCD. No significant effects were observed with any treatment in turning, 
pivoting and shuffling.
3a. Epileptoid behavior
Under control conditions, none of the monkeys showed epileptoid behavior. Moreover, L- 
DOPA never induced epileptoid behavior. However, SKF 82958 induced epileptoid behavior 
in both the drug-naive (2 out of 4) and L-DOPA pre-treated group (3 out of 4, see Table I). The 
attacks induced by SKF 82958 consisted of a short period of extreme hyperactivity in which 
jumping, shuffling and running was displayed. This was followed by a longer period in which 
the animal lied down on the floor and was suffering from uncontrolled contractions and relaxation 
of facial, limb and trunk muscles. In some cases the attack ended with an atonic phase, during 
which the animal lied motionless on the floor.
Tabel 1.
Induction of undesired effects in drug-naive and pre-trcated monkeys by L-DOPA and 
SKF 82958
Monkey Dyskinesia 
at day:
epileptoid
behavior
L-DOPA, drug- #1 8 -
naive #2 12 -
#3 4 -
#4 - -
#5 1 +
SKF 82958, drug- 
naive #6 4 -
#7 15 -
#8 1 +
#1 1 +
SKF 82958, pre- #2 1 -
treated #3 1 +
#4 4 +
Discussion
General discussion
In the present study, a quantitative analysis was used to evaluate the therapeutic and undesired 
effects of the dopamine D1 receptor agonist SKF 82958 in pre-treated and drug-naive bilaterally 
MPTP-treated monkeys. Since the predictive validity of the MPTP-treated monkey as an animal
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model of Parkinson’s disease (PD) is uncertain (see Andringa et al., 1999b), we first discuss the 
validity of the model that is used in this study, namely the bilaterally MPTP-treated monkey, 
using L-DOPA as the gold standard.
The bilaterally MPTP-treated monkey as a model ofPD
Whereas unilateral MPTP treatment is commonly administered via the infusion of MPTP 
in the carotid artery, a bilateral lesion can be induced in many ways. We choose the method of 
Smith et al., (1993), since this method induces a stable syndrome while the animals remain fit 
and able to feed, groom etc. Moreover, the effects of intracarotid administration on dopamine 
levels are well known; doses of 2.5 and 1.25 mg MPTP decrease dopamine levels to 10 and 40 
% of control levels respectively (Gutman et al., 1990). Although aged monkeys have been 
claimed to be more sensitive to the MPTP treatment, one of our monkeys included in the L- 
DOPA and SKF 82958,P group, was relatively young. However, as in older monkeys, MPTP 
induced a clear bilateral syndrome in this animal, and the monkey showed responses similar to 
those of the older animals. Therefore we did not exclude this animal from the analysis.
L-DOPA increased motor behaviors that are classically used to evaluate drug effects in 
MPTP monkeys, namely body displacement, rotational behaviors and limb movements. More 
importantly, our detailed ethogram made clear that the L-DOPA-induced increase in motor 
behaviors consisted of functional movements; it greatly increased goal-directed forelimb 
movements, especially of the most affected limb. Moreover, after repeated administration of L- 
DOPA, undesired effects such as dyskinesia and dystonia developed and increased during the 
course of the experiment.
Thus, the behavioral effects of L-DOPA in the drug-naive bilaterally MPTP-treated monkey 
are comparable with the therapeutic and undesired effects of L-DOPA in patients with PD. 
Therefore, it is concluded that the bilaterally MPTP-treated monkey has predictive validity and 
is an adequate model to study the chronic behavioral effects of dopamine D1 receptor agonists 
for the treatment of PD.
Therapeutic and undesired effects o f the dopamine D1 agonist SKF 82958.
Our data show that SKF 82958, like L-DOPA, stimulated gross motor behaviors, such as 
body displacement and rotational behaviors. However, in contrast to L-DOPA, it did not restore 
goal-directed limb movements. Moreover, SKF 82958 initially induced severe dystonia and 
dyskinesia that were reduced after 8 days of chronic treatment, suggesting that behavioral 
desensitization occurred. Unlike L-DOPA, SKF 82958 induced epileptoid behavior. Indeed, 
dopamine D1 agonists, but not L- DOPA, have been found to induce this disabling behavior in 
dopamine depleted animals (Gnalalingham et al., 1995ab; Shiosaki et al., 1996). Importantly, 
SKF 82958 has been found to be the most potent dopamine D1 receptor agonist to reduce the 
threshold for chemically and electrically induced seizures in rats (Starr, Starr, 1993). In sum, 
SKF 82958 elicited severe undesired effects at a dose that did not induce therapeutic effects. 
Therefore, it is concluded that this dopamine D1 receptor agonist may not be suitable in the 
treatment of PD.
In one animal that showed no response to L-DOPA, however, the dopamine D1 agonist had 
very clear behavioral effects, including an increase in body displacement and goal-directed 
limb movements. Therefore, it remains to be established to what extent dopamine D1 agonists 
may prove to be useful in a sub-population of patients with PD, namely patients not responding 
to L-DOPA.
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Effects o f chronic treatment
L-DOPA and SKF 82958 had different behavioral effects in time. L-DOPA, but not SKF 
82958, induced a time-dependent increase in goal-directed forelimb movements, dystonia and 
dyskinesia. In the SKF 82958,N group, the duration of dyskinesia and dystonia and, to a lesser 
extent, limb movements, rapidly increased and, thereafter, decreased during chronic 
administration. The fact that the dopamine D1 receptor agonist and L-DOPA treatment had 
very different effects in time suggests that dopamine D1 receptor agonist- and L-DOPA-induced 
behavioral sensitization are mediated by different mechanisms; furthermore, it underlines the 
importance of studying the chronic effects of distinct dopaminergic treatments.
Effects o f L-DOPA pre-treatment on SKF 82958-induced behaviors
In general, the SKF 82958-induced effects on goal-directed forelimb movements, rotational 
behaviors and body displacement were comparable between the L-DOPA pre-treated and the 
drug-naive group. However, in the pre-treated animals, dyskinesia was less fluctuating; in the 
latter group SKF 82958 did not induce the high dyskinesia level at day 8, which was elicited in 
the naive monkeys. This is in line with the findings of Goulet et al who have reported that SKF 
82958 induces a higher dyskinesia score in drug-naive, as compared to L-DOPA-pre-treated 
monkeys (Goulet et al., 1996).
Our data also show that treatment of MPTP-treated monkeys with various dopaminergic 
drugs has major consequences; it alters the onset, duration and severity of drug-induced effects 
in such pre-treated monkeys a phenomenon that is also observed in parkinsonian patients. This 
suggests that pre-treated monkeys are considerably less suitable for predicting clinical efficacy 
in drug-naive patients than for predicting therapeutic effects and undesired effects of putative 
anti-parkinsonian drugs in chronically L-DOPA-treated patients.
General conclusion
Taken together, the bilaterally MPTP-treated rhesus monkeys was found to be a valid model 
to predict the clinical effects of pharmaco-therapies in patients with PD; chronic administration 
of L-DOPA improved MPTP-induced parkinsonian symptoms and, in addition, elicited undesired 
effects that are also seen in PD patients treated chronically with L-DOPA. Furthermore, the 
present study showed that the dopamine D1 agonist SKF 82958 did not restore MPTP-induced 
deficits at a dose that elicited severe undesired effects, namely dystonia, dyskinesia and epileptoid 
behaviors. It is suggested that SKF 82958 has less therapeutic potential than L-DOPA. 
Nevertheless, it cannot be excluded that it has some therapeutic effects in so-called non­
responders to L-DOPA, although, even in this case, it may be unsuitable because of its undesired 
effects.
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The alleged dopamine D1 agonist SKF S3959is a dopamine D1 receptor antagonist 
in primate cells and interacts with other catecholaminergic receptors.
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Abstract
So far, no clear correlation has been found between the effects of dopamine D1 receptor 
agonists on motor behavior in primate models of Parkinson’s disease and their ability to stimulate 
AC in rats, the benzazepine SKF 83959(3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]- 
2,3,4,5-tetrahydro-]H-3-benzazepine) being the most striking example. Since this discrepancy 
might be attributed to: A) the different species used to study these effects or B) the interaction 
of SKF 83959 with other catecholamine receptors, the aims of this study were: 1) to study the 
ability of SKF 83959 to stimulate adenylate cyclase in cultured human and monkey glial cells 
equipped with dopamine D1 receptors and 2) to evaluate the affinity for and the functional 
interaction of SKF 83959 with other catecholamine receptors. Binding studies revealed that 
SKF 83959 displayed the highest affinity for the dopamine D1 receptor (pKi= 6.72) and the a2 
adrenoceptor (pKi = 6.41) and moderate affinity for the dopamine D2 receptor and the 
noradrenaline transporter. In monkey and human cells, SKF 83959 did not stimulate cyclic 
adenosine mono-phosphate (cAMP) formation to a significant extent, but antagonized very 
potently the dopamine-induced stimulation of cAMP formation in both cell types. The compound 
stimulated basal dopamine outflow and inhibited depolarization-induced acetylcholine release 
only at concentrations > 10 ^M. Finally, SKF 83959 concentration dependently increased 
electrically evoked noradrenaline release, indicating that it had a2 adrenoceptor blocking activity 
and interfered with the noradrenaline transporter. In conclusion, SKF 83959 is a potent dopamine 
D1 receptor and a2 adrenoceptor antagonist. Thus, the antiparkinsonian effects of SKF 83959 
in primates are not mediated by striatal dopamine D1 receptors coupled to AC in a stimulatory 
way.
Introduction
Dopamine receptors were originally classified on the basis of their coupling to the AC 
second messenger system, with activation of dopamine D1-like and D2-like receptors having a 
stimulatory and inhibitory effect on cyclic adenosine mono-phosphate (cAMP) formation 
respectively (Kebabian and Calne, 1979; Stoof and Kebabian, 1981). Whereas dopamine D2 
receptor stimulating agents, such as bromocriptine and pergolide, have already found their way 
into the clinic to relieve motor symptoms in parkinsonian patients (Parker et al., 1976; Langtry, 
Clissold, 1990), the consequences of dopamine D1 receptor stimulation on parkinsonian 
symptoms are still under investigation, in particular in animal models of Parkinson’s disease.
In the prim ate model of Park inson’s disease, the 1-m ethyl-4-phenyl-1,2,3,6- 
tetrahydropyridine (MPTP)-treated monkey, the behavioral effects of compounds with high 
affinity for the dopamine D1 receptor have been evaluated (Kebabian et al., 1990; Gnanalingham 
et al., 1995a; Johnson et al., 1995; Goulet et al., 1996; Domino, 1997). Indeed, several of these 
compounds have been reported to partly restore motor behavior in parkinsonian monkeys. 
Intriguingly, there appears to be no clear relationship between their therapeutic efficacy on the 
one hand and their ability to stimulate cAMP formation on the other. Some of these so-called 
“dopamine D1 receptor agonists” exert anti-parkinsonian effects in monkeys but do not, or 
only mildly, stimulate the formation of cAMP in vitro (Andersen, Jansen, 1990; Izenwasser, 
Katz, 1993; Watts et al., 1993). This discrepancy is most clearly manifested by the benzazepine 
(3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3-benzazepine) SKF 
83959 (Deveney, Waddington, 1995; Gnanalingham et al., 1995c). Compared to other 
benzazepines, which do stimulate cAMP formation, SKF 83959 shows high therapeutic efficacy
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(Gnanalingham et al., 1995a; Andringa et al., 1998), however the compound does not increase 
cAMP formation in rat striatal tissue (Arnt et al., 1992; Gnanalingham et al., 1995c). These 
data strongly suggest that SKF 83959 and perhaps other so-called dopamine D1 receptor agonists 
do not use striatal D1 receptors coupled to cAMP to exert their behavioral effects in monkeys.
However, it cannot be excluded that methodological factors have played a role in the reported 
lack of correlation between cAMP formation and stimulation of motor behavior. Thus far, the 
intrinsic activity of most dopamine D1 receptor agonists, including SKF 83959, on cAMP 
formation has been studied in rat striatal tissue, whereas the therapeutic efficacy of these 
compounds has been studied in primate models. Various studies suggest that the intrinsic activity 
of dopamine receptor agonists differs between human, monkey and rat dopamine D1 receptors 
(Pifl et al., 1991; Izenwasser, Katz, 1993; Watts, 1993; Vermeulen et al., 1994). For instance, 
Vermeulen et al., (1994) reported that the ability of the dopamine D1 receptor agonists SKF 
38393 and SKF 81297 to stimulate dopamine D1 receptors differed between human, monkey 
and rat tissue. Thus, species differences may underlie the discrepancy between the cAMP 
formation measured in rat tissue and the behavioral responses observed in monkeys. 
Consequently, it cannot be excluded that SKF 83959 has a higher intrinsic activity at monkey 
dopamine D1 receptors than at rat dopamine D1 receptors. Therefore, the first aim of the present 
study was to examine the ability of SKF 83959 to stimulate cAMP formation in both monkey 
and human cells.
Another factor that might contribute to the lack of correlation between the intrinsic activity 
and therapeutic efficacy of drugs with affinity for the AC-coupled D1 receptor is the fact that 
most of the currently available dopamine D1 receptor agonists display high affinity, but only 
moderate selectivity, for the dopamine D1 receptor (Murray, Waddington, 1990; DeNinno et 
al., 1991). Many dopamine D1 receptor agonists are known to have additional affinities for 
other catecholamine receptors and/or transporters. For instance, CY 208-235 displays significant 
affinity for dopamine D2 and 5-HT receptors, whereas A 68930 has moderate affinity for 
noradrenaline and 5-HT receptor subtypes and dopamine transporters. Since the affinity for 
other catecholamine receptors and transporters might contribute to the therapeutic effects of 
SKF 83959, the second goal of our study was to investigate the affinity of SKF 83959 for these 
receptors and transporters and, more importantly, the effects of this compound on functional 
paradigms for these entities.
Materials and methods
Chemicals
SKF 83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3- 
benzazepine) was provided by Research Biochemicals International (Natick, USA). Tissue culture media 
and supplements were obtained from Gibco Netherlands BV (Breda, The Netherlands). 3-Isobutyl-1- 
methylxanthine was obtained from Aldrich (Brussels, Belgium). [125I]-iodosulpiride, [3H]adenine, 
[3H]choline, [3H]dopamine and [3H]noradrenaline were from Amersham (Little Chalfont, UK). 
[3H]nisoxetine, [3H]prazosin, [3H]rauwolscine, [3H]SCH-23390, [3H]WIN34528 and [125I]- 
iodocyanopindolol were obtained from New England Nuclear (Du Pont, Dreieich, Germany). All other 
chemicals were obtained from Sigma Chemical Co (St Louis, US).
Receptor binding assays
For details about assays and assay conditions, the reader is referred to Schotte et al., (1996) and 
Leysen et al., (1996). The investigated receptors, tissues or cell systems and radioactive ligands are listed 
in Table 1. Membrane preparations of the tissues or cells were incubated in a volume of 0.5 ml with a low 
nanomolar concentration of the radioactive ligand in the absence (for total binding) or presence of SKF-
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83959 for inhibition of radioactive ligand binding. SKF 83959 was first screened at 0.1, 1 and 10 pM. 
Where activity was observed inhibition curves were prepared over the concentration range of 0.01 to 10 
pM, using 8 concentration points. After incubation, the membranes with bound radioactivity were collected 
on glass fiber filters by filtration under suction, using semi-automated filtration devices. The radioactivity 
on the filters was counted in a liquid scintillation or gamma spectrophotometer and counts were directly 
transferred to a personal computer. Data are expressed as percentages of total binding. Inhibition curves, 
plotting the percent total binding versus log concentration of SKF 83595, were generated automatically. 
The sigmoidal inhibition curves were analyzed by computerized curve fitting, using non-linear regression 
analysis (modification of equations described by Oestreicher and Pinto, 1987). The pIC50 values (-log 
IC50 = - log of the concentration inhibiting 50 % of the specific radioligand binding or neurotransmitter 
uptake) were derived from individual curves. Ki-values were calculated according to the Cheng-Prusoff 
equation: K=IC50/[1+[C]/KD], where Ki is the equilibrium inhibition constant of the investigated 
compound, [C] the concentration and KD the equilibrium dissociation constant of the labeled ligand 
(Cheng, Prusoff, 1973). Inhibition curves were determined in two completely independent experiments.
Culture of human and monkey glial cells
For this study established cell cultures were used. To study the human dopamine D1 receptor, a 
human glioma cell line D384, which was derived post mortem from frontal cortex/subcortical white 
matter, was used. The monkey dopamine D1 receptor was studied using a striatal astrocyte primary culture 
that was isolated from the brain of a rhesus monkey (Macaca Mulatta). Cultures of astrocytes were 
prepared as described previously (Vermeulen et al., 1994).
The cells were grown as monolayer cultures in culture medium consisting of Dulbecco’s Modified 
Eagle’s Medium and F-10 nutrient (1:1), 10% fetal calf serum, 2 mM L-glutamine, non-essential amino 
acids, penicillin (100 IU/ml), and streptomycin (50 pg/ml). They were plated into poly-L-lysine-coated 
culture flasks. After 2-3 weeks in culture (37 o C, 5% CO2), the cells were trypsinized and subcultured in 
12-well dishes (5x104 cells per well).
Adenylate cyclase activity
Experiments were performed with 7-day-old confluent cultures. AC activity was determined by 
measuring the conversion of [3H]ATP into [3H]cAMP. Briefly, the cell cultures were washed with phosphate 
buffer saline (PBS) and exposed for 10 min to a PBS solution containing 10 pCi [3H]adenine, 1 mM 3- 
isobutyl-1-methylxanthine (IBMX), 1 pM propanolol and the dopaminergic drugs (10 pM dopamine, 
SKF 83959 in the concentration range of 0.01-30 pM, or a combination). The reaction was stopped by 
the addition of 1 ml ice-cold trichloroacetic acid (5%) containing 1 mM of non-tritiated ATP and cAMP. 
The [3H]cAMP formed was separated from [3H]ATP by sequential chromotography on Dowex and Alumina 
columns and measured by liquid scintillation counting.
The activity of AC was determined by dividing the amount of [3H]cAMP by the sum of the amounts 
of [3H]ATP and [3H]cAMP Finally, the effects of SKF 83959 on AC activity and the effects of SKF 
83959 on dopamine-stimulated AC activity were calculated as percentages of the maximal dopamine- 
induced stimulation ofAC activity, in order to compare the intrinsic activity of SKF 83959 with dopamine.
In vitro acetylcholine, dopamine and noradrenaline release
Male Wistar rats weighing 180-220 g were killed by decapitation. The brains were removed and the 
striatum (for the measurement of acetylcholine and dopamine release) or frontal cortex (for the measurement 
of noradrenaline release) was dissected. The dissected tissue was cut in to slices of 300 pm with a 
McIlwain tissue chopper. The slices were washed and incubated with radiolabeled choline, dopamine or 
noradrenaline (5 pCi [3H]choline/2ml, 5 pCi [3H]dopamine/2ml and 5 pCi [3H]noradenaline/2ml) in a 
Krebs-Ringer bicarbonate medium containing (in mM): NaCl 121, KCl 1.87, KH2PO4 1.17, MgSO4 
1.17, NaHCO3 25, CaCl2 1.2 and D(+) glucose 10. The medium was kept under a constant atmosphere of 
95% O2, 5% CO2 at a temperature of 37° C. After a 15-min incubation period, the slices were washed and 
aliquots (approximately 5 mg of tissue) were transferred to each of the chambers of a 24-chamber 
superfusion apparatus. Three to four chambers were used for each experimental condition and each
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condition was repeated in at least three separate experiments. The chamber volume was 0.2 ml and the 
superfusion rate was 0.20 ml/min. After 40 min, four 10-min fractions were collected. The first fraction 
(t=40-50 min) was used to determine the basal efflux of radioactivity. With respect to the basal dopamine 
outflow, in total five fractions were collected. The drugs were added just before the collection of the third 
fraction, (t=60) and were present until the end of the experiment. With respect to the electrically evoked 
acetylcholine and noradrenaline release, in total seven fractions were collected. During collection of the 
second (50-60) and fifth (80-90) fractions release was stimulated electrically by exposing the tissue for 
10 min ([3H]acetylcholine) and 5 min ([3H]noradrenaline) to biphasic square wave pulses (1 Hz, 24 mA). 
The drugs were added to the medium 10 min before the second stimulation, (t=70) and were present until 
the end of the experiment. At the end of the experiment the remaining radioactivity was extracted from 
the tissue. The amount of radioactivity (dpm) present in the collected fractions and tissue extracts was 
estimated by liquid scintillation counting. For additional information concerning tissue preparation and 
experimental procedures see Stoof and Kebabian (1982).
The radioactivity present in each superfusion chamber was expressed as the fractional rate, in order 
to correct for small differences in the amount of tissue present in each chamber. The fractional rate is 
defined as the amount of radioactivity present in a certain fraction divided by the sum of the amount of 
radioactivity present in that particular fraction, the subsequent fractions and the extract. The basal outflow 
of dopamine was calculated as the mean of fractions 4 and 5. With respect to electrically stimulated 
acetylcholine and noradrenaline release the amount of radioactivity released as a consequence of electrical 
stimulation was calculated by correcting the amount of radioactivity released in the stimulated fractions 
for basal release (through subtraction). The majority of stimulation-induced release occurred in fractions 
2 (stimulation 1) and 5 (stimulation 2). Therefore, basal release was calculated as the mean of the fractions
1, 3 and 4 for stimulation 1, and 4, 6 and 7 for stimulation 2. The effects of all drugs were expressed as a 
percentage of release under control conditions. For further details see Stoof and Kebabian, (1982).
Statistics
The cAMP data were subjected to a one-sample t-test. With respect to the release data, a one-way 
analysis of variance (ANOVA) was used, followed by a post hoc Bonferroni where appropriate. The 
accepted level of significance was p < 0.05.
Results
Receptor affinity
As depicted in Table 1, the benzazepine SKF 83959 displayed the highest affinity (pKi= 
6.72) for the dopamine D1 receptor but also had considerable affinity (pKi respectively 6.41 
and 6.33) for the a2B and a2C adrenoceptor subtypes.
Moderate affinity was observed for the dopamine D2 and D3 receptors (pKi = 5.2 and 5.74, 
respectively). Finally, moderate affinity (pKi = 5.46) could be observed for the noradrenergic 
transporter.
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Table 1. Receptor binding profile of SKF 83959
Receptor Radioactive ligand Tissue Binding affinity 
pKi
Adrenergic ocl [3H]prazosin Rat total cortex 5.1
Adrenergic a lA [3H]prazosin cloned human la  CHO cells 5,63
Adrenergic a2 [3H]rauwolscine Rat cortex 6.13
Adrenergic a2A [3H]rauwoIscine Cloned human 2A CHO cells 6.08
Adrenergic a2B [3H]rauwolscine Cloned human 2B CHO cells 6.41
Adrenergic a2C [3H]rauwolscine Cloned human 2C CHO cells 6.33
Adrenergic-al [l35I]-iodocyanopindolol Human cqcloned CHO cells < 5
Adrenergic-a2 [i:sI]-iodocyanopindolol Human a2 cloned CHO cells < 5
Adrenergic-ot3 [li3I]-iodocyanopindolol Human a ,  cloned CHO cells < 5
Dopamine D1 [sH]SCH23390 Rat striatum 6,72
Dopamine D2 [sH]spipcrone Cloned human D2 CHO celts 5.2
Dopamine D3 [1!!l]-iodosulpiride Cloned human D3-CHO cells 5.74
Dopamine-D4 [!H]spiperone cloned human D4-2 CHO cells < 5
Dopamine [JH]WIN35428
transporter
Noradrenaline [3H]nisoxetine 
transporter
rat stnatum
rat cortex
< 5
5.46
Table 1 : Values represent the binding affinity (pKi) for subtypes of dopaminergic and noradrenergic 
receptors and transporters
Adenylate cyclase activity
Dopamine, over the concentration range 0.01 to 30 ^M, stimulated the formation of 
[3H]cAMP in monkey astrocytes, with the maximal effect occurring at 10 ^M (data not shown). 
This amounted to a mean ± S.E.M. of 744 ± 48 % of control. SKF83959, in the range 0.01 to 10 
^M, did not stimulate AC activity (Table 2). On the contrary, SKF 83959 concentration 
dependently antagonized (IC50 = between 0.01 and 0.1 ^M) AC activity induced by 10 ^M 
dopamine (Fig. 1A).
In human glial cells, dopamine stimulated the formation of [3H]cAMP maximally at 10 ^M 
to a mean ± S.E.M. of 870 ± 60 % of control (data not shown). SKF 83959, in a concentration 
of 0.01 ^M, did not significantly stimulate AC activity but in the range 0.1 to 10 ^M marginally 
increased cAMP formation (Table 2). Also in this preparation, SKF 83959, in the range 0.01 to 
10 ^M, concentration dependently antagonized (IC50 = approximately 0.1 ^M) AC activity 
induced by 10 ^M dopamine (Fig. 1B).
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Drug concentration cAMP production 
stimulation)
(expressed as % of dopamine-induced
Monkey glial cells Human glial cells
Dopamine 10 pM 100 ±3.4 100 ±2.8
SKF 83959 0.01 nM 2.3 ± 2.3 3.4 ±4.1
SKF 83959 O.luM 6.3 ± 2.9 7.6 ± 1.3*
SKF 83959 1 pM 4.4 ± 3.5 7.7 ± 2.3*
SKF 83959 10 nM 0.1 ± 1.4 9.2 ± 1.8*
Table 2. Effects of dopamine and SKF 83959 on cAMP formation in human and monkey glial cells. The 
effects of the different concentrations of SKF 83959 on AC activity are expressed as percentages of the 
10 pM dopamine-induced stimulation of cAMP formation. The activity ofAC was determined by dividing 
the amount of [3H]cAMP by the sum of the amounts of [3H]ATP and [3H]cAMP. Data are presented as 
means ± S.E.M. from 9-12 observations obtained in 3-4 independent experiments. In monkey astrocytes 
the 10 pM dopamine-stimulated and control AC activity (i.e. the percentage of ATP converted into 
cAMP) amounted to 0.46 ± 0.01 % and 0.06 ± 0.003 % respectively. In the human glial cells the 10 pM 
dopamine-stimulated and control AC activity amounted to 0.87 ± 0.03 % and 0.05 ± 0.002 % respectively.
Fig. 1AB. Effects of SKF 83959 on dopamine-induced cAMP formation in monkey (Fig. 1A) and human 
(Fig. 1B) cells in culture. The activity of AC was determined by dividing the amount of [3H]cAMP by the 
sum of the amount of [3H]ATP and [3H]cAMP. The effects of SKF 83959 on dopamine stimulated AC 
activity are expressed as percentages of the 10 pM dopamine-induced stimulation of cAMP formation. 
Data are represented as means ± S.E.M. from 9-12 observations obtained in 3-4 independent experiments. 
SKF 83959 strongly inhibited dopamine-induced cAMP formation, both in human and monkey cells. 
Monkey astrocytes: F(7,49)=35.0, p< 0.01: *p<0.01 SKF 83959 (0.1- 10 pM) vs. dopamine (10 pM), 
post hoc Bonferroni.Human cells: F(4,44)=76.7, p< 0.01: *p<0.01 SKF 83959 (0.1- 10 pM) vs. 
dopamine(10 pM), post hoc Bonferroni.
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In vitro electrically evoked acetylcholine release
As shown in Figure 2, the dopamine D2 agonist LY 171555, in a concentration of 1 pM, 
strongly and significantly reduced electrically evoked [3H]acetylcholine release to 10 ± 2 % of 
the control ratio. SKF 83959, in a concentration of 1 and 3 pM, had no effect on [3H]acetyl- 
choline release. However, 10 pM of SKF 83959 significantly inhibited electrically evoked 
[3H]acetylcholine release to 70 ± 5 % of the control ratio.
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Fig. 2. Effects of SKF 83959 on electrically evoked acetylcholine release from rat striatal tissue. The 
amount of radioactivity released as a consequence of electrical stimulation was calculated by subtracting 
the amount of radioactivity released under basal conditions from the amount of radioactivity released 
under stimulated conditions. Ratios were calculated, whereby the amount of radioactivity released upon 
the second electrical stimulation was divided by the amount of radioactivity released upon the first 
stimulation. Under control conditions, this ratio of [3H]acetylcholine release amounted to 0.80 ± 0.05. 
Ratios in the presence of drugs are expressed as percentages of the control ratio and depicted as such in 
the Figure. Data represent means ± S.E.M. from 9-12 observations obtained in 3-4 individual experiments. 
* p <0.05: SKF 83959 (10 pM) vs. control; # p <0.05: LY 171555 vs. SKF 83959 (10 pM); * p <0.01: LY 
171555 vs. control; post hoc Bonferroni.
In vitro basal dopamine outflow
SKF 83959 in a concentration of 0.25 and 1.25 pM, had no effect on the basal outflow of 
dopamine, whereas at 6.25 and 31.25 pM, SKF 83959 significantly increased basal dopamine 
outflow to 146 ± 4 and 329 ± 30 % of the control ratio respectively (see Fig. 3).
Electrically evoked acetylcholine release from rat 
striatal tissue
0 1 3 10 LY 171555
concentration SKF' 83959 (uM)
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Fig. 3. Effects of SKF 83959 on basal dopamine outflow from rat striatal tissue. The data are expressed 
as percentages of transmitter outflow under control conditions, i.e. outflow in the absence of drugs. Data 
represent means ± S.E.M. from 9-12 observations obtained in 3-4 individual experiments. F(6,65)= 
61.07, p <0.01 and * p <0.01: SKF 83959 (6,25 and 31.25 pM) vs. control; post hoc Bonferroni.
In vitro electrically stimulated noradrenaline release
SKF 83959, concentration dependently increased electrically evoked noradrenaline release 
(range 0.1 - 10 pM) to 391 ± 56 % of the control ratio (see Fig. 4). The a 2- adrenoceptor 
antagonist phentolamine , in a supramaximal concentration of 3 pM, increased noradrenaline 
release to 195 ± 7 % of the control ratio.
fig.4
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Fig. 4. Effects of SKF 83959 on electrically evoked noradrenaline release from rat cortical tissue. The 
amount of radioactivity released as a consequence of electrical stimulation was calculated by subtracting 
the amount of radioactivity released under basal conditions from the amount of radioactivity released 
under stimulated conditions. Ratios were calculated, whereby the amount of radioactivity released upon 
the second electrical stimulation was divided by the amount of radioactivity released upon the first 
stimulation. Under control conditions, this ratio of [3H]noradrenaline release amounted to 0.90 ± 0.03. 
Ratios in the presence of drugs are expressed as percentages of the control ratio and depicted as such in 
the Figure. Data represent means ± S.E.M. from 9-12 observations obtained in 3-4 individual experiments. 
F(9,81)=23.2, p<0.01: *p <0.01: SKF 83959 (0.1-10 pM) vs. control; post hoc Bonferroni. Phentolamine 
significantly increased noradrenaline release. # p <0.01: Phentolamine vs. control; post hoc Bonferroni.
Discussion
General discussion
Since the majority of dopamine D1 receptors in the striatum are coupled to the AC second 
messenger system (Battaglia et al., 1986), dopamine and dopamine agonists were thought to 
exert their action via this second messenger system (Stoof, Kebabian, 1984). However, with 
respect to the anti-parkinsonian effects of dopamine D1 receptor agonists, the incongruity 
between the behavioral effects and the in vitro effects of SKF 83959 suggests that this assumption 
is not always correct.
The lack of correlation between the stimulation of cAMP by dopamine D1 receptor agonists 
and their effects on motor behavior in animal models of Parkinson’s disease can be attributed to 
several factors. In the present study we investigated whether or not this disparity is due to a 
higher intrinsic activity of SKF 83959 at primate dopamine D1 receptors than at rat dopamine 
D1 receptors. Moreover, the functional interaction of SKF 83959 with other catecholamine 
receptors was investigated.
Intrinsic activity o f SKF 83959 at primate dopamine D1 receptors
Our data show that, as in rat striatal tissue, SKF 83959 was not able to increase cAMP 
formation significantly in monkey striatal cells and only weakly increased cAMP formation in 
human cells. Thus, in contrast to other dopamine D1 receptor agonists, no large species 
differences appear to exist in the effects of SKF 83959 on cAMP formation. Moreover, SKF 
83959 was very potent as a dopamine D1 antagonist in these cells. At this moment, it remains 
uncertain whether the blockade of striatal D1 receptors coupled to cAMP can stimulate motor 
behavior in MPTP-treated primates. However, this is not very likely given the fact that the 
dopamine D1 antagonist SCH 23390 blocks the behavioral effects of SKF 83959 (Gnanalingham 
et al., 1995b). Nevertheless, these data support the view that the behavioral effects of SKF 
83959 in monkeys are not mediated via dopamine D1 receptors coupled to cAMP in a stimulatory 
way. However, before drawing this conclusion, one should realize that the effects of SKF 83959 
on motor behavior are more pronounced in dopamine-depleted animals than to intact animals. 
Whereas SKF 83959 strongly increases locomotor behavior in MPTP-treated monkeys 
(Gnanalingham et al., 1995a; Andringa et al., 1998) and 6-OHDA rats (Gnanalingham et al., 
1995ac), it does not in intact animals (Downes, Waddington, 1993). This phenomenon has 
been attributed to the fact that the MPTP and 6-OHDA-induced decrease in synaptic dopamine 
levels changes the interaction between dopamine D1 receptor agonists and D1 receptors. Both 
dopamine and several dopamine D1 receptor agonists have an increased intrinsic activity at the 
dopamine D1 receptor coupled to AC after dopamine depletion (Mishra et al., 1980; Pifl et al., 
1992 Pinna et al., 1997). However, with respect to SKF 83959, this appears not to be the case
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because SKF 83959 does not significantly increase cAMP formation in dopamine-depleted 
tissue (Gnanalingham et al., 1995c). Therefore, even when synaptic dopamine levels are low, it 
is unlikely that the therapeutic effect induced by this drug is mediated via striatal dopamine D1 
receptors coupled to AC in a stimulatory way.
A different type of interaction between SKF 83959 and the dopamine D1 receptor might 
play a role in the induction of motor behavior in MPTP-treated animals. SKF 83959 may 
interact with dopamine D1 receptors coupled to second messenger systems other than cAMP. 
Phosphoinositide hydrolysis, resulting in the formation of diacylglycerol and inositol triphos­
phate (IP 3), is mediated through a site that is sensitive to dopamine D1 receptor agonists and 
antagonists (Undie, Friedman 1990, 1992). The ability of dopamine D1 receptor agonists to 
stimulate this site varies, and significant disparities have been demonstrated between the potency 
of drugs to stimulate cAMP and IP formation (Undie et al., 1994). Therefore, it cannot be 
excluded that SKF 83959, while having virtually no intrinsic activity on cAMP-coupled 
dopamine D1 receptors, significantly stimulates IP hydrolysis. However, it remains to be 
established how potent SKF 83959 is in this respect and how relevant IP3 stimulation is for the 
induction of behavioral effects.
Functional interaction o f SKF 83959 with other catecholamine receptors
Since the majority of currently available dopamine D1 receptor agonists have additional 
affinity for other catecholamine receptors, we decided to study the functional interaction of 
SKF 83959 with other catecholamine receptors and transporters, an interaction, which may be 
involved in the behavioral effects of SKF 83959. From our binding studies it became apparent 
that the compound displays significant affinity for the a2 adrenoceptor, the dopamine D2 receptor 
and the noradrenaline transporter. Functional paradigms used to investigate whether a compound 
behaves as an agonist or antagonist at a2 adrenoceptors or dopamine D2 receptors are electrically 
stimulated noradrenaline (from brain cortex) and acetylcholine (from striatum) release, 
respectively. Additionally, study of the effects of a compound on dopamine and noradrenaline 
release may provide insight into re-uptake inhibiting and/or release stimulating effects mediated 
by the catecholamine transporters.
SKF 83959 mildly stimulated dopamine outflow from rat striatal tissue only at high 
concentrations. Moreover, only at high concentrations, SKF 83959 reduced acetylcholine release 
in rat striatal tissue, an effect that is mediated by dopamine D2 receptor stimulation (Stoof, 
Kebabian, 1982). As anticipated, the selective dopamine D2 agonist LY 171555 almost 
completely inhibited the release of acetylcholine at a concentration of 1 pM . Since the affinity 
of SKF 83959 for the dopamine D2 receptor is relatively low (receptor binding experiments of 
the present study: pKi= 5.2) and the compound releases dopamine, it is suggested that the 
decrease in acetylcholine release induced by higher concentrations of SKF 83959 is mediated 
by its dopamine releasing effect.
Although dopamine D2 receptor stimulation relieves motor symptoms in MPTP-treated 
monkeys, it is unlikely that the modest dopamine outflow is completely responsible for the 
therapeutic effects of SKF 83959, for the following reason, namely SKF 83959 is able to stimulate 
motor behavior in low dosages (0.1 mg/kg) whereas the effects on dopamine and acetylcholine 
release are only induced in the high micromolar range. Taken together, it is unlikely that the 
dopamine-releasing effect of SKF 83959 is responsible for the therapeutic effects induced by 
SKF 83959.
As observed in our binding studies, SKF 83959 had high and moderate affinity for the a2 
adrenoceptors and the noradrenergic transporter respectively. In accord with these data are our
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findings, which show that, in rat cortical areas, SKF 83959 increased noradrenaline release. 
Apparently, two actions of the compound are responsible for this phenomenon. Firstly, the 
increased noradrenaline release may be induced by blockade of presynaptically located a2 
adrenoceptors. This hypothesis is strengthened by the observation that the a2 receptor antagonist 
phentolamine, in a supramaximal concentration of 3 pM, increased noradrenaline release to 
approximately 200% of control. As has been demonstrated previously in our laboratory (Wemer 
et al., 1979) noradrenaline, under the presented stimulation conditions, inhibits its own release. 
This inhibition is abolished by phentolamine. However SKF 83959, in concentrations of 3 and 
10 pM, induced a much higher noradrenaline than did phentolamine (Fig. 4) and, moreover, 
the release was not completely blocked by the a2 adrenoceptor agonist oxymetazoline (data not 
shown). These data strongly suggest that the interaction of SKF 83959 with a2 adrenoceptors 
is, at least not completely, responsible for the high noradrenaline release. Since SKF 83959 
also has micromolar affinity for the noradrenergic transporter, it is suggested that the additional 
increase in noradrenaline release is due to the interaction of SKF 83959 with the noradrenergic 
transporter.
The effects of noradrenergic stimulation on motor behavior in animal models of Parkinson’s 
disease have been studied because in Parkinson’s disease there is degeneration not only of 
dopaminergic neurons, but also of noradrenergic neurons, especially in the locus coeruleus and 
cortical areas (Fahn et al., 1971; Alvord et al., 1974). However, the noradrenergic system 
appears to have only a subtle, modulating role in the control of locomotor behavior (Dickinson 
et al., 1988). In reserpine-treated animals, it appears that, besides dopaminergic stimulation, 
noradrenergic stimulation is required to give a full restoration of motor behavior (Anden et al., 
1973; Dolphin et al., 1976). Moreover a2 antagonists and a1 agonists have been reported in 
some studies to potentiate dopamine receptor agonist-induced motor behavior in these 
monoamine-depleted rodents (Pichler, Pifl, 1989; Starr, Starr, 1994). A few studies suggest a 
role for noradrenergic agents in diminishing motor symptoms in other animal models for 
Parkinson’s disease. For instance, in the unilaterally 6-OHDA-treated rat, an increase and 
decrease of noradrenergic tone via a 1 and a2 adrenoceptor stimulation is claimed to facilitate 
and inhibit amphetamine-induced rotation respectively (Madrivis et al., 1991). One study reports 
a therapeutic effect of the a2 antagonist R 62 561 in one monkey treated with MPTP (Colpaert 
et al., 1991). Thus, although the evidence for anti-parkinsonian effects of a2 adrenoceptor 
antagonists is not very strong, it cannot be completely ruled out that the a2 adrenoceptor 
antagonistic effect of SKF 83959 plays a role in the anti-parkinsonian effect of SKF 83959.
General conclusion
It is concluded that the reported anti-parkinsonian effects of SKF 83959 are unlikely to be 
mediated by striatal dopamine D1 receptors coupled to AC in a stimulatory way, especially 
since the compound behaves as a potent antagonist of this receptor subtype. Moreover, SKF 
83959 interacts with other catecholamine receptors, stimulating the release of noradrenaline 
and to a lesser extent dopamine.
Whether blockade of the AC-coupled dopamine D1 receptor or blockade of a dopamine 
D1-like receptor linked to a different transduction mechanism is involved in the anti-parkin­
sonian effects of SKF 83959 or whether these effects are mediated via other catecholamine 
receptors requires further study.
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Abstract
SKF 83959 acts as a dopamine D1 antagonist in virobut has been claimed to induce anti­
parkinsonian effects after acute administration in MPTP-treated marmosets. The aim of the 
present study was to evaluate the therapeutic and undesired effects of sub-chronic administration 
of SKF 83959 in bilaterally MPTP-treated rhesus monkeys and to compare these effects with 
the effects of L-DOPA and the dopamine receptor agonist SKF 82958. MPTP was given in the 
left carotid artery (2.5 mg) and, 6 weeks later, the right carotid artery (1.25 mg). The monkeys 
(n = 4) had previously been treated chronically with L-DOPA (22 days, 10 mg/kg) and SKF 
82958 (22 days, 1 mg/kg). 3 Months after the last administration of SKF 82958, SKF 83959 
was given in a dose of 0.5 mg/kg from day 1 to day 15 and in a dose of 1.0 mg/kg from day 16 
to day 18. SKF 83959 increased goal-directed limb movements in all animals, including the 
animal unresponsive to L-DOPA. This therapeutic effect did not diminish during the treatment. 
With respect to body displacement and undesired effects, a large variation in the response to 
SKF 83959 was found: a large increase in body displacement co-occurred with oro-facial 
dyskinesia (n=2), whereas a small increase in body displacement co-occurred with dystonia 
(n=2). In contrast to the undesired effects of L-DOPA, the dyskinetic effects of SKF 83959 
were primarily limited to the first treatment day. Unlike L-DOPA and SKF 82958, SKF 83959 
did not induce epileptoid behavior. In conclusion, sub-chronic administration of SKF 83959 
induced both clear-cut therapeutic effects that remained stable in time, and a limited number of 
dyskinetic effects that wore off during the treatment. The dopamine D1 antagonist SKF 83959 
may be considered as an alternative treatment in Parkinson’s disease, especially in those patients 
that do not respond to L-DOPA.
Introduction
Patients suffering from Parkinson’s disease (PD) experience a satisfactory response to L- 
DOPA for the first few years. Thereafter, the majority eventually develops motor response 
complications such as dyskinesia, on-off fluctuations and wearing off effects (Marsden, Parkes, 
1976; Chase et al., 1993; Nutt, 1994).
L-DOPA is converted into dopamine that stimulates both dopamine D1-like and dopamine 
D2-like receptors. Stimulation of the dopamine D1 receptor subtype activates adenylate cyclase 
(AC) that converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), 
whereas stimulation of the dopamine D2 receptor subtype inhibits AC (Stoof, Kebabian, 1981). 
Unlike dopamine D2 receptor agonists, dopamine D1 receptor agonists are not widely applied 
in the clinic. The putative anti-parkinsonian effects of dopamine D1 agonists are still under 
investigation in the primate model for PD that has been developed in the eighties (Langston et 
al., 1984b), the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkey (Burns 
et al., 1983). In the MPTP model, compounds with affinity for the dopamine D1 receptor vary 
in their efficacy to stimulate motor behavior (DeNinno et al., 1991; Watts et al., 1993; 
Gnanalingham et al., 1995; Johnson et al., 1995; Shiosaki et al., 1996).
Interestingly, some compounds stimulate motor behavior in MPTP-treated monkeys but do 
not act as full receptor agonists at the dopamine D1 receptor coupled to the AC (Andersen, 
Jansen, 1990; Izenwasser, Katz, 1993). In fact, the anti-parkinsonian effect of compounds with 
affinity for the dopamine D1 receptor does not correlate with their ability to stimulate cAMP 
formation via AC (Deveney, Waddington, 1995; Gnanalingham et al., 1995). In this respect, 
the most striking example is the benzazepine SKF 83959. This compound does not stimulate
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cAMP formation in striatal tissue of the rat (Arnt et al., 1992) or the monkey (Arnt et al., 
1992). In contrast, SKF 83959 strongly inhibits the dopamine-induced stimulation of AC, which 
shows that it acts, among others, as a dopamine D1 antagonist at dopamine D1 receptors coupled 
to AC (Arnt et al., 1992; Andringa et al., 1999a). Nevertheless, it has been reported that SKF 
83959 is one of the most effective benzazepines in reducing parkinsonian symptoms in MPTP- 
treated marmosets (Gnanalingham et al., 1995). Thus, these data lead to the contradictory 
prediction that the dopamine D1 antagonist SKF 83959 may be a good candidate for the treatment 
of Parkinson’s disease in man.
However, the above-mentioned anti-parkinsonian effect of SKF 83959 is solely based on 
the outcome of a single study, in which just the acute effects of this compound have been 
investigated (Gnanalingham et al., 1995). Because most dopaminergic drugs develop motor 
response complications, especially after long term treatment (Langston, Ballard, 1984a), it 
becomes important to investigate the sub-chronic effects of SKF 83959.
Therefore, the effects of the sub-chronic administration of SKF 83959 were investigated in 
a primate model with a good predictive validity for the pharmaco-therapy of PD, the bilaterally 
MPTP-treated rhesus monkey (Smith et al., 1993). Thereby, the recently developed and validated 
behavioral ethogram that allows a clear-cut distinction between therapeutic and undesired effects 
of drugs (Andringa et al., 1999b) was assessed. Since the monkeys were pre-treated chronically 
with L-DOPA respectively the dopamine D1 agonist SKF 82958 under identical experimental 
conditions, the effects of SKF 83959 could be compared with those of L-DOPA and SKF 
82958 in the same individual. An additional advantage of this paradigm is the fact that the 
clinical efficacy of new treatments is generally evaluated in patients in whom chronic treatment 
with L-DOPA or dopaminergic receptor agonists is no longer effective.
Materials and methods
Animals
The study was carried out in accordance with the “principles of laboratory care” (NIH publication 
No. 85-23, revised 1985) and institutional guidelines. 4 Male rhesus monkeys (Macaca Mulatta) over 
age of 7 years and weighing between 4 and 12 kg., were used in this study. The animals were individually 
housed in cages (90*180*200 cm), equipped with a climbing bar, toys and a “squeeze cage” (60*60*70). 
They were given lab chow at 9.00 h and 1600 h and fruit at 15.50 h; water was available ad libitum. The 
room temperature was kept at 22° C and a light-dark cycle was maintained (light on 7.00 a.m. -  7.00 
p.m>
MPTP treatment
Prior to the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-hydrochloride (MPTP-HCl Research 
Biochemi-cals Incorporated, Natick, USA) treatment, the dominant limb was selected as described earlier 
(Andringa et al., 1999b). The method of Smith et al., (1993) was used to make a bilateral MPTP lesion. 
A dose of 2.5 mg MPTP was given in the carotid artery contralateral to the dominant limb. After a period 
of at least 6 weeks a second dose of 1.25 mg MPTP was infused in the other carotid artery (for detailed 
procedure: Smith et al., 1993). This second dose was lower in order to prevent a severe incapacitation or, 
even, the death of animals. 2 Animals were included in a SPECT study, which revealed that striatal 
accumulation of the dopamine transporter ligand FP-CIT was significantly reduced in these animals, 
indicating that the chosen MPTP-treatment procedure was effective (Booij et al., 1997).
Administration of L-DOPA, SKF 82958 and SKF 83959
The animals were firstly treated with L-DOPA (L-3,4,-dihdroxyphenylalanine methyl ester, Sigma:
10.0 mg/kg) and benserazide-HCl (Sigma: 2.5 mg/kg) for 22 consecutive days and, subsequently, with
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the dopamine D1 agonist SKF 82958 (2,3,4,5,-tetrahydro-6-chloro-7,8-dihydroxy-1-phenyl-1H-3- 
benzazepine hydrobromide, Research Biochemical International, Natick, USA: 1.0 mg/kg) for 22 
consecutive days (for details: Andringa et al., 1999c). Thereafter, the monkeys received SKF 83959 (3- 
methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3-benzazepine Research 
Biochemical International, Natick, USA) in a dose of 0.5 mg/kg from day 1 to day 15 and in a dose of 1.0 
mg/kg from day 16 to day 18. The interval between the administration of L-DOPA and SKF 82958 was
2 months and that between SKF 82958 and SKF 83959 3 months. The monkeys received the drugs in 
their home cages between 13.00 and 15.00 p.m. Because chronic administration prevents oral 
administration, all compounds were dissolved in saline (0.2 ml/kg) and given i.m. Since the use of rhesus 
monkeys hampers extensive dose response studies, the doses were based on previously published data 
(Gnanalingham et al., 1995). Saline served as control and was injected 2 days before the start of all 
treatments.
Behavioral analysis
The analysis of the data was carried out in two parts.
In Part A, a detailed behavioral analysis of the sub-chronic effects of SKF 83959 is provided. The 
detailed behavioral effects of L-DOPA and SKF 82958 in these monkeys are described in Andringa et al., 
1999c.
Since the experimental paradigm of the treatments with L-DOPA, SKF 82958 and SKF 83959 were 
identical, these data were used to compare the therapeutic and undesired effects of the three compounds 
after a sub-chronic, 15-day administration period, as described in Part B.
Part A: Behavioral analysis of the sub-chronic effects of SKF 83959
Behavior was recorded on videotape for 60 consecutive minutes, immediately after the injection of 
saline or the drug. The analysis of behavior was limited to the effects that were recorded on day 1, 3, 5, 8,
12, 15, 16 and 18 of the treatment as well as on the day of the saline treatment (day -2). Behavioral 
parameters were analyzed with a recently developed and validated ethogram that allows a clear-cut 
distinction between therapeutic and undesired effects of drugs (Andringa et al., 1999b and c). For the 
sake of comparison drug-induced changes in a classically used parameter, namely body displacement 
was also analyzed. The percentage of the total observation time spent on each item was calculated, using 
thereby an event recording computer program (Observer 3.0).
The following behavioral items known to be displayed by MPTP-treated rhesus monkeys (Andringa 
et al., 1999b and c) were included.
1.Therapeutic effect:
1a. Goal-directed limb movements These are defined as normal hand movements directed either at 
the body itself or at objects such as bars, ball and feeding-trough. Thus, items such as self-grooming, 
masturbating, caressing, grasping, etc. are clustered into this class.
2. C lassically  assessed variable:
2a. Body displacement This is defined as any displacement of (parts of) the animal over a minimum 
distance of 50 cm. This item includes walking straight forwards, climbing and all types of rotational 
behavior.
3. U ndesired effects:
3a. Oro-facial Dyskinesia (OFD) This is defined as small, sometimes repetitive, contractions of 
individual muscles or small groups of muscles in the face region that are often followed by tongue 
protrusions (Jaspers et al., 1989).
3B. Limb Dyskinesia This encompasses 2 types of movements:
Athetoid movements being defined as non goal-directed, spontaneous limb movements while the 
monkey is standing, sitting or lying on its side: the whole pattern is purposeless, non-adaptive and 
compulsive in character. The movements begin slowly: the limb is lifted from the floor, and the lower 
arm, hand and/or fingers undergo alternating hyperextension and flexion movements. The movements 
occur independently of the ongoing activity of the monkey. The monkey itself has no visual interest in the
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induced limb movements.
Choreiform movements being defined as rapid, jerky shaking-off movements involving lower arm, 
wrist and/or fingers and occurring only when the monkey is standing or sitting. The movements are 
repeated several times and violent in nature and the monkey has continuous visual interest in these 
movements.
Athetoid and choreiform movements were lumped together and labeled as dyskinetic movements. 
3c. Dystonia This is defined as a contorted and twisted posture marked by the presence of the total, or 
a part, of the following behavior elements: torticollis, a shrugged shoulder, an abducted upper-arm, 
flexion of the elbow, pronation of the wrist with abducted digits, abducted thigh with flexion of the knee- 
joint and pronation of the ankle with abducted toes of the motionless animal.
Part B: Comparison of the effects of SKF 83959 with those of L-DOPA and SKF 82958
The therapeutic and undesired effects of the three treatments were studied after the sub-chronic 
treatment period of 15 days using the following parameters.
- Therapeutic efficacy: The increase in the percentage of observation time spent on goal-directed limb 
movements on day 15 of the drug treatment as compared to saline treatment. This was calculated by 
subtracting the percentage of time spent on limb movements during saline treatment from the percentage 
of time spent on limb movements at day 15 of the drug treatments.
- Severity of undesired effects: Sum of percentages of observation time spent on OFD, limb dyskinesia 
and dystonia on day 15 of the drug treatments.
- Onset of undesired effects: number of treatment days proceeding the day at which undesired effects 
started to appear.
- Type of undesired effects that are predominantly displayed.
- Body parts being predominantly involved in the undesired effects.
- Presence of epileptoid behavior.
Statistical analysis
All data are expressed as individual values for each monkey. However, for the statistical analysis, 
data of the 4 monkeys were lumped. In Part A, behaviors that were absent during saline treatment and 
newly introduced by the SKF 83959 treatment, were tested using a one-sample t-test. Behaviors that 
were present during the saline treatment were tested using a paired samples t-test. In Part B, the therapeutic 
effects and undesired effects of SKF 83959 as compared to L-DOPA and SKF 82958 were tested using an 
independent sample t-test. The accepted level of significance was p<0.05.
Results
Part A: The sub-chronic effects o f SKF 83959
1. Therapeutic effect
1a. Goal-directed limb movements
Under saline conditions the time spent on goal-directed limb movements ranged from 0 to 
2,7 % (see Fig. 1A). 0.5 mg/kg SKF 83959 significantly increased the performance of goal- 
directed limb movements in all monkeys (day 5: t(3)=4,0 day 8: t(3)=3,8 and day 15: t(3)= 3,8: 
p<0.05). At day 1, a high variation in the response was observed; the effects were less variable 
and remained more or less stable throughout the rest of treatment. Increasing the dose to 1.0 
mg/kg did not affect goal-directed movements in monkey 1 and 2, decreased this parameter in 
monkey 3 and greatly started to increase this therapeutic effect in monkey 4, at day 18. At day 
18 1.0 mg/kg significantly increased goal-directed limb movements (day 18: t(3)= 3,9: p<0.05).
2. Classical assessed variable:
2a. Body displacement
Under saline conditions, the time spent on body displacement ranged from 0 to 18,7 % (see
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Fig. 1B). 0.5 mg/kg SKF 83959 did not change the time spent on this item in monkey 1 and 2, 
but strongly increased the time spent on body displacement in monkeys 3 and 4; these effects 
remained more or less stable throughout the treatment in all monkeys. The effects of 1.0 mg/kg 
SKF 83959 were more or less similar to the effects of 0.5 mg/kg 83959 (Fig 1B).
Fig. 1ABCDE. Effects of the 18 day intramuscular administration of SKF 83959 (0.5 mg/kg: day 1-15,
1.0 mg/kg: day 16-18) in bilaterally MPTP-treated rhesus monkeys, on goal-directed limb movements 
(Fig. 1A), body displacement (Fig. 1B), oro-facial dyskinesia (Fig. 1C), limb dyskinesia (Fig. 1D) and 
dystonia (Fig. 1E). Saline (depicted as S) served as control and was injected 2 days before the start of the 
SKF 83959 treatment. The data represent the percentage of the observation time spent on the particular 
behavior in each individual monkey.
3. Undesired Effects
3a. Oro-facial dyskinesia
As shown in Fig. 1C, saline did not induce oro-facial dyskinesia (OFD) in any of the animals. 
Again, a large variation in the drug response was present. 0.5 mg/kg SKF 83959 had nearly no 
effect on OFD in the monkeys having a low displacement activity response, namely monkey 1
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and 2. In contrast, the compound elicited severe OFD in the animals that had a high response in 
displacement activity to SKF 83959, namely monkey 3 and 4 on day 1; this effect was less 
severe on day 3 to day 8 and nearly completely disappeared on day 15 of the treatment. Increasing 
the dose to 1.0 mg/kg again elicited OFD in monkey 3 and 4 but not in monkey 1 and 2.
3b. Limb dyskinesia
Under saline conditions, no limb dyskinesia was present in any of the tested animals (Fig. 
1D). SKF 83959 elicited limb dyskinesia in the monkeys 1, 3 and 4 while this undesired effect 
was almost absent in monkey 2. In monkey 1 and 2, the degree of limb dyskinesia was more or 
less stable in time. In monkey 3 and 4 SKF 83959 elicited severe limb dyskinesia on day 1; this 
effect was significantly less on day 3 and then remained stable till the end of the treatment (day 
15). 1.0 mg/kg SKF 83959 further increased dyskinesia in monkey 4, whereas the effect was 
more or less similar to the effect of 0.5 mg/kg SKF 83959 in the other monkeys.
Given the absence of real group differences on day 3 to 16, all 4 monkeys were included in 
the statistical analysis: this analysis revealed that the dyskinetic effects of SKF 83959 were 
significantly different from those seen during saline on day 1, 8, 12 and day 18 of the treatment 
(day 1: t(3)=2,6 day 8: t(3)=2,7 day 12: t(3)= 3,1 and day 18 t(3)= 2,9: p <0.05).
3c. Dystonia
Under saline conditions, no dystonia was seen in any of the treated monkeys as shown in 
Fig. 1E. 0.5 mg/kg SKF 83959 elicited dystonia in monkey 1, 2 and 4 and to a lesser extent in 
monkey 3 on day 1. This effect wore off in the animals that displayed a high response in 
displacement activity (monkey 3 and 4). In monkey 1 and 2, however, dystonia was far more 
fluctuating; it reached a peak value on day 12. 1.0 mg/kg SKF 83959 did not elicit severe 
dystonia in the monkeys 1, 3 and 4, but induced severe dystonia in monkey 2 on day 18. 
Incorporation of all animals in the statistical analysis revealed that dystonia was significantly 
different from saline at day 1 (day 1: t(3)= 3,6: p < 0.05).
Part B. Comparison o f the therapeutic and undesired effects SKF 83959 with those o f L-DOPA 
and SKF 82958
SKF 83959 was more therapeutically effective than SKF 82958, as shown in table 1 (SKF 
83959 vs. SKF 82958: t(6)= 2.48: p < 0.05). Although the therapeutic effect of SKF 83959 was 
less than that of L-DOPA (SKF 83959 vs. L-DOPA: t(5)= 4.44: p<0.05), SKF 83959 was 
effective in all treated monkeys, even in the monkey that did not respond to L-DOPA. With 
regard to undesired effects, SKF 83959 re-initiated the dyskinetic and dystonic effects that 
were previously seen after administration of L-DOPA and SKF 82958, to an equal extent (SKF 
83959 vs. SKF 82958: t(6)= 0.98: p > 0.05 and SKF 83959 vs. L-DOPA: t(5)= 1.05: p > 0.05). 
Whereas the initial treatment of the drug-naive monkeys with L-DOPA triggered these side- 
effects for the first time after a treatment of 4 to 12 days in 3 monkeys, SKF 83959 like SKF 
82958 re-initiated these effects in all 3 monkeys immediately after the first administration. 
Furthermore, SKF 83959 re-initiated side-effects in the monkey that was unresponsive to L- 
DOPA, but developed these side-effects after treatment with SKF 82958; again, this re-initiation 
occurred on the first day of treatment with SKF 83959. The nature of the side-effects, as reflected 
by the type of side-effects displayed and the body parts involved, were individual-specific, but 
not drug-specific. In contract to SKF 82958, SKF 83959 did not induce epileptoid behavior 
(see Table 1).
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Table 1
Monkey Treatment Therapeutic
Effects
Undcsircd effects
I SKF 83959
Time %
5.26
Time
(%)
2.10
Onset 
Day 1
Tvjk
Choreatic
Body parts 
Forelimbs/oral
Epileptoid
behavior
T.-DOPA 28.64 6.42 Day 12 Choreatic Forelimbs/oral -
SKF 82958 -1.0 0.78 Day 1 Choreatic Forelimbs/oral +
2 SKF 83959 13.24 1.94 Day] Choreatic Forelimbs -
L-DOPA 59.35 1.05 Day 4 Choreatic Forelimbs -
SKF 82958 -21.69 1.39 Day 1 Choreatic Forelimbs -
3 SKF 83959 6.5 7.26 Day 1 Choreatic/Dystoni c 1'orc/hindlimbs -
L-DOPA 49.34 20.2 Day 8 Choreatic/Dystoni c Fore/hi ndlimhs -
SKF 82958 -10.05 3.15 Day 1 Chorcatic/Dystonic Fore/hindlimbs +
4* SKF 83959 14.64 1.56 Day 1 Dystonic Hi ndli mbs/oral -
L-DOPA 0 0 - - Hind limbs/oral -
SKF 82958 6.91 1.56 Day 4 Dystonic 1 li ndli mbs/oral +
* monkey 4 did not respond to L-DOPA administration
Table 1: Comparison of the therapeutic and undesired of SKF 83959 (0.5 mg/kg), L-DOPA (10.0 mg/kg) 
and SKF 82958 (1.0 mg/kg) after a sub-chronic 15-day administration period in bilaterally MPTP-treated 
rhesus monkeys. The following parameters were evaluated for each individual monkey. Therapeutic 
efficacy: The increase in the percentage of observation time spent on goal-directed limb movements on 
day 15 of the drug treatment as compared to saline treatment. This was calculated by subtracting the 
percentage of time spent on limb movements during saline treatment from the percentage of time spent 
on limb movements at day 15 of the drug treatments. Severity of undesired effects: Sum of percentages of 
observation time spent on limb dyskinesia, OFD and dystonia on day 15 of the drug treatment. Onset of 
undesired effects: number of treatment days proceeding the day at which undesired effects started to 
appear. Type of undesired effects that are predominantly displayed. Body parts being predominantly 
involved in the undesired effects. Presence (+) or absence (-) of epileptoid behavior.
Discussion
It has been reported that the dopamine D1 antagonist SKF 83959 exerts anti-parkinsonian 
effects in MPTP-treated marmosets after acute administration (Gnanalingham et al., 1995). 
However, the majority of dopaminergic drugs induce severe response complications, especially 
after long-term treatment (Langston, Ballard, 1984a; Clarke et al., 1987). Therefore, SKF 
83959 was sub-chronically given in order to study its therapeutic and undesired effects on the 
long run. The previously validated animal model of PD, namely the bilaterally MPTP-treated 
monkey (Andringa et al., 1999c) was used for the evaluation of its therapeutic and unwanted 
side-effects.
0.5 and 1.0 mg/kg SKF 83959 significantly increased the time spent on goal-directed limb 
movements in all 4 animals, including the animal unresponsive to L-DOPA. This shows that, in
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contrast to the dopamine D1 agonist SKF 82958 that has either no effect or, even, worsens the 
MPTP-symptomatology (Gnanalingham et al., 1995; Andringa et al., 1999c), the dopamine 
D1 antagonist SKF 83959 had therapeutic effects in the MPTP-treated monkey. Thus, in line 
with the report of Gnanalingham et al., (1995), the present data show that SKF 83959 has anti­
parkinsonian effects in the MPTP-treated monkey.
More importantly, the present study provides the original finding that the therapeutic effects 
of SKF 83959 remains stable in time: no wearing off effects were seen in the long run. Whereas 
the therapeutic effects of SKF 83959 remained present throughout the treatment, the dyskinetic 
effects that were elicited on the first treatment day, rapidly wore off. At present, it is unclear 
how this wearing off effect is mediated. SKF 83959 may have desensitized the receptors involved 
in this dyskinetic behavior, although a role of the prior L-DOPA and SKF 82958 administration 
can also not be excluded. However, it is unlikely that the pre-treatment history would lead to 
conditioning phenomena, since the administration of saline 2 days earlier did not induce 
dyskinesia. This finding, together with the fact that SKF 83959 did not re-initiate epileptoid 
behavior in any of the tested monkeys show that the dopamine D1 antagonist SKF 83959 has a 
better pharmaco-therapeutic profile than L-DOPA, dopamine D2 agonists and the dopamine 
D1 agonist SKF 82958 as far as it concerns unwanted side-effects. The dyskinetic effects elicited 
by the latter agents have been found to increase with time (Bedard et al., 1992; Blanchet et al.,
1995).
A few dopamine D1 receptor agents have been reported to produce the wearing off of both 
the therapeutic and the undesired effects after chronic treatment (Pearce et al., 1999). However, 
to our knowledge, SKF 83959 is the first dopaminergic drug with stable therapeutic effects and 
wearing off dyskinesia.
Enhancement of the dose of SKF 83959 from 0.5 mg/kg to 1.0 mg/kg resulted in the increase 
of the unwanted side-effects in 3 monkeys, whereas it did not alter the severity of these effects 
in the other monkey. Increasing the dose did not substantially increase the therapeutic effect of 
the compound; whereas the goal directed limb movements increased in one monkey, this 
parameter remained the same or even declined in the other monkeys. These data clearly reveal 
that enhancing the dose from 0.5 mg/kg to 1.0 mg/kg does not improve the therapeutic efficacy 
of SKF 83959, indicating that the therapeutic window is limited.
A bimodal variation in the response to SKF 83959 was found: a large increase in body 
displacement co-occurred with oro-facial dyskinesia in 2 monkeys, whereas a small increase in 
body displacement co-occurred with dystonia in the remaining monkeys. Although no 
straightforward explanation can be given, it is important to mention that neither L-DOPA nor 
SKF 82958 produced such a dichotomy in these monkeys (Andringa et al., 1999c), suggesting 
that it was the drug that played an important role in this respect. Still, it is also known that the 
behavioral response to dopaminergic drugs varies according to the rank and/or baseline activity 
of the monkey in the group (Masiyama et al., 1970; Miczek, Gold, 1983; Ellenbroek et al., 
1997). Moreover, it is known that the dose required for eliciting motor deficits in monkeys 
varies across individuals (Schneider, 1989; Blanchet et al., 1996), suggesting that there exists 
a great variation in the vulnerability to MPTP. Given these facts, it can not be excluded that the 
latter two factors may also have contributed to the occurrence of the remarkable dichotomy 
seen in the present study (Elsworth et al., 1987). Despite of the fact that body displacement is 
certainly not an adequate predictor of drug-induced therapeutic effects (cf. Andringa et al., 
1999c), this parameter may be useful for predicting the individual-specific vulnerability to 
develop particular dyskinetic and/or dystonic effects; future research is required to confirm 
this.
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The present study provides additional evidence in favor of the hypothesis that there is no 
correlation between the ability of compounds to stimulate the dopamine D1 receptor coupled 
to AC and their therapeutic efficacy in the MPTP-treated monkey; SKF 83959, which was 
found to have therapeutic effects, does not stimulate, but actually inhibits this receptor (Arnt et 
al., 1992; Andringa et al., 1999a). At present, it remains to be established whether SKF 83959 
stimulates dopamine D1 receptor coupled to other second messenger systems, such as the IP3 
receptor system (Downes, Waddington, 1993) or whether its interaction with noradrenergic 
receptors or nonstriatal D1 receptors play an important role in the induction of anti-parkinsonian 
effects (Andringa et al., 1999a).
In conclusion, the present study shows that sub-chronic administration of the dopamine D1 
antagonist SKF 83959 induces both clear-cut therapeutic effects that remain stable in time and 
a limited number of dyskinetic effects that wear off during the treatment. Given the finding that 
this drug was even effective in the monkey that did not respond to L-DOPA, it is suggested that 
this dopamine D1 antagonist should be considered as an alternative treatment of patients with 
PD, especially of those patients that do not respond to L-DOPA.
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SKF 83959 is an antagonist ofdopamine D1 receptors in the prefrontal cortex and nucleus 
accumbens: a key to its anti-parkinsonian effects in animals?
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Abstract
The benzazepine SKF 83959 is a potent in vitro dopamine D1 antagonist, with additional 
affinity for a2 adrenoceptors and adrenergic transporters. Nevertheless, the compound effectively 
reduces parkinsonian symptoms in animal models of Parkinson’s disease. Adrenoceptors in the 
nucleus accumbens and the prefrontal cortex are putative target sites for SKF 83959, because 
these receptors regulate the release of striatal dopamine. In the present study it was examined 
how SKF 83959 interacts with these receptors. The effects of intra-accumbal injection of SKF 
83959 on locomotor activity were compared to the effects of the dopamine D1 agonist SKF 
81297 and the dopamine D1 antagonist SCH 39166. In addition, the effects of unilateral intra- 
prefrontal injection of SKF 83959 on rotational behavior were compared to the effects of the 
dopamine D1 receptor agonist SKF 81297, the dopamine D1 antagonists SCH 23390 and SCH 
39166, the a1 adrenoceptor agonist phenylephrine, the a1 adrenoceptor antagonist phentolamine, 
the a 2 adrenoceptor agonist clonidine and the a 2 adrenoceptor antagonist rauwolscine, in rats 
that were selected on basis of their high locomotor response to novelty and pre-treated with a 
subcutaneous injection of 0.75 mg/kg dexamphetamine. Similarly to SCH 39166, the intra- 
accumbal administration of SKF 83959 did not affect locomotor activity by itself, but 
counteracted the SKF 81297-induced stimulation of locomotor activity. In addition, like SCH 
39166 and SCH 23390, the intra-prefrontal injection of SKF 83959 induced a bias for rotating 
contralaterally. Finally, like SCH 39166 and all adrenergic compounds, the intra-prefrontal 
injection of SKF 83959 blocked the SKF 81297-induced bias for the rotating ipsilaterally. The 
data indicate that SKF 83959 inhibits the dopamine transmission in the nucleus accumbens and 
prefrontal cortex, either directly, through dopamine D1 receptor inhibition and/or indirectly, 
through interaction with a2 adrenoceptors and/or adrenergic transporters. Given the fact that 
reduced prefrontal and accumbal dopamine D1 receptor transmission stimulates the activity of 
nigrostriatal dopamine fibers, SKF 83959 may mediate its anti-parkinsonian effects through 
interaction with these receptors.
Introduction
The cellular biology of the dopamine D1 receptor has been extensively studied. At present, 
two dopamine D1 receptor subtypes (D1A/B) are known (Grandy et al., 1991; Sunahara et al., 
1991). The majority of dopamine D1 receptors is coupled to the adenylate cyclase (AC) 
transduction system in a stimulatory way (Stoof, Kebabian, 1981; Battaglia et al., 1986), although 
also other second messenger systems have been recently identified (Mahan et al., 1990; Undie, 
Friedman, 1990).
The behavioral effects of both partial and full receptor agonists to AC-coupled dopamine 
D1 receptors have been studied, both in intact (Daly, Waddington, 1993; Tirelli, Terry, 1993) 
and in dopamine-depleted animals (Fornaguera et al., 1995; Pearce et al., 1999). These studies 
have shown that some partial dopamine D1 receptor agonists are equally or, even, more effective 
in stimulating motor behavior than full agonists (Arnt et al., 1992; Deveney, Waddington, 
1995; Gnanalingham et al., 1995a). The mismatch between the ability to stimulate motor 
behavior and the efficacy to stimulate AC is especially large with respect to the benzazepine 
SKF 83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3- 
benzazepine). This compound is a potent in vitro dopamine D1 antagonist: it inhibits the 
dopamine-induced stimulation of AC-coupled dopamine D1 receptors both in rats (Arnt et al., 
1992; Gnanalingham et al., 1995c) and in primates (Andringa et al., 1999a). Moreover, SKF
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83959 has a moderate affinity for a2 adrenoceptors and adrenergic transporters (Andringa et 
al., 1999a). Nevertheless, SKF 83959 is very effective in reducing parkinsonian symptoms in 
in vivo animal models of Parkinson’s disease (PD; Gnanalingham et al., 1995b; Andringa et 
al., 1999b). Since it is known that relieve of parkinsonian symptoms is produced by compounds 
that replenish the loss of dopamine in the caudate nucleus/putamen complex (Tedroff et al.,
1996), viz. the primate analogue of the rodent dorsal striatum, these findings show that SKF 
83959 acts as a dopamine agonist in in vivo models of PD. Indeed, like selective, full dopamine 
D1 receptor agonists, this compound stimulates grooming behavior and elicits vacuous chewing 
in intact rats (Downes, Waddington, 1993). Thus, there exists an apparent discrepancy between 
the in vivo ability of SKF 83959 to act as a dopamine receptor agonist and its in viro  ability to 
inhibit dopamine receptors. Therefore, the question arises which mechanism of action underlies 
the anti-parkinsonian effects of SKF 83959 in in vivo models of PD. In theory, there are two 
putative target sites:
a) striatal dopamine D1 receptors coupled to an alternative transduction system, such as 
the IP3 system (Deveney, Waddington, 1995; Adachi et al., 1999),
b) extra-striatal receptors that elicit behavior that is identical to that seen after an increased 
release of dopamine in the dorsal striatum.
Although several investigators have focused their attention on the possibility that SKF 83959 
stimulates the IP3 system (Deveney, Waddington, 1995; Undie, pers. communication), no direct 
evidence is provided in favor of this hypothesis.
In contrast, several lines of evidence have shown that adrenoceptors in the nucleus accumbens 
(ACC) and the prefrontal cortex (PFC) control the release of striatal dopamine. Given the fact 
that SKF 83959 has affinity for dopamine D1 receptors, a2 adrenoceptors and adrenergic 
transporters, we decided to investigate how SKF 83959 affects these target sites in the ACC 
and PFC (Dreher, Jackson, 1989; Hauber, 1998).
At the level of the ACC, stimulation of dopamine D1 receptor is known to inhibit the release 
of dopamine in the striatum (Koshikawa et al., 1996), showing that selective changes in the 
dopamine activity in the ACC produces diametrically opposite changes in the dopamine activity 
of the striatum. Indeed, pharmaco-behavioral studies have shown that increased mesolimbic 
dopamine activity elicits a number of symptoms which can also be elicited by decreasing 
nigrostriatal dopamine activity; the reverse holds also true (see for review Cools, 1984; Scheel- 
Kruger, Arnt, 1985). At the level of the PFC, inhibition of a1 adrenoceptors has been found to 
inhibit the experimentally induced release of dopamine in subcortical structures (Tassin et al., 
1986). This is highly relevant in view of the fact that SKF 83959 has been found to stimulate 
the release of noradrenaline in the PFC, probably via its ability to block the presynaptic a2 
adrenoceptor and/or the adrenergic transporter (Andringa et al., 1999a). Apart from this, there 
is ample evidence that depletion of dopamine or inhibition of dopamine D1 receptors in the 
PFC enhances the dopamine activity in the ACC (Louilot et al., 1989; Deutch et al., 1990; 
Duvauchelle et al., 1992; King et al., 1997) and dorsal striatum (Kalivas, Stewart, 1991; 
Kolachana et al., 1995). These data show that also selective changes in the adrenergic and/or 
dopaminergic activity in the PFC produce diametrically opposite changes in the dopaminergic 
activity of the striatum. This inverse relationship has been confirmed in a variety of pharmaco- 
behavioral studies (Pycock et al., 1980; Vezina et al., 1994; Wilkinson, 1997).
The following paradigms were used to investigate how SKF 83959 interacts with aminergic 
target sites in the ACC and PFC, respectively. Given the well known role of accumbal dopamine 
receptors in stimulating locomotor activity (Dreher, Jackson, 1989), SKF 83959, alone or in 
combination with selective dopamine D1 agents, was bilaterally administered into the ACC of
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freely moving rats in order to study its locomotor effects. For sake of comparison, the effects of 
prototypes of dopamine D1 receptor agonists (SKF 81297) and dopamine D1 antagonists (SCH 
39166) were also studied in this paradigm. Furthermore, the selectivity of the effects was studied, 
where appropriate.
Using the slightly modified procedure of Vezina et al., (1994) to study the behavioral role 
of dopamine D1 receptors in the PFC, the effects of unilateral prefrontal administration of SKF 
83959 were studied by analyzing the drug-induced rotational behavior. In addition, the effects 
of SKF 83959 were compared to the effects of prototypes of dopamine D1 receptor, a1 and a2 
adrenoceptor agonists and antagonists and counteracted by selective aminergic agents, where 
appropriate. Given the finding that adrenoceptors in the PFC affect especially the responsiveness 
of subcortical dopamine function, the drug-induced effects were evaluated in rats that were 
pre-treated with a dose of dexamphetamine that is known to release dopamine in the ACC. For 
the same reason, we used rats with a relatively high release of accumbal dopamine in response 
to minor challenges such as novelty and injection (Saigusa et al., 199
Methods
Subjects
180 Male rats (outbred Wistar rat strain, 7-9 animals per group), weighting 190 - 220 grams were 
used for this study. Animals were bred and reared in the Central Animal Laboratory of the University of 
Nijmegen. Before the start of the experiments, animals were housed in groups of eight to ten animals per 
standard metal cage, in a temperature-controlled room (20° ± 2°). During the experiment, the rats were 
housed individually (cage: 40 x 20 x 15cm). Water and food pellets (Hope Farms, Woerden, The 
Netherlands) were available ad libitum. A fixed light-dark cycle (light on at 7.00 a.m.; light off 7.00 p.m.) 
was maintained. Animals were used only once. All experiments were performed according to international 
and institutional guidelines for animal care.
Compounds
SKF 83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-]H-3- 
benzazepine) and the dopamine D1 receptor agonist SKF 81297 (2,3,4,5,-tetrahydro-6-chloro-7,8- 
dihydroxy-phenyl-1H-3-benzazepine) were provided by Research Biochemical International, Natick, USA. 
The dopamine D1 receptor antagonist SCH 39166 (trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy- 
N-methyl-5H-benzo[d]naptho-{2,1-b}azepine) was obtained from Schering, Bloomfield, USA. The a1 
adrenoceptor agonist phenylephrine, the a1 adrenoceptor antagonist phentolamine, the a2 adrenoceptor 
agonist clonidine and the a2 adrenoceptor antagonist rauwolscine were obtained from Sigma chemical 
Co. St. Louis, USA. All drugs were dissolved in distilled water.
Surgery
Rats were anaesthetized with sodium pentobarbital (Narcovet®, Sigma, 60 mg/kg, i.p.) and placed in 
a stereotaxic apparatus (day 1). All rats were implanted bilaterally with 2 stainless steel guide cannulae, 
which were aimed either at the ACC or the PFC according to the atlas of Konig and Klippel (ACC: 
stereotaxic co-ordinates: anterior: 9.8 from bregma, lateral: 1.2 from the midline of the skull, dorsoventral 
from the skull surface: 2.7, angle of the cannulae: 10°, PFC: stereotaxic co-ordinates: anterior: 10.3 from 
bregma, lateral:- 0.8 from the midline of the skull, dorsoventral 2.5 angle of the cannulae: 20°). Rats were 
allowed to recover from the operation for at least one week.
Locomotor activity measurements after intra-accumbal drug injection
Locomotor activity was analyzed in rats equipped with canulae aimed at the ACC. Directly after 
surgery, rats were individually housed. One week after the surgery, measurements for locomotor activity 
were conducted in individual photocell cages (36 x 24 x 25 cm), as described earlier (Oosterloo, Cools,
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1985). Each cage was fitted with two infrared photocell beams 1 cm above the floor, spaced equally 
along the long access of the cage. Interruption of either beam resulted in a photocell count for that cage. 
Locomotor activity was assessed through photocell counts that were recorded at a 10-min interval using 
a computer.
In order to habituate the rats to the activity cage and the intra-accumbal injection procedure, animals 
were taken from their home cage on day 8, 9, and 10 and placed in the activity cages for 40 min; rats were 
bilaterally injected with 0.5 ul of the solvent of the drugs, distilled water, into the ACC on day 11. On the 
experimental day (day 12) rats received a bilateral injection of SCH 39166 (0.5 and 5.0 ug), SKF 83959 
(1.0, 5.0 or 10.0 ug), SKF 81927 (1.0, 5.0 and 10.0 ug) or the solvent of these drugs, distilled water, in 
order to study their effects on locomotor activity. Drugs that had no effect on locomotor activity (e.g. 
SCH 39166) were given three minutes prior to the local administration of the drug that enhanced locomotor 
activity (e.g. SKF 81297), using the above-mentioned doses. All compounds were injected in a volume 
of 0.5 ul distilled water. Directly after the drug injection, rats were placed in the activity cages, and 
locomotor activity was recorded for a period of 5 hours.
Rotational behavior measurements after intra-prefrontal drug injections
Given the finding that the effects of the PFC on motor behavior are greater when subcortical dopamine 
levels are high (Vezina et al., 1994), the effects of intra-prefrontal drug injection on rotational behavior 
were evaluated rats in which the novelty-induced increase in the extra-cellular concentration of accumbal 
dopamine has been found to be relatively high, namely in High Responders to novelty (HR; Saigusa et 
al., 1999). Therefore, prior to the surgery, HR were selected according to a validated standard procedure 
developed in our laboratory (Cools et al., 1990). In short, rats were selected on basis of their locomotor 
activity in response to a novel environment, using an open field. The open field consisted of a 160 x 160 
cm flat table, 95 cm high and surrounded by a white neutral background. Prior to the start of the selection 
procedure each rat was individually housed during 3 to 5 days. On the day of the selection rats were 
transported to the open field room and allowed to habituate for 30 minutes. Animals were then placed on 
the open field for a period of 30 minutes. The behavior was recorded with a computerized automated 
tracking system as described by Cools et al., (1990). Rats were selected on basis of two criteria, namely 
traveled distance (the overall distance traveled in cm) and habituation time (the amount of time between 
the moment the rat was placed on the open field and the moment the locomotor behavior of the rat was 
stopped for at least 90 sec, in sec). Rats that covered a distance more than 6000 cm / 30 min and habituated 
after a period of minimally 840 s were included in the experiment.
Thereafter, rats were equipped with canulae aimed at the PFC as described above. At least one week 
after the surgery, the rotational behavior of the animals was measured. Because the selected HR rats 
showed a slight, but significant preference for turning towards the right PFC after a systemic injection of 
dexamphetamine (0.75 mg/kg, s.c.; see below), SCH 39166 was injected into the right PFC in order to 
prevent any turning bias: pilot studies showed that the dose of 0.1 ug was sufficient in this respect, when 
given three minutes prior to dexamphetamine. Because adrenoceptors in the PFC affect especially the 
responsiveness of subcortical dopamine function, the rats received dexamphetamine in a dose that is 
known to release dopamine in the ACC, namely 0.75 mg/kg, sc.
Immediately after the injection of SCH 39166 into the right PFC, SKF 81297 (5.0, 7.5 and 10.0 ug), 
SKF 83959 (1.0, 5.0 and 10.0 ug), SCH 39166 (0.5 ug), SCH 23390 (5.0 ug), rauwolscine (10.0 ug), 
clonidine (10.0 ug), phenylephrine (10.0 ug), phentolamine (10.0 ug) or their solvent, distilled water, 
was injected into the left PFC in order to establish their effect on rotational behavior. In order to establish 
the putative role of dopaminergic receptors and/or adrenoceptors in the effects of SKF 81297, various 
aminergic agonists/antagonists were combined with SKF 81927 in a cocktail that was injected into the 
PFC three minutes prior to dexamphetamine. Both the single drugs as well as the cocktails were injected 
in a volume of 0.5 ul distilled water. Immediately after the dexamphetamine injection, rats were returned 
to their home cage in the experimental room for a period of 15 minutes. Then, rats were placed in a so- 
called rotation bowl (diameter of 47 cm, height 17 cm) for a period of 60 minutes. Behavior was recorded 
on videotape, allowing off-line analysis of rotational behavior. A trained observer that was blind to the 
treatment counted the number of contralateral (away from the left PFC) and ipsilateral (towards the left
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PFC) rotations. Only complete rotations (360°) were included.
Histology
After completion of the experiments the rats were transcardially perfused under pentobarbiatal 
anesthesia (Narcovet, 240 mg/kg, i.p.). After perfusion the rats were decapitated, and the brains were 
removed. The brains were sectioned (50 um sections) to determine the injections sites. Only rats with 
correctly placed injections sites were included in the analysis.
Statistics
All values are expressed as mean + SEM. The data were statistically analyzed using SPSS 7.5 software 
(SPSS inc., Il, USA). The effects of intra-accumbal drug injection on locomotor activity were subjected 
to a two-way ANOVA, using the general linear method including the factors treatment and time (time 
bin: 10 minutes). Post hoc Bonferroni-corrected t-tests were performed where appropriate. The effects of 
a single drug injection into the PFC on rotational behavior were tested using the independent samples t- 
test, whereas the effects of combined injections were analyzed with the help of the one-way ANOVA, 
subjecting the data to a post hoc Bonferroni-corrected t-test, where appropriate. A p-value < 0.05 was 
considered significant.
Results
Histology
Fig. 1A and 1B illustrate the tracks of the canulae aimed at the ACC (Fig. 1A) and PFC 
(Fig. 1B). Histological verification of the brain sections revealed that only 1 of the rats equipped 
with canulae aimed at the ACC and 1 of the rats equipped with canulae directed at the PFC had 
to be discarded due to misplacement. All groups contained 9 or 8 animals.
Fig. 1. Tracks of the canulae aimed at the ACC (Fig. 1A) and PFC (Fig. 1B).
Effects o f intra-accumbal injection o f dopaminergic compounds on locomotor activity.
Rats that received a bilateral injection of distilled water into the ACC, displayed a very low 
amount of locomotor activity (Fig. 2A). The intra-accumbal injection of SKF 81297 significantly 
increased locomotor activity in a dose-dependent manner (Fig. 2A). Post hoc analysis showed 
that the effect of 10.0 ug SKF 81297 was significantly greater than that of 5.0 ug and 1.0 ug 
SKF 81297, while the latter two doses increased locomotor activity to an equal extent [F(3,960) 
= 112,22; p < 0.001; Bonferroni p < 0.01; Fig. 2A]. 5.0 ug SCH 39166, that by itself had no 
effect on locomotor activity (Fig. 2B), counteracted the effect of 10.0 ug SKF 81297. [F(3,900)
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= 84,35; p <0.001; post hoc Bonferroni p < 0.05; Fig. 2C]. The SCH 39166-induced suppression 
was not complete: the amount of locomotor activity in this group still significantly differed 
from that of the distilled water-treated group [F(3,900) = 84,35; p <0.001; post hoc Bonferroni 
p < 0.05; Fig. 2C]. Remarkably, the effect of 10.0 ug SKF 81297 was potentiated by 0.5 ug of 
SCH 39166 (Fig. 2C), that by itself had no effect on locomotor activity [F(3,900) = 84,35; p 
<0.001; post hoc Bonferroni p < 0.05; Fig. 2BC].
Effects o f intra-accumbal injection o f SKF 83959 on locomotor activity.
The effects of intra-accumbal injection of SKF 83959 were very similar to those of SCH 
39166. SKF 83959 (dose 1G.G ug) remained ineffective when given alone (Fig. 2B). High 
doses (5.G ug and 1G.G ug) of SKF 83959 counteracted the SKF 81297-induced increase in 
locomotor activity (Fig. 2D). The effect of 1G.G ug SKF 83959 was greater than that of 5.G ug. 
Moreover, 1G.G ug SKF 83959 suppressed the SKF 81297-induced locomotor activity such 
that this group did not differ from the control (distilled water) group. Finally, low doses (l.G ug 
and G.l ug) of SKF 83959 potentiated the effects of SKF 81297. The potentiating effect of G.l 
ug SKF 83959 was significantly greater than that of l.G ug SKF 83959 [F(5,141G) = 87.75; p 
<G.GG1; Fig. 2D].
Fig.2: Effects of intra-accumbal administration of SKF 81297 (Fig. 2A), SCH 39166 and SKF 83959 
(Fig. 2B), the combined intra-accumbal administration of SCH 39166 and SKF 81297 (Fig. 2C) and the 
combined administration of SKF 83959 and SKF 81297 (Fig. 2D) on locomotor activity. Locomotor 
activity was measured for 5 hours and reflects the number of interruptions of photocell beams recorded at 
a lG-min interval.
Effects o f intra-prefrontal injection o f dopaminergic compounds on rotational behavior 
Rats that received distilled water into the left PFC, displayed an average of 60 ipsilateral 
and 49 contralateral rotations during the 60-min observation period (Fig. 3A). There was no
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rotational bias; the number of ipsilateral and contralateral rotations did not significantly differ. 
The injection of 10.0 ug SKF 81297 into the left PFC induced a bias for rotating ipsilaterally: 
it increased the number of ipsilateral rotations, but did not alter the number of contralateral 
rotations [t(15) = -3,9; *p < 0.05; Fig. 3A]. Lower doses of SKF 81297 (7.5 and 5.0 ug) were 
no longer effective (data not shown).
In contrast, the unilateral intra-prefrontal injection of SCH 39166 and SCH 23390 induced 
a bias for rotating contralaterally; SCH 39166 (dose 0.5 ug) had a tendency to decrease the 
number of ipsilateral rotations but significantly increased the number of contralateral rotations 
[t(15) = 2,8; *p < 0.05; Fig. 3A], while SCH 23390 (dose 5.0 ug) significantly reduced the 
number of ipsilateral rotations [t(15) = 2,7; *p < 0.05; Fig. 3A], but did not affect the number 
of contralateral rotations. Moreover, SCH 39166 significant reduced the SKF 81297-induced 
increase in the number of ipsilateral rotations [F(2,25) = 14.7; p <0.001; post hoc Bonferroni: 
#p <0.05 Fig. 3B], bringing it back to control (distilled water) levels (Fig. 3B).
Effects o f intra-prefronto cortical injection o f SKF 83959 on rotational behavior
The effects of SKF 83959 were very similar to the effects of the dopamine D1 antagonists. 
Likewise, 10.0 ug SKF 83959 induced a bias for rotating contralaterally by decreasing the 
number of ipsilateral rotations [t(15) = 2,5; *p < 0.05; Fig. 3A], without affecting the number of 
contralateral rotations (Fig. 3A). Moreover, like SCH 39166, SKF 83959 significantly reduced 
the SKF 81297-induced increase of ipsilateral rotations [F(2,26) = 14.6; p <0.001; post hoc 
Bonferroni: #p <0.05; Fig. 3B], bringing it back to control (distilled water) levels.
Effects o f intra-prefronto cortical injection o f adrenergic compounds on rotational behavior
The intra-prefrontal injection of clonidine (dose 10.0 ug) and rauwolscine (dose 10.0 ug) 
did not significantly affect the number of ipsilateral or contralateral rotations (Fig. 3C). In 
contrast, 10.0 ug phenylephrine induced a bias for rotating contralaterally: it significantly 
increased the number of contralateral rotations [t(14) = -2.24; *p < 0.05; Fig. 3C], but not the 
number of ipsilateral rotations. Phentolamine (dose 10.0 ug) had the opposite effect on the 
rotating bias: it significantly decreased the number of contralateral rotations [t(15) = 2.2; *p < 
0.05; Fig. 3C], but did not affect the number of ipsilateral rotations.
Phenylephrine, clonidine and rauwolscine significantly reduced the SKF 81297-induced 
bias for rotating ipsilaterally [phenylephrine F(2,24) = 14.9; p <0.001; clonidine: F(2,25) = 
10.6; p <0.0015; rauwolscine: F(2,24) = 8.12; p <0.001; all drugs, post hoc Bonferroni: #p 
<0.05; Fig. 3D]. Moreover, these drugs suppressed the effect of SKF 81297 such that these 
groups did not significantly differ from the control (distilled water) group.
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Fig. 3 Effects of the administration of dopaminergic (Fig. 3AB) and adrenergic (Fig. 3CD) compounds, 
administered alone (Fig. 3AC) or in combination (Fig. 3BD) with SKF 81297, into the left PFC, on the 
number of ipsilateral (towards the left PFC) and contralateral (away from the left PFC). Rats had been 
selected on the basis of their locomotor activity response to novelty and were pre-treated subcutaneously 
with 0.75 mg/kg dexamphetamine. Rotations were scored during a 60-minute period.
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Discussion
General comments
The in viro  dopamine D1 receptor antagonist SKF 83959 acts as an in vivo dopamine 
agonist: its systemic administration reduces parkinsonian symptoms in animal models of PD. 
Putative target sites for mediating these in vivo effects are adrenoceptors in the ACC and PFC: 
these receptors have been found to regulate the release of striatal dopamine (Louilot et al., 
1989; Deutch et al., 1990; Kalivas, Stewart, 1991; Koshikawa et al., 1996), and, moreover, 
SKF 83959 has affinity for dopamine D1 receptors, a2 adrenoceptors and adrenergic transporters 
(Arnt et al., 1988; Andringa et al., 1999a). For this reason, the behavioral effects of intra- 
accumbal and intra-prefrontal injection of SKF 83959 were examined and compared to the 
effects of prototypes of dopamine D1 receptor, a1 adrenoceptor and a2 adrenoceptor agonists 
and antagonists.
Effects o f intra-accumbal dopamine D1 receptor manipulations on locomotor behavior
At the level of the ACC, the stimulation of dopamine D1 receptors, using the typical dopamine 
D1 receptor agonist SKF 81297, stimulated locomotor behavior. Moreover, dopamine D1 
receptor blockade, using the typical dopamine D1 receptor antagonist SCH 39166, counteracted 
this effect. However, a lower dose of this dopamine D1 antagonist slightly potentiated the 
effect of the dopamine D1 receptor agonist. It is not clear what mediated the latter effect; 
however, it cannot be excluded that low doses of dopamine D1 antagonists predominantly 
interact with presynaptic receptors and adrenergic transporters, which may induce an increase 
in the dopamine release. Anyhow, the data indicate, in line with several studies (Dreher, Jackson, 
1989; Messier et al., 1991; Meyer et al., 1993), that locomotor behavior is regulated by 
dopamine D1 receptor at the level of the ACC. Therefore, this paradigm appears suitable for 
studying how SKF 83959 interacts with accumbal dopamine D1 receptors. The effects of intra- 
accumbal injection of SKF 83959 on locomotor behavior were completely different from the 
effects of the dopamine D1 receptor agonist, but were almost identical to the effects of the 
selective dopamine D1 antagonist. These data indicate that SKF 83959 inhibits dopamine D1 
receptor function in the ACC, probably through the blockade of dopamine D1 receptors in this 
area. Behavioral (for review: Cools, 1984; Scheel-Kruger, Arnt, 1985) and micro-dialysis studies 
(Koshikawa et al., 1996) have shown that changes in the dopaminergic activity at the level of 
the ACC have an inverse effect on the dopamine activity in the striatum (see introduction). 
Thus, the dopamine D1 receptors in the ACC are putative target sites for the regulation of the 
anti-parkinsonian effects of SKF 83959: the compound may mediate its anti-parkinsonian effects 
through inhibition of these dopamine receptors in the ACC. This hypothesis implies that 
stimulation of the accumbal dopamine D1 receptors that are inhibited by SKF 83959 has no 
anti-parkinsonian effect: future studies are required to (in)validate this.
Effects o f intra-prefrontal dopamine D1 receptor, a l  adrenoceptor and a2  adrenoceptor 
manipulation on rotational behavior
At the level of the PFC, stimulation of dopamine D1 receptor and inhibition of a1 
adrenoceptors, using respectively the typical dopamine D1 receptor agonist SKF 81297 and 
the a1 adrenoceptor antagonist phentolamine, induced a bias for rotating ipsilaterally. In contrast, 
inhibition of prefrontal dopamine D1 receptors and stimulation of prefrontal a1 adrenoceptors, 
using respectively the dopamine D1 receptor antagonists SCH 23390 and SCH 39166 and the 
a1 adrenoceptor agonist phenylephrine, induced the opposite effects: this induced a bias for
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rotating contralaterally. Finally, both dopamine D1 receptor blockade and a1 adrenoceptor 
stimulation were able to completely block the ipsiversive bias induced by dopamine D1 receptor 
stimulation.
The effects of dopamine D1 receptor and a1 adrenoceptor manipulation on rotational behavior 
are well in line with the known role of these receptors in motor behavior. The role of 
prefrontocortical dopamine D1 receptors is more or less opposed to the role of subcortical 
dopamine D1 receptors (Koshikawa, 1994; Saigusa et al., 1995), which can be explained by 
the fact that the dopamine function in the PFC and subcortical terminal fields are linked in an 
inverse manner (see introduction: Deutch et al., 1990; Kalivas, Stewart, 1991; Vezina et al., 
1994). At the level of the ACC and striatum, animals rotate away from the subcortical side with 
highest dopamine activity (Ungerstedt et al., 1974; Messier et al., 1992), while our data show 
that the opposite holds true for the PFC. The effects of a1 adrenoceptor manipulation on rotational 
behavior can be attributed to the finding that the latter receptors have a regulatory role on 
prefrontal dopamine transmission: stimulation (inhibition) of a 1 adrenoceptors inhibits 
(stimulates) the dopamine transmission mediated through dopamine D1 receptors (Tassin et 
al., 1986; Blanc et al., 1994; Darracq et al., 1998). Thus, as anticipated, a decrease in dopamine 
transmission, induced either by inhibition of dopamine D1 receptors or by stimulation of a1 
adrenoceptors, increases the dopamine transmission in the ACC and striatum which, in turn, is 
hypothesized to elicit the rotating bias away from the prefrontal side with the lowest dopamine 
function.
However, prefrontal injection of the a2 adrenoceptors antagonist rauwolscine, that by itself 
elicited no effects on rotational behavior, counteracted the effects of dopamine D1 receptor 
stimulation. This effect can be ascribed by the inhibitory effects of rauwolscine on presynaptic 
a2 adrenoceptors, which increases the noradrenaline release and, subsequently, inhibits the 
dopamine activity at the level of the PFC. However, also the prefrontal injection of the a2 
adrenoceptors agonist clonidine counteracted the effects of dopamine D1 receptor stimulation. 
It is quite likely that the rather high dose of clonidine stimulated not only a2, but also a1 
adrenoceptors.
Anyhow, at the level of the PFC both dopamine D1, a1 adrenoceptors and, perhaps, a2 
adrenoceptors, regulate rotational behavior. Therefore, this paradigm appears suitable for 
studying the effects of SKF 83959 on prefrontal dopamine receptors and adrenoceptors.
In the PFC the effects of SKF 83959 were very similar to the effects of the dopamine D1 
receptor blockade and, to a lesser extent, a2 adrenoceptor blockade. Given the finding that 
SKF 83959 is not only an in vitro dopamine D1 receptor antagonist but also releases cortical 
noradrenaline (Andringa et al., 1999), the data indicate that SKF 83959 inhibits prefrontal 
dopamine transmission, either via its inhibitory effect on dopamine D1 receptors or via its 
stimulatory effects on noradrenaline release, or both. The inhibitory effects of SKF 83959 on 
prefrontal dopamine transmission may in turn stimulate the dopamine transmission at the level 
of the striatum and ACC. Thus, dopamine D1 receptors, a2 adrenoceptors and adrenergic 
transporters at the level of the PFC are putative target sites for the regulation of the anti­
parkinsonian effects of SKF 83959. Although it is not clear whether systemic administration of 
SKF 83959 elicits a preferential interaction with the latter receptors, data of Herve et al., 
(1992) show that this may indeed be the case. They found that the ratio between dopamine 
binding sites to which respectively dopamine D1 receptor antagonist and agonists bind was 
more than seven-fold higher in the PFC than that observed in the striatum.
Taken together, the in vitro dopamine D1 receptor antagonist SKF 83959 exerts an inhibitory 
action on dopamine transmission in the ACC and PFC, which may be involved in the anti­
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parkinsonian effects of the drug in animal models of PD. Given the fact that SKF 83959 relieves 
parkinsonian symptoms without inducing severe side-effects in animal models of PD, insight 
into the brain areas possibly involved in the anti-parkinsonian effects of SKF 83959 is important 
for improving the treatment strategies for patients with Parkinson’s disease.
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7
Systemic administration of the propargylamine CGP 3466B prevents behavioral and 
immunocytochemical deficits in rats with 6-hydroxydopamine-induced lesions in the 
substantia nigra.
G. Andringa, RV. van Oosten, W. Unger, JC. Stoof, TGM. Hafmans, J. Veening and AR. Cools 
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Abstract
The ability of CGP 3466B to attenuate the behavioral and morphological consequences of 
experimentally induced cell death was investigated in a recently updated animal model of 
Parkinson’s disease. 6-Hydroxydopamine was infused bilaterally into the substantia nigra, pars 
compacta of rats that were pre-treated with desimipramine and 2 hours later subcutaneously 
injected with CGP 3466B (0.0014 - 1.4 mg/kg) or its solvent, twice a day for 14 days. After a 
washout period of 14 days changes in motor behavior were evaluated, using the open field test 
(analysis of normal and abnormal stepping, e.g.) and the paw test (analysis of retraction time of 
limbs). Changes in learning and memory were evaluated with the help of the Morris water maze 
task. Following immunocytochemical staining of tyrosine hydroxylase, the extent of the lesion 
was quantified using a computerized system. CGP 3466B prevented all deficits produced by 6- 
hydroxydopamine, though at different doses. It prevented: abnormal stepping (0.0014 - 0.014 
mg/kg), increased forelimb and hindlimb retraction time (0.014 - 0.14 resp. 0.0014 - 0.14 mg/ 
kg), delayed learning (1.4 mg/kg) and reduced tyrosine hydroxylase immunoreactivity in the 
substantia nigra (0.0014 - 0.014 mg/kg). CGP 3466B (0.0014 - 0.14 mg/kg) induced no deficits 
in sham-treated rats. 1.4 mg/kg CGP 3466B, however, did not show any benefit on motor 
deficits in 6-OHDA-lesioned rats and induced abnormal movements and decreased the tyrosine 
hydroxylase immunoreactivity in the substantia nigra, pars compacta and the ventral tegmental 
area of sham-lesioned animals. It is concluded that CGP 3466B prevents all 6-hydroxydopamine- 
induced behavioral and immunocytochemical deficits, though at different doses. CGP 3466B 
is suggested to be a valuable agent for inhibiting the dopaminergic degeneration in patients 
with Parkinson’s disease.
Introduction
Parkinson’s disease (PD) is characterized by the progressive degeneration of dopaminergic 
cells, especially in the substantia nigra, pars compacta (SNc). Evidence is accumulating that 
this degeneration involves an apoptotic process (Anglade et al., 1997), which may be triggered 
by a variety of mechanisms such as oxidative stress, mitochondrial dysfunction, excitotoxicity 
and excessive iron deposition in the SNc (Olanow, 1996).
Current drug therapy of PD is purely symptomatic, relying primarily on restoring 
dopaminergic function (L-DOPA, dopamine agonists of different subtype specificity). A possible 
exception may be the monoamine oxidase B (MAO-B) inhibitor deprenyl, which has been 
shown to exert neuroprotective effects in a variety of cellular and animal models (see e.g. 
Mytilineou, Cohen, 1985; Tatton, Greenwood, 1991; Tatton et al., 1994; Koutsilieri et al., 
1996; Iwasaki et al., 1996, Mytilineou et al., 1997a; Paterson et al., 1998a; Gelowitz, Paterson, 
1999), which are independent of MAO-B inhibition (Tatton et al., 1995) but may be related to 
its binding to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Kragten et al., 1998). 
However, it is still vigorously debated whether its modest clinical effects (LeWitt, 1991; 
Shoulson, 1992) are symptomatic rather than neuroprotective (see Calne, 1995 vs. Olanow, 
1996). It is possible that this issue is confounded by the metabolism of deprenyl, since its 
neuroprotective properties are believed to be due to its desmethylated metabolite (Mytilineou 
et al., 1997b), and its other main metabolites, amphetamine and methamphetamine, were shown 
to antagonize them (Tatton et al., 1996).
Recently, a new anti-apoptotic com pound has been discovered, namely the 
dibenzo[6,f]oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine (CGP 3466B). This compound is
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structurally related to deprenyl, shares its ability to bind to GAPDH (Kragten et al., 1998) and 
to rescue neurons in v iro from death induced by apoptotic stimuli (Kragten et al., 1998; Paterson 
et al., 1998b), but does not inhibit MAO-B (P. Waldmeier, unpublished observations) and cannot 
be metabolized into amphetamine and methamphetamine. In vivo studies on this propargylamine 
are limited, but promising: it increases not only the life span of mice mutant with motoneuron 
degeneration (Kato et al., 1996), but also the survival of CA1 pyramidal neurons in an animal 
model of ischemia (Paterson et al., 1998c). Our goal was to analyze the neuroprotective effects 
of this agent in a valid in vivo animal model of PD.
CGP 3466B was hypothesized to be a potent neuroprotective agent in in vivo animal models 
of neurodegenerative diseases. For these reasons, the effects of CGP 3466B were analyzed 
with the help of a recently updated animal model of PD, namely the model in which effects of 
bilateral intra-nigral injections of small amounts of 6-hydroxydopamine (6-OHDA) in rats are 
evaluated with a renewed behavioral test-battery (Van Oosten et al., 1998, see also: Whishaw, 
Dunnett, 1985; Fornaguera et al., 1993; Sakai, Gash, 1994; Schwarting, Huston, 1997) and 
tyrosine hydroxylase immunocytochemistry (Zigmond et al., 1984; Wolf et al., 1989). Among 
others, this model was chosen for the following reasons. The mechanisms underlying 6-OHDA- 
induced cell death play a definite role in the pathophysiology of PD (inhibition of mitochondrial 
complexes I and IV: (Jenner, Olanow, 1996); formation of free radicals: (Glinka et al., 1996; 
Glinka et al., 1997) apoptosis: (Walkinshaw, Waters, 1994). The behavioral test-battery including 
an open field (cf. (Olsson et al., 1995), the so-called paw test (Ellenbroek, Cools, 1988) and the 
Morris water maze task (Morris, 1984) allow a more detailed analysis than the ones used 
previously.
CGP 3466B is found to prevent all deficits produced by the 6-OHDA treatment in rats, 
though at different doses
Methods
Animals
102 Male rats (outbred Wistar rat strain: TNO Rijswijk, The Netherlands), weighing 190 - 220 grams 
were incorporated in this study. The animals were individually housed (cage: 40 x 20 x 15 cm) in a 
temperature-controlled room (20° ± 2° C), and water and food pellets (Hope Farms, Woerden, The 
Netherlands) were available ad libitum. A fixed light-dark cycle (light on at 7.00 a.m; light off at 7.00 
p.m.) was maintained. All experiments were performed according to international and institutional 
guidelines for animal care.
Compounds
Dibenzo[ b,/]oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine (CGP 3466B) was provided by Novartis 
Pharma (Basel, Switzerland). Desimipramine (DMI), 6- hydroxydopamine (6-OHDA), ascorbic acid, 
pentobarbital (Narcoveta), bovine serum albumin (BSA), triton, 3,3’-diaminobenzidine (DAB) and all 
chemicals present in the phosphate buffer saline (PBS) were obtained from Sigma (St Louis, MO). 
Paraformaldehyde, nickel, hydrogenperoxide (H2O2), chromealum, gelatine and Entelan were purchased 
from Merck (Darmstadt, Germany). Tyrosine hydroxylase (TH) primary antibody was obtained from 
Incstar (Stillwater, MN; batch number 803216). Biotinylated donkey anti-mouse secondary antibody 
was obtained from Jackson Immuno Research (West Grove, PA). Avidin-biotin-peroxydase complex 
(Elite ABC Vectastain kit) was purchased from Brunschwig (Amsterdam, the Netherlands).
Solutions
CGP 3466B was dissolved in distilled water and stored at 4° C. DMI was dissolved in distilled water. 
6-OHDA was dissolved in saline containing 0.1 % ascorbic acid and stored at -80° C.
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6-OHDA treatment
The bilateral sham- and 6-OHDA treatments were given on day 0. Rats were anesthetized with sodium 
pentobarbital (Narcovet: 60 mg/kg, i.p.) and placed in a stereotaxic frame. Then, the animals were injected 
with DMI (20 mg/kg, i.p.) in order to protect noradrenergic cells against 6-OHDA-induced cell death 
(Breese, Traylor, 1971). Next, the co-ordinates of the injection site were determined using an approach 
originally developed by H.J. Groenewegen and coworkers (personal communication). In short, a rectangular 
piece of the skull was removed with the help of a dental drill in order to visualize the most anterior aspect 
of the frontal pole. This landmark was used to further determine the co-ordinates of the injection site as 
follows: posterior/anterior co-ordinate: 10.0 mm posterior to the border of the frontal lobes; lateral co­
ordinate: 2.0 mm lateral to the saggital surture; dorsal/ventral co-ordinate: 7.8 mm (6-OHDA) or 7.4 mm 
(sham) ventral to the dura surface. At least 30 min after the DMI injection, the needle (internal diameter 
0.2 mm) of the Hamilton syringe, either empty (sham treatment) or filled with 3|J,g 6-OHDA in 1|J,l 
solution (6-OHDA treatment), was then directed at that site and manually emptied where appropriate. 
The infusion lasted 5 min. Thereafter the needle was left at the site for another 10 min to prevent reflux 
of the solution. The infusions were given bilaterally. Finally, the pieces of skull were replaced and the 
incision was closed.
Administration of CGP 3466B
Two hours after the sham- or 6-OHDA treatment, rats were subcutaneously injected with CGP 3466B 
(0.0014, 0.014, 0.14 or 1.4 mg/kg) or its solvent, distilled water. During the 13 consecutive days (day 1­
13), the rats were injected twice daily, at 8.00 a.m. and 6.00 p.m.
Body weight
The body weight of the rats was measured at day 0 to 13, day 28, 38 and 45 at about 8.00 a.m.
Behavioral tests
The behavioral tests started after a washout period of 14 days. The open field test was performed on 
day 28 between 11.00 a.m. and 2.00 p.m. The paw test was performed on day 28 to 32 and day 34, 36 and 
38 between 9.00 and 11.00 a.m. and the Morris water maze task was performed on day 38 and 39 between 
10.00 a.m. and 4.00 p.m. All data were evaluated by subjects blind to the treatments.
Open field test
Open field tests have been previously used in rats injected with 6-OHDA into the SNc (Sakai, Gash, 
1994). In short, the rat is placed on an open field (glass: 160 cm x 160 cm and 95 cm high) for a period 
of 30 min and the behavior is recorded via a closed TV-circuit on videotape, allowing off-line analysis. 
A mirror was mounted under the glass top with an angle of 30°, allowing detailed analysis of the stepping 
pattern (Cools, Jongen-Relo, 1991). The following behavioral items were scored using Observer 3.0 
software to calculate the duration (sec ± 0.5 sec).
Rearing: the rat is putting its body weight on its hindlimbs, holding its trunk in upright position, and 
lifting both forelimbs from the floor.
Grooming: the rat is manipulating its fur with forelimbs and/or mouth.
Normal stepping: the rat is moving in forward and/or lateral direction, keeping its trunk in horizontal 
direction, and lifting and placing each limb at least once. Meanwhile, the limbs are carrying the body 
weight in an adequate manner.
Abnormal stepping: the rat is moving, but the limbs are unable to carry the body weight in an adequate 
manner, resulting in (1) walking on the toes, (2) not placing the limb(s) at all, (3) dragging the limb(s), or 
(4) strongly flexing the limb(s), whereby the distance between the belly and the floor is less than 1 cm. 
The percentage time of the total observation period spent on each of these items was calculated.
Paw test
This test has been extensively validated and assessed in a variety of studies, showing that alterations 
in (meso)striatal dopaminergic activity change the retraction time of the forelimbs and hindlimbs 
(Ellenbroek, Cools, 1988). The test apparatus consists of a Perspex platform (30 by 30 cm, with a height
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of 20 cm) having 4 holes, two holes (4 cm diameter) for the forelimbs and two holes (5 cm diameter) for 
the hindlimbs. The rat is placed on the platform with its hind- and forelimbs into the appropriate holes. 
The retraction time of the limbs is recorded on videotape, allowing off-line analysis of the retraction time 
of each limb by means of a timer. A single session per day consists of 3 trials with an inter-trial interval 
of approximately 10 min. Per trial the retraction time (in sec ± 0.4 sec) of both hindlimbs (forelimbs) was 
averaged; next, these values were averaged per session; finally, the resulting values were averaged across 
all test-days, providing the mean retraction time of the hindlimbs (HRT, in sec) and the mean retraction 
time of the forelimbs (FRT, in sec).
Morris water maze task
The effects of 6-OHDA in this test have been assessed earlier (Whishaw, Dunnett, 1985). The procedure 
of (Whishaw, 1985) was followed, with minor modifications. In short, the water maze consists of a 
circular pool (diameter 120 cm, height 80 cm) filled with water (23° C ± 1° C) in which a Plexiglas 
platform (diameter 8 cm) is submerged 15 mm below the surface of the water. The platform is invisible 
due to milk powder dissolved in the water. The platform is placed in the middle of the North/West 
quadrant, 30 cm from the edge of the pool. The rat is able to locate the platform with the help of visual, 
auditory and olfactory cues on the walls of the room. The animal is placed in the water with the snout 
facing the wall and allowed to swim for maximally 120 sec. When the platform is found or when the 
maximal time of 120 sec is reached, the rat is kept on the platform for 30 sec. The rats were subjected to 
3 sessions of 4 trials (inter-trial interval: 2-3 min): the first two sessions (inter-session interval: 4 h) were 
assessed on day 38, whereas the third set was assessed on day 39, 24 h after the first trial on day 38. Four 
start positions (South, East, North and West) were used. The sequence, at which the starting positions 
were used, was at random, although the start position of each rat was the same in the first trial of each 
session. A fully computerized and automated tracking system (Cools et al., 1990) was used for calculating: 
escape latency, namely the time required to find the platform (escape latency: sec ± 0.1 sec), distance 
traveled (distance: m ± 0.01 m) and swimming speed (ratio of distance and escape latency: m/sec).
Perfusion
At the end of experiments (day 45), the animals were deeply anesthetized with sodium pentobarbital 
(Narcovet, i.p., 240 mg/kg). Under deep anesthesia the rats were transcardially perfused with 100 ml. 
saline followed by 300 ml fixative containing 4 % paraformaldehyde in 0.1 M PBS. After perfusion the 
rats were decapitated, and the dorsal part of the skull was removed. The head was placed in a stereotaxic 
frame, and a transverse incision was made to allow sectioning of the brain in a standardized transverse 
plane. Thereafter, the remainder of the skull was removed, and the brains were postfixated in 1 % 
paraformaldehyde for 3 days.
Tyrosine Hydroxylase staining procedure
Coronal sections (50 pm) were cut of the tegmental and nigral area using a vibratome (Leica VT1000S). 
TH immunocytochemistry was processed according to the immunoperoxidase staining method of 
(Sternberger et al., 1970). The staining was processed free floating and under a constant room temperature 
of 22° ± 1° C. Between each step, the sections were rinsed thoroughly with PBS. Sections were pre­
incubated with PBS containing 0.1 % BSA and 0.5 % triton for 60 min and, thereafter, incubated with a 
mouse monoclonal antibody to TH (1: 10.000) overnight. Then, sections were incubated with biotinylated 
donkey anti-mouse secondary antibody (1:1000) for 90 min. Sections were then incubated in avidin- 
biotin-peroxydase complex using the Elite ABC Vectastain kit (agent A: 1:800, agent B: 1:800). 
Subsequently, sections were pre-incubated with DAB (0.2 mg/ml) in Tris buffer including nickel (2 mg/ 
ml) as the chromogen enhancer for 10 min. The reaction was started and tyrosine hydroxylase 
immunoreactivity (TH-irj was visualized with H2O2 (1:8300) and terminated after 10 min by rinsing 
thoroughly with PBS. Thereafter, the sections were mounted on slides coated with chromealum (0.5 mg/ 
ml) and gelatine (5 mg/ml) and cover-slipped with Entelan. In order to standardize the TH staining 
procedure all incubation times were fixed. Nevertheless all experimental groups were equally divided 
over the staining sessions to prevent confounding by staining procedure variances. The site of the 6- 
OHDA injection was determined by evaluating the needle track using dark field microscopy. Rats in
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which the tip of the needle was more than 300 pm away from the aimed spot within the SNc on either 
side, were excluded.
Tyrosine hydroxylase quantification
A quantitative analysis of TH-ir in the sections at the intra-aural (IA) levels 3.7, 3.9 and 4.1 (anterior 
posterior level -5.3, -5.1, -4.9 mm from bregma, respectively) was done to estimate the size of the 6- 
OHDA lesion (Paxinos, Watson 1982). The medial terminal nucleus of the accessory optic tract (MT) 
served as an anatomical landmark: this tract just touches the ventral side of the ventral tegmental area 
(VTA) and SNc at the anterior posterior co-ordinate IA 3.9. Since the sections were cut and mounted in 
sequence, the section at the anterior/posterior levels 4.1 (4 sections posterior of IA 3.9) and 3.7 (4 sections 
anterior of IA 3.9) could be found (see also (Sauer, Oertel, 1994). At these levels, the left and the right 
VTA and SNc were digitized under a 25x magnification, and shade correction was performed. In order to 
determine the anatomical border between the SNc and the VTA a line was drawn between the MT, 
serving as the ventral landmark, and the lowest point of the curve formed by the VTA and SNc, serving 
as the dorsal landmark.
The sections were analyzed using the Scion Image computerized image analysis system (Scion 
Corporation, Frederick, MD). The total image consisted of 750 by 500 pixels and 146 pixels were equal 
to 1 mm. The system distinguished 256 gray levels, ranging from absolute white (0) to absolute black 
(256). The total area of the pixels (in mm2) with a gray level higher than 85 was calculated and estimated 
as TH positive (see also (Lu, Hagg, 1997). At each IA level, the TH positive area in the left and right SNc 
respectively and VTA were averaged.
Statistics
All values are expressed as mean ± S.E.M. Statistics were performed using SPSS 7.5 software (SPSS 
Inc., Il). The following comparisons were made. First, differences between sham-treated rats that had 
received CGP 3466B (sham/CGP 3466B) and sham-treated rats that had received the solvent of CGP 
3466B (sham/H2O) were evaluated as follows: (1) one-way ANOVA followed by Bonferroni where 
appropriate: parameters of the open field test (rearing, grooming, normal and abnormal stepping), 
parameters of the paw test (retraction time of the limbs), and TH-ir; (2) two-way ANOVA using the 
general linear method (factors: treatment and trial) with repeated measurements (trial): parameters of the 
Morris water maze task (escape latency, distance, speed); and (3) two-way ANOVA (factors: treatment 
and day) with repeated measurements (day): body weight. Because the outcome of this analysis revealed 
that the highest dose of CGP 3466B (1.4 mg/kg), but none of the lower doses of CGP 3466B, significantly 
affected the behavior of sham-treated rats, the effects of this dose were separately analyzed in the remaining 
experiments.
Second, differences between 6-OHDA-lesioned rats that had received distilled water (6-OHDA/H2O) 
and sham-treated rats that had received distilled water (sham/H2O) were evaluated as follows: (1) indepen­
dent one-sample t-test: parameters of the open field test, parameters of the paw test, and TH-ir; (2) two­
way ANOVA: parameters of the Morris water maze task (see above); and (3) two-way ANOVA: body 
weight (see above).
Third, differences between 6-OHDA-treated rats that had received 0.0014, 0.014 and 0.14 mg/kg 
CGP 3466B (6-OHDA/CGP 3466B) and 6-OHDA-lesioned rats that had received the solvent of CGP 
3466B (6-OHDA/H2O) were evaluated with the help of the statistical tests used for the evaluation of the 
differences between the sham/CGP 3466B and sham/H2O groups (see above); the same holds true for the 
evaluation of differences between the 6-OHDA/CGP 3466B groups and the sham/H2O group.
Finally, the differences between the 6-OHDA-treated rats that had received 1.4 mg/kg CGP 3466B 
and the 6-OHDA/H2O group were evaluated with the help of the statistical tests used for the evaluation 
of the differences between the sham/H2O and 6-OHDA/H2O groups (see above); the same holds true for 
the evaluation of differences between the 6-OHDA-treated rats that had received 1.4 mg/kg CGP 3466B 
and the sham/H2O group.
The accepted level of significance was p < 0.05.
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Results
Histology
In 27 out of 1G2 rats, the tip of the needle was found to be more than 3GG mm away from the 
aimed spot at the SNc: these rats were excluded from the analysis. The groups contained the 
following numbers of animals: sham/H2O: n = 9, sham/G.GGl4 mg/kg CGP 3466B: n = 7, 
sham/G.Gl4 mg/kg CGP 3466B: n = 8, sham/G.14 mg/kg CGP 3466B: n = 8, sham/1.4 mg/kg 
CGP 3466B: n = 9, 6-OHDA/ H2O: n = 6, 6-OHDA/G.GG14 mg/kg CGP 3466B: n = 7, 6- 
OHDA/G.G14 mg/kg CGP 3466B: n = 7, 6-OHDA/G.14 mg/kg CGP 3466B: n = 7 and 6- 
OHDA/1.4 mg/kg CGP 3466B: n = 7. 2 Sham/ H2O -treated rats had to be excluded from the 
paw test because of blurred video images.
Effects o f  CGP 3466B in sham-treated rats
One-way ANOVA indicated that CGP 3466B was not without effects in sham-treated rats 
on the percentage of time spent on abnormal stepping [F(4, 36) = 5.5; p < G.GG1; Fig. 1A], the 
HRT [F(4, 36) = 5.5; p < G.GG1; Fig 1B], and the amount of TH-ir at the various levels of the 
SNc and VTA [SNc, IA-level 3.7: F (4,35) = 11.1; p<G.GGl, SNc, IA-level 3.9: F(4,35) = 
15.G6; p<G.GGl; SNc, IA-level 4.1: F(4,35) = 6.4; p < G.GG1; Fig. 1D; VTA, IA-level 3.7: 
F(4,35) = 9.2; p<G.GGl; VTA, IA-level 3.9: F(4,35) = 12.4; p<G.GGl; VTA, IA-level 4.1: F(4,35) 
= 13.9; p<G.GGl; data not shown]. However, post hoc analysis revealed that none of the analyzed 
parameters significantly differed between the sham-treated groups that had received G.GG14, 
G.G14 or G.14 mg/kg CGP 3466B and the sham-treated group that had received the solvent of 
CGP 3466b (Fig. 1ABCD).
In contrast, the time spent on abnormal stepping and the HRT were significantly higher in 
the sham-treated rats that had received 1.4 mg/kg CGP 3466B than in the sham-treated rats that 
had received the solvent of CGP 3466B [abnormal stepping: Bonferroni: +p < G.G5; Fig. 1A; 
HRT: Bonferroni: +p < G.G5; Fig. 1B]. Moreover, the amount of TH-ir was significantly lower 
in both the SNc (Fig. 1D) and the VTA (data not shown) in the sham-treated animals that had 
received 1.4 mg/kg CGP 3466B than in the sham-treated animals that had received the solvent 
of CGP 3466B [all IA-levels: Bonferroni: +p < G.G5]. For these reasons, the effects of 1.4 mg/ 
kg CGP 3466B were separately analyzed (see also Methods).
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Fig. 1. Effects of CGP 3466B in sham-treated rats on abnormal stepping in the open field (Fig. 1A), FRT 
and HRT in the paw test (Fig. 1B), escape latency time in the Morris water maze (Fig. 1C) and nigral TH- 
ir (Fig. 1D). Data are expressed as mean + SEM. Fig 1A: The open field was performed at day 28 after the 
6-OHDA or sham treatment. The percentage of time of the total 30-minute observation time spent on 
abnormal stepping is expressed. Fig. 1B: The paw test was performed at day 28 to 32 and 34, 36, 38 after 
the 6-OHDA or sham treatment. Each daily session consisted of 3 trials. Values represent the mean value 
(in sec) of the two forelimbs (FRT) or hindlimbs (HRT) of the total of trials performed in the 10-day 
testing period. Fig. 1C: The Morris water maze was performed at day 38 and 39 after the 6-OHDA or 
sham treatment. Data represent the escape latency (the amount of time in sec that was required to the find 
the platform) at trial 1 to 12. Fig. 1D: Data represent the mean amount of TH-ir (in mm2) of the left and 
right SNc at the IA-levels 3.7, 3.9 and 4.1
Effects o f 6-OHDA 
Body weight
The body weight did not significantly differ between the 6-OHDA-treated rats that had received 
distilled water and the sham-treated rats that had received distilled water (data not shown). 
Open field test
The percentage of time spent on normal stepping, grooming or rearing behavior did not 
differ between the 6-OHDA-treated rats that had received distilled water and the sham-treated 
rats that had received distilled water (data not shown). In contrast, the percentage of time spent 
on abnormal stepping was significantly higher in the 6-OHDA/ H2O group than in the sham/ 
H2O group [t(13) = -6.0; *p < 0.05; Fig. 2A].
Paw test
The FRT and the HRT were significantly higher in the 6-OHDA-treated rats that had received 
distilled water than in the sham-treated rats that had received distilled water. [FRT: t(12) = - 
23.24; *p < 0.05; HRT: t(12) = - 2,73; *p < 0.05; Fig. 2B].
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Morris water maze test
Apart from the fact that the speed was significantly increased [two-way ANOVA: speed, factor 
trial: F(11,143)= 3.23; p < 0.001; data not shown], the escape latency and distance traveled 
were significantly reduced across the 12 trials [two-way ANOVA: escape latency, factor trial: 
F(11,143) = 11.38; p < 0.001; Fig. 2C; distance, factor trial; F(11,143) = 8.16; p < 0.001; data 
not shown]. The overall learning curve of escape latency did not differ between the 6-OHDA- 
treated rats that had received distilled water and the sham-treated rats that had received distilled 
water. However, careful comparison revealed that the acquisition was slightly delayed in the 6- 
OHDA/ H2O group. Therefore, the curve was divided in three parts, consisting of trial 1 to 3, 
trial 4 to 6, and trial 7 to 12. Subsequent analysis revealed that the escape latency time (Fig. 2C) 
and distance (data not shown) during trial 4 to 6 were significantly higher in the 6-OHDA- 
treated rats that had received distilled water than in the sham-treated group that had received 
distilled water [two-way ANOVA: escape latency, factor group: F(1,13)= 48.93; *p < 0.05; 
Fig. 2C; distance, factor group: F(1,13)= 48.13 ; *p < 0.05; data not shown], whereas there 
were no significant differences in escape latency and distance between the 6-OHDA/ H2O 
group and the sham/ H2O group during trials 1 to 3 and trials 7 to 12. The swimming speed did 
not significantly differ between the 6-OHDA-treated rats that had received distilled water and 
the sham-treated group that had received distilled water (data not shown).
Tyrosine hydroxylase immunoreactivity
The effects of the 6-OHDA treatment on the amount of TH-ir in the SNc and VTA are 
illustrated in Fig. 4A and 4B. The amount of TH-ir in the SNc was significantly lower in the 6- 
OHDA/ H2O group than in the SHAM/ H2O group at all levels [IA-level 3.7: t(13) = 4.83; *p 
< 0.05, IA 3.9-level: t(13) = 6.24; *p < 0.05 IA 4.1-level: t(13) = 3.52; *p < 0.05; Fig. 2D]. The 
amount of TH-ir in the VTA was not significantly different between the 6-OHDA-treated rats 
had received distilled water and the sham-treated group that had received distilled water at any 
level (data not shown).
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Fig. 2. Effects of 6-OHDA on abnormal stepping in the open field (Fig. 2A), FRT and HRT in the paw 
test (Fig. 2B), escape latency time in the Morris water maze (Fig. 2C) and the amount of nigral TH-ir 
(Fig. 2D). Data are expressed as mean + SEM. Fig. 2A: The open field was performed at day 28 after the 
6-OHDA or sham treatment. The percentage of time of the total 30-minute observation time spent on 
abnormal stepping is expressed. Fig. 2B: The paw test was performed at day 28 to 32 and 34, 36, 38 after 
the 6-OHDA or sham treatment. Each daily session consisted of 3 trials. Values represent the mean value 
(in sec) of the two forelimbs (FRT) or hindlimbs (HRT) of the total of trials performed in the 10-day 
testing period. Fig. 2C: The Morris water maze was performed at day 38 and 39 after the 6-OHDA or 
sham treatment. Data represent the escape latency (the amount of time in sec that was required to the find 
the platform) at trial 1-12 (Fig. 2C). Fig. 2D: Data represent the mean amount of TH-ir (in mm2) of the 
left and right SNc at the IA-levels 3.7, 3.9 and 4.1.
Effects o f CGP 3466B in 6-OHDA-treated animals 
Body weight
The body weight did not significantly differ between the 6-OHDA-treated rats that had received 
CGP 3466B and the 6-OHDA-treated rats that had received the solvent of CGP 3466B (data 
not shown).
Open field test
One-way ANOVA showed that CGP 3466B had significant effects on the percentage of 
time spent on stepping in the 6-OHDA-treated rats [F(3,26) = 5,84; p<0.01; Fig. 3A]. Post hoc 
analysis revealed that the percentage of time spent on abnormal stepping was significantly 
lower in the 6-OHDA-treated rats that had received 0.0014 and 0.014 mg/kg CGP 3466b than 
in the 6-OHDA-treated rats that had received the solvent of CGP 3466B [post hoc Bonferroni: 
#p<0.05; Fig. 3A]. The additional statistical analysis revealed that the 6-OHDA-treated group 
that had received 0.014 mg/kg CGP 3466B did not anymore differ from the sham-treated group 
that had received distilled water. The percentage of time spent on abnormal stepping did not 
significantly differ between the 6-OHDA-treated group treated with 1.4 mg/kg CGP 3466B 
and the 6-OHDA-treated group treated with the solvent of CGP 3466B (data not shown).
Paw test
One-way ANOVA showed that CGP 3466B had significant effects on the FRT and HRT of 
6-OHDA-treated rats [FRT: F(3,27)= 7.0; p < 0.01; HRT: F(3,27)= 5,8; p < 0.01; Fig. 3B]. Post 
hoc analysis showed that the FRT was significantly lower in the 6-OHDA-treated rats that had 
received 0.014 and 0.14 mg/kg CGP 3466B than in the 6-OHDA-treated rats that had received 
the solvent of CGP 3466B [Bonferroni: #p < 0.05; Fig. 3B]. The HRT was significantly lower 
in the 6-OHDA-treated rats that had received 0.0014, 0.014 and 0.14 mg/kg CGP 3466B than 
in the 6-OHDA-treated rats that had received the solvent of CGP 3466B [Bonferroni: #p <
0.05; Fig. 3B]. The additional analysis revealed that the HRT and FRT in these groups did not 
anymore differ from the sham-treated group that had distilled water. In contrast, t-tests showed 
that the FRT, but not the HRT, was significantly higher in the 6-OHDA rats that had received 
1,4 mg/kg CGP 3466B than in the 6-OHDA-treated rats that had received the solvent of CGP 
3466B [t(12) = 6.86; p < 0.05; data not shown].
Morris water maze test
Two-way ANOVA showed that the escape latency (Fig. 3C) and distance (data not shown), 
but not the speed (data not shown), were significantly lower in the 6-OHDA-treated rats injected 
with 1.4 mg/kg CGP 3466B than in the 6-OHDA-treated rats that had received the solvent of 
CGP 3466B [escape latency, factor group: F(1,11)= 14.44; p<0.01; Fig. 3C; distance, factor 
group: F(1,11)= 30.99; p<0.001; data not shown]. The additional statistical analysis revealed 
that the escape latency and distance did not anymore significantly differ between the latter
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groups and the sham/ H2O group. As a final remark, the speed, escape latency and distance did 
not significantly differ between the 6-OHDA-treated rats that had received the lower doses of 
CGP 3466b (G.GG14 to G.14 mg/kg) and the 6-OHDA-treated rats that had received the solvent 
of CGP 3466B (two-way ANOVA; data not shown).
Tyrosine hydroxylase immunoreactivity
The effects of G.G14 mg/kg CGP 3466b on the amount of TH-ir in the SNc and VTA of 6- 
OHDA-treated rats are illustrated in Fig. 4B and 4C.
One-way ANOVA revealed that CGP 3466b reduced the 6-OHDA-induced decrease in 
TH-ir at the various levels of the SNc of the 6-OHDA-treated rats [F(3,25)= 5.46; p < G.G1; 
Fig. 3D]. Post hoc analysis revealed that the amount of TH-ir at the IA-level 3.7 was significantly 
higher in the 6-OHDA-treated rats that had received G.GG14 mg/kg and G.G14 mg/kg CGP 
3466b than in the 6-OHDA-treated rats that had received the solvent of CGP 3466B [Bonferroni: 
#p<G.G5]. Moreover, the amount of TH-ir at the IA-level 3.9 was significantly higher in the 6- 
OHDA-treated rats that had received G.G14 mg/kg than in the 6-OHDA-treated rats that had 
received the solvent of CGP 3466B [Bonferroni: #p<G.G5]. The amount of TH-ir at the level 
IA 3.7 did not anymore significantly differ between the 6-OHDA-treated groups that had received 
G.GG14 and G.G14 mg/kg CGP 3466B and the sham-treated group that had received its solvent. 
In contrast, independent sample t-tests revealed that the amount of nigral TH-ir at the IA-levels 
IA 3.7 and 3.9 was significantly lower in the 6-OHDA-treated group that had received 1.4 mg/ 
kg CGP 3466B than in the 6-OHDA-treated group that had received the solvent of CGP 3466B 
[IA-level 3.7: t( l l )  = 2.44; p<G.G5, IA 3.9-level: t( l l)  = 3,8; p<G.G5; data not shown].
Fig. 3: Effects of CGP 3466B on the 6-OHDA-induced effects on abnormal behavior in the open field 
(Fig. 3A), FRT and HRT in the paw test (Fig. 3B), escape latency time in the Morris water maze (Fig. 3C) 
and nigral TH-ir (Fig. 3D). Data are expressed as mean + SEM. Fig. 3A: The open field was performed 
at day 28 after the 6-OHDA or sham treatment. The percentage of time of the total 30-minute observation
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time spent on abnormal stepping is 
expressed. Fig. 3B: The paw test 
was performed at day 28 to 32 and 
34, 36, 38 after the 6-OHDA or 
sham treatment. Each daily session 
consisted of 3 trials. Values 
represent the mean value (in sec) 
of the two forelimbs (FRT) or 
hindlimbs (HRT) of the total of 
trials performed in the 10-day 
testing period. Fig. 3C: The Morris 
water maze was performed at day 
38 and 39 after the 6-OHDA or 
sham treatment. Data represent the 
escape latency (the amount of time 
in sec that was required to the find 
the platform) at trial 4 to 6. Fig. 3D: 
Data represent the mean amount of 
TH-ir (in mm2) of the left and right 
SNc at the IA-levels 3.7, 3.9 and 
4.1.
Fig. 4. Photographs of 
representative sections of the SNc 
and VTA at the IA-level 3.9 after 
treatment with sham/ H2O (A), 6- 
OHDA/ H2O (B) and 6-OHDA/ 
CGP 3466B 0.014 mg/kg (C). 
Sections are immunocyto- 
chemically stained for TH. The 
magnification is 10 x 6,3. The 
vertical line depicts the border of 
the SNc and VTA. SNc = substantia 
nigra pars compacta. VTA = ventral 
tegmental area. MT = medial part 
of the accessory optic tract.
Discussion
General Discussion
CGP 3466B has been reported to potently prevent neuronal apoptosis in vitro (Kragten et al., 
1998). Moreover, in vivo studies have suggested that this compound reduces the degenerative 
processes in animal models of amyotrophic lateral sclerosis (Kato et al., 1996) and ischemia 
(Paterson et al., 1998b). The present study is the first to show that CGP 3466B is able to
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prevent both the behavioral and morphological consequences of degeneration of nigrostriatal 
dopaminergic neurons induced by 6-OHDA, in a prominent rodent model of Parkinson’s disease.
Effects o f 6-OHDA
The bilateral intranigral administration of 3.0 ug 6-OHDA induced both behavioral and 
morphological abnormalities. First, the 6-OHDA treatment induced motor deficits: it enhanced 
the retraction time of the fore- and hindlimbs and elicited abnormal stepping. These deficits 
clearly reflect the extensively reported sensorimotor deficits that are induced by damage to the 
dopaminergic nigrostriatral tract and decreased dopaminergic input of the striatum (Barneoud 
et al., 1995). Second, 6-OHDA induced learning deficits: in the Morris water maze, it increased 
the escape latency time to find the platform at trial 4 to 6, but not at the later trials, showing that 
the 6-OHDA treatment delayed the acquisition of this task. The fact that 6-OHDA did not 
prevent the acquisition together with the finding that it did not alter the swimming speed of the 
rats reveals that the noted delay is not simply due to motor deficits. As shown earlier (Cools, 
1980), the striatal dopamine allows the organism to select arbitrarily the best strategy under 
stressful conditions. Therefore, the 6-OHDA treatment may have hampered this function of the 
striatum, resulting in the noted delay of the acquisition in the Morris water maze task. Finally, 
and in concord with many studies (Hefti et al., 1980), 6-OHDA induced morphological deficits: 
it reduced the TH positive area in the SNc, which reflects the extent of the damage to the 
dopaminergic neurons in this area. (Wolf et al., 1989).
While the classical unilateral lesion procedures often induce widespread degeneration of 
all midbrain dopaminergic areas at one side of the brain (Ungerstedt et al., 1974; Zigmond, 
Stricker 1989; Zigmond, Stricker, 1989; Schwarting, Huston, 1997), the bilateral degeneration 
produced by the updated procedure affected the TH activity only in the SNc. In addition, unlike 
the classical models (Ungerstedt, 1971; Hodge, Butcher, 1980; Whishaw et al., 1997), this 
updated model did not induce severely incapacitating behavioral deficits: it did not alter 
grooming, rearing and walking behavior of the rats. Moreover, it did not significantly reduce 
the body weight. In sum, our data confirm that a moderate dose of 6-OHDA locally and bilaterally 
administered into the SNc induces a relatively specific destruction of the nigrostriatal 
dopaminergic system, which is accompanied by moderate but characteristic behavioral 
disturbances (Schwarting, Huston, 1997). For these reasons, the present model appeared suitable 
for studying the effects of compounds like CGP 3466B.
Effects o f CGP 3466B
CGP 3466B was able to prevent the display of all the deficits seen in our 6-OHDA-treated 
rats. Remarkably, however, the dose-range required to prevent the symptoms varied per deficit 
studied: impaired stepping was prevented by 0.0014 and 0.014 mg/kg CGP 3466B; impairments 
in the paw test were prevented by 0.014 to 0.14 mg/kg; impaired acquisition in the Morris 
water maze was prevented by 1.4 mg/kg; and, finally, impaired TH-ir was prevented by 0.0014 
and 0.014 mg/kg CGP 3466B. Thus, it prevented the display of behavioral and morphological 
deficits that normally occur in rats with nigral dopamine depletion. These data clearly show 
that CGP 3466B that is highly effective in rescuing cells in in viro  studies is also extremely 
potent in preventing dopaminergic degeneration in vivo.
However, at the highest dose of CGP 3466B (1.4 mg/kg), the protective effects against 6- 
OHDA in the motor tests as well as those seen in the quantitative TH evaluation were lost. 
Moreover, this dose increased the HRT, generated abnormal stepping and reduced the amount 
of TH-ir in sham-treated rats qualitatively similar to those seen after local administration of 6-
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OHDA. This suggests a biphasic dose-response relationship of the compound, with an optimum 
around 0.014 -  0.14 mg/kg s.c. Whether this biphasic action is inherent to the mechanism of 
action or reflects independent processes occurring at different dose levels is impossible to say 
on the basis of the present experiments.
It is very unlikely that the effects of CGP 3466B were symptomatic, since the effects of 
CGP 3466B were evaluated at least 14 days after the last administration of the compound. 
Moreover, unlike most propargylamines (Gerlach et al., 1992), CGP 3466B does not increase 
synaptic dopamine via an inhibitory effect on MAO-B (Waldmeier, personal communication). 
It is also not conceivable that CGP 3466B interfered with the toxicity or uptake of 6-OHDA, 
since it was administered two hours after the injection of 6-OHDA. Therefore, it is suggested 
that CGP 3466B mediates its protective effects via a direct interference with the degenerative 
process initiated by 6-OHDA.
Although the precise action of CGP 3466B remains elusive, (Kragten et al., 1998) have 
reported that CGP 3466B binds to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
Besides its role as enzyme in the glycolysis, GAPDH has been found to play a role in apoptosis 
(Sunaga et al., 1995). Indeed, CGP 3466B prevents neuronal apoptosis induced by GAPDH 
over-expression in vitro (Kragten et al., 1998). These data strongly suggest that GAPDH is 
involved in the mechanism by which CGP 3466B rescues cells from apoptosis.
In conclusion, CGP 3466B was able to prevent all the 6-OHDA-induced deficits, though at 
different doses. The data suggest that, at appropriate doses, CGP 3466B may be able to prevent 
the progression of dopaminergic degeneration in patients with PD, especially in the early stage 
of the disease.
Acknowledgements: The authors would like to thank Dr. P. Waldmeier for his critical and 
helpful comments on the manuscript and Novartis Pharma, Basel, Switzerland, for generously 
providing CGP 3466B.
References
Anglade P, Vyas S, Javoy AF, Herrero MT, Michel PP, Marquez J, Mouatt PA, Ruberg M, Hirsch EC, Agid Y (1997) 
Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol.Histopathol. 12:25-31.
Barneoud P, Parmentier S, Mazadier M, Miquet JM, Boireau A, Dubedat P, Blanchard JC (1995) Effects of complete 
and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 
67:837-848.
Breese GR, Traylor TD (1971) Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br.J.Pharmacol. 
42:88-99.
Calne DB (1995) Selegiline in Parkinson’s disease - No neuroprotective effect: Increased mortality. BMJ 311:1583­
1584.
Cools AR (1980) Role of the neostriatal dopaminergic activity in sequencing and selecting behavioural strategies: 
facilitation of processes involved in selecting the best strategy in a stressful situation. Behav.Brain Res. 1:361-378.
Cools AR, Brachten R, Heeren D, Willemen A, Ellenbroek B (1990) Search after neurobiological profile of individual- 
specific features of Wistar rats. Brain Res.Bull. 24:49-69.
Cools AR, Jongen-Relo AL (1991) Role of neostriatum and nucleus accumbens in stepping induced by apomorphine 
and dexamphetamine. Brain Res.Bull. 26:909-917.
Ellenbroek B, Cools AR (1988) The Paw test: an animal model for neuroleptic drugs which fulfils the criteria for 
pharmacological isomorphism. Life Sci. 42:1205-1213.
112
CGP 3466B prevents 6-OHDA-induced deficits in vivo
Fornaguera J, Schwarting RK, Boix F, Huston JP (1993) Behavioral in dices o f moderate nigro-striatal 6- 
hydroxydopamine lesion: a preclinical Parkinson’s model. Synapse 13:179-185.
Gelowitz DL, Paterson IA (1999) Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)Deprenyl, 
following kainic acid administration. Pharmacol Biochem Behav 62:255-262.
Gerlach M, Riederer P, Youdim MB (1992) The molecular pharmacology of L-deprenyl. Eur.J.Pharmacol. 226:97­
108.
Glinka Y, Tipton KF, Youdim MB (1996) Nature o f inhibition of mitochondrial respiratory complex I by 6- 
Hydroxydopamine. J.Neurochem. 66:2004-2010.
Hefti F, Melamed E, Wurtman RJ (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical 
characterization. Brain Res. 195:123-137.
Hodge GK, Butcher LL (1980) Pars compacta of the substantia nigra modulates motor activity but is not involved 
importantly in regulating food and water intake. Naunyn Schmiedebergs Arch.Pharmacol. 313:51-67.
Iwasaki Y, Ikeda K, Kobayashi T, Tagaya N, Kinoshita M (1996) Deprenyl and pergolide rescue spinal motor neurons 
from axotomy-induced neuronal death in the neonatal rat. Neurol Res 18:168-170.
Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47:S161-S170
Kato AC, Bernheim L, Waldmeier P, Sagot Y, (1997) CGP 3466B, a dibenzoxepine derivate, increases life-span in an 
animal model of motoneuron disease. Soc. for Neurosci. Abstr. 23: 554 (abstr no 215.14).
Kirik D, Rosenblad C, Bjorklund A (1998) Characterization of behavioral and neurodegenerative changes following 
partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp.Neurol. 
152:259-277.
Koutsilieri E, Chen T-S, Rausch WD, Riederer P (1996) Selegiline is neuroprotective in primarybrain cultures treated 
with 1-methyl-4-phenylpyridinium. Eur J Pharmacol 306:181-186.
Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Muller D, van OJ, Waldmeier P, Furst P (1998) 
Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(- 
)-deprenyl. J.Biol.Chem. 273:5821-5828.
LeWitt PA (1991) Deprenyl’s effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson 
Study Group. Acta Neurol.Scand.Suppl. 136:79-86:79-86.
Lu X, Hagg T (1997) Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, 
of injured nigrostriatal neurons in adult rats. J.Comp.Neurol. 388:484-494.
Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J.Neurosci.Methods 
11:47-60.
Mytilineou C, Cohen G (1985) Deprenyl protects dopamine neurons from neurotoxic effects of 1-methyl-4- 
phenylpyridinium ion. J Neurochem 45:1951-1953.
Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW (1997a) L-Deprenyl protects mesencephalic dopaminergic 
neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68:33-39.
Mytilineou C, Radcliffe PM, Olanow CW (1997b) L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], 
protects mesencephalic dopamine neurons from excitotoxicity in vitro. J.Neurochem. 68:434-436.
Olanow CW (1996) Selegiline: Current perspectives on issues related to neuroprotection and mortality. Neurology 47 
Suppl. 3:S210-S216.
Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995) Forelimb akinesia in the rat Parkinson model: differential 
effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J.Neurosci. 15:3863-3875.
113
Chapter 7
Paterson IA, Zhang D, Warrington RC, Boulton AA (1998a) R-deprenyl and R-2-heptyl-N-methylpropargylamine 
prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. 
J.Neurochem. 70:515-523.
Paterson IA, Waldmeier P, Boulton AA (1998b) CGP 3466 and CGP 3466B prevent cytosine arabinoside-induced 
apoptosis in cultures of cerebellar neurones. J Neurochem 70 (Suppl. 1):S11B.(Abstract)
Paterson IA, Fennig CJ, Gelowitz DL, Waldmeier P, Boulton AA (1998c) CGP3466 prevents neuronal death in models 
of ischaemia and seizure in vivo. J Neurochem 70 (Suppl.1):S6C.(Abstract)
Parkinson Study Group (1998) Mortality in DATATOP: a multicenter trial in early Parkinson’s disease. Ann.Neurol. 
43:318-325.
Paxinos G and Watson C, (1982) The rat brain in stereotaxic coordinates. New York Acedemic Press.
Sakai K, Gash DM (1994) Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. 
Brain Res. 633:144-150.
Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal 
lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. 
Neuroscience 59:401-415.
Schwarting RK, Huston JP (1997) Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine 
lesions. Neurotoxicology. 18:689-708.
Shoulson I (1992) An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early 
Parkinson’s disease. The Parkinson Study Group. Eur.Neurol. 32 Suppl 1:46-53:46-53.
Sternberger LA, Hardy-PH J, Cuculis JJ, Meyer HG (1970) The unlabeled antibody enzyme method of 
immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase- 
antihorseradish peroxidase) and its use in identification of spirochetes. J.Histochem.Cytochem. 18:315-333.
Sunaga K, Takahashi H, Chuang DM, Ishitani R (1995) Glyceraldehyde-3-phosphate dehydrogenase is over-expressed 
during apoptotic death of neuronal cultures and is recognized by a monoclonal antibody against amyloid plaques 
from Alzheimer’s brain. Neurosci.Lett. 200:133-136.
Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J 
Neurosci Res 30:666-672.
Tatton WG, Ju WYL, Holland DP, Tai C, Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new 
protein synthesis. J Neurochem 63:1572-1575.
Tatton WG, Ansari K, Ju W, Salo PT, Yu PH (1995) Selegiline induces “trophic-like” rescue of dying neurons without 
MAO inhibition. Adv Exp Med Biol 363:15-16.
Tatton WG, Ju WYH, Wadia J, Tatton NA (1996) Reduction of neuronal apoptosis by small molecules: promise for 
new approaches to neurological therapy. In: Neurodegeneration and Neuroprotection in Parkinson’s Disease (Olanow 
CW, Jenner P, Youdim MBH eds), pp 209-220. London: Academic Press.
Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to 
detect and confirm apoptotic nuclei in Parkinson’s disease. Ann Neurol 44 Suppl. 1:S142-S148.
Tompkins MM, Basgall EJ, Zamrini E, Hill WD (1997) Apoptotic-like changes in Lewy-body-associated disorders 
and normal aging in substantia nigral neurons. Am.J.Pathol. 150:119-131.
Ungerstedt U (1971) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine 
system. Acta Physiol.Scand.Suppl. 367:
Ungerstedt U, Ljungberg T, Steg G (1974) Behavioral, physiological, and neurochemical changes after 6- 
hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv.Neurol. 5:421-6:421-426.
114
CGP 3466B prevents 6-OHDA-induced deficits in vivo
Van Oosten RV, van de Witte SV, Voorn P, Groenewegen HJ, Stoof JC, Cools AR (1998) A subtle unilateral 6-OHDA 
lesion, specific of the A9 cell-group, changes the A9 and A10 function in behavioral programs of two types of Wistar 
rat. Soc. for Neurosci. Abstr. 645: 1644 (abstr no 646.1214).
Walkinshaw G, Waters CM (1994) Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of 
apoptosis. Neuroscience 63:975-987.
Ward CD (1994) Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP 
study. J.Neurol.Neurosurg.Psychiatry 57:217-220.
Whishaw IQ (1985) Formation of a place learning-set by the rat: a new paradigm for neurobehavioral studies. 
Physiol.Behav. 35:139-143.
Whishaw IQ, Coles BL, Pellis SM, Miklyaeva EI (1997) Impairments and compensation in mouth and limb use in free 
feeding after unilateral dopamine depletions in a rat analog of human Parkinson’s disease. Behav.Brain Res. 84:167­
177.
Whishaw IQ, Dunnett SB (1985) Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation 
and locomotion dependent upon beacon or distal cues. Behav.Brain Res. 18:11-29.
Wolf ME, Zigmond MJ, Kapatos G (1989) Tyrosine hydroxylase content of residual striatal dopamine nerve terminals 
following 6-hydroxydopamine administration: a flow cytometric study. J.Neurochem. 53:879-885.
Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM (1984) Neurochemical compensation after nigrostriatal 
bundle injury in an animal model of preclinical parkinsonism. Arch.Neurol. 41:856-861.
Zigmond MJ, Stricker EM (1989) Animal models of parkinsonism using selective neurotoxins: clinical and basic 
implications. Int.Rev.Neurobiol. 31:1-79.
115
Chapter 7
116
Summary and Discussion
Chapter 8
Summary and Discussion
117
Chapter 8
At present, the current medical treatments for patients with PD have two major disadvantages. 
Firstly, severe response complications are induced in the longer run and, secondly, the progression 
of the neurodegenerative process underlying the disease is not substantially inhibited. 
Consequently, pharmacotherapy can be improved by the development of alternative symptomatic 
treatments that induce less response complications and by new protective treatments that are 
capable of inhibiting the detrimental process of neurodegeneration. The aim of the present 
study was to increase the insight into the effectiveness of three of such new pharmaco-therapies 
for the treatment of PD, using the MPTP-treated primate and the 6-OHDA-treated rat as models 
of the disease.
The study deals with three issues.
Given the fact that the large variety of MPTP-treated primate models give unanimous results 
concerning the therapeutic efficacy of alternative symptomatic treatments, we firstly examined 
the predictive validity of two models commonly used to study the effectiveness of these new 
therapies: the unilaterally and bilaterally MPTP-treated rhesus monkey.
Secondly, the therapeutic efficacy of putative new symptomatic treatments that interact 
with the dopamine D1 receptor, namely SKF 82958 and SKF 83959, were evaluated in the 
primate model that was found to have predictive validity in our previous experiments, namely 
the bilaterally MPTP-treated rhesus monkey. Moreover, the mechanisms underlying the 
therapeutic effects of SKF 83959, that is an antagonist to rat dopamine D1 receptors, were 
studied both in vivo and in vitro.
Finally, the therapeutic efficacy of the putatively neuroprotective compound CGP 3466B 
was evaluated. The neuroprotective properties of this propargylamine were studied in an updated 
6-OHDA rat model that has been found to be a suitable model for studying the effects of 
neuroprotective compounds like CGP 3466B.
Below, the most important findings of these three issues will be shortly summarized and 
discussed. Moreover, the relevance of these findings for the treatment of PD is considered, and 
future prospects are given.
1. The validity of the MPTP-treated primate as animal model for PD
The utilization of a valid animal model is critical for increasing our insight into the therapeutic 
potential of new treatment strategies for PD. The neurotoxin MPTP offers a powerful tool for 
developing such models; however, the variety of MPTP primate models and behavioural analyses 
currently used to evaluate new treatments is very large. Consequently, there is much variation 
between the results of different reports obtained with the same drug treatments, being serious 
constraints for predicting the clinical efficacy of new drug treatments in a reliable manner.
Therefore, in the first part of this study it was decided to examine the predictive validity of 
two commonly used MPTP primate models, namely the unilaterally MPTP-treated monkey 
and the bilaterally MPTP-treated monkey. In order to enable a clear-cut separation of drug- 
induced behavioral items into therapeutic and undesired effects we developed a detailed 
quantitative behavioral analysis of operationally defined behavioral parameters, to gain insight 
into the predictive validity of these two models. As described in Chapter 2, the predictive 
validity of the unilaterally MPTP-treated monkeys was investigated by evaluating the behavioural 
effects of the dopamine D2 receptor agonist LY 171555 and the dopamine D1 receptor agonist 
SKF 81297. We studied these drugs in the most commonly used unilateral primate model, 
namely the model in which the monkeys have a dopamine agonist pre-treatment history. Neither
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agonists had any therapeutic effect: goal-directed, functional movements were not re-instated. 
Instead, the new ethogram made clear that both agonists induced non-goal-directed, contralateral 
forelimb movements and contralateral rotational behaviors. Moreover, the drug treatments did 
not only induce dyskinesia and dystonia, but also epileptoid behavior, that was confirmed by 
EEG analysis. Given the fact that dopamine D2 receptor agonists have therapeutic effects in 
patients without inducing epileptoid behaviors (Biesemeyer et al., 1983), the data indicate that 
the primed unilaterally MPTP-treated monkey does not adequately predict the clinical effects 
of the dopamine D2 receptor agonist. Thus, we have concluded that the pre-treated, unilaterally 
MPTP-treated monkey is not a valid model to predict the therapeutic and undesired effects of 
dopaminergic drugs in humans. It remains to be established whether this limited predictive 
validity is due to the pre-treatment history of the monkeys or the unilaterality of the lesion.
Given these data, we choose to evaluate the predictive validity of the drug-naive and the 
dopamine agonist pre-treated, bilaterally MPTP-treated monkey in Chapter 3. While many 
methods used to induce bilateral damage to the dopamine system elicit almost complete, bilateral 
dopamine depletion and severe behavioral deficits, we used the method of Smith et al., (1993), 
that induces less severe dopamine depletion on one side and that induces a stable syndrome 
while the animals remain fit and able to feed, groom etc. We studied the chronic effects of L- 
DOPA in this model. This study revealed that L-DOPA had clear therapeutic effects as reflected 
by an increase in the use of goal-directed forelimb movements. Moreover, L-DOPA induced 
dystonia and dyskinesia after chronic treatment, but not acutely. Given the fact that the acute 
(day 1) and subchronic (day 21) therapeutic and undesired effects of L-DOPA were very similar 
to respectively the acute and chronic effects of this drug in patients, we have concluded from 
this experiment that the drug-naive and L-DOPA pre-treated bilaterally MPTP-treated monkey 
is an animal model with predictive validity, and thus an excellent model for increasing our 
insight into the therapeutic and undesired effects of new symptomatic pharmaco-therapies for 
PD. Moreover, the use of detailed qualitative analyses of behavioral parameters that allow a 
clear distinction between therapeutic and undesired effects of symptomatic treatments contributes 
to a more reliable evaluation of such treatments.
While at least one primate model is thus available for screening new treatment strategies, so 
far there are only limited tools for studying the progressive neurodegenerative processes 
underlying PD, given the lack of progressiveness (Irwin et al., 1990; Graybiel et al., 1993) 
induced by the (sub)acute administration of MPTP in the available models. A few groups have 
attempted to develop a MPTP model of progressive parkinsonism in primates (Albanese et al., 
1993; Hantraye et al., 1993; Blanchet et al., 1998). These studies suggest that during long term 
administration of very low doses of MPTP, animals show a pattern of degeneration that shows 
even closer resemblance to the neuropathology of PD than the (sub)acute administration of the 
compound. The development of such models may be of ultimate importance for our 
understanding of the neurodegenerative processes underlying PD. However, “progressive” 
models are hardly applicable for evaluating the effects of new symptomatic and protective 
treatments strategies: both the continuous changes in the lesion size and motor behavior induced 
by chronic injection of MPTP and the interaction between the drug under study and the toxin 
may confound the results of such studies. The “acute” bilaterally MPTP-treated primate may 
remain the most adequate model in this respect.
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2. The possible role of dopamine D1 receptor manipulation in the treatment of PD
2.1 The therapeutic efficacy o f the dopamine D1 receptor agonist SKF 82958
Given the finding that the bilaterally MPTP-treated monkey has predictive validity, this 
model was used for evaluating the clinical efficacy of the dopamine D1 receptor agonist SKF 
82958, both in drug-naive and in L-DOPA pre-treated animals. It was found that SKF 82958, 
like L-DOPA, stimulated gross motor behaviors. However, the therapeutic effect of the compound 
varied: in one animal that showed no response to L-DOPA, SKF 82958 restored goal-directed 
limb movements, while in the other animals the compound, unlike L-DOPA, did not restore 
functional goal-directed limb movements. SKF 82958 also induced severe side-effects: it 
produced dyskinesia and dystonia in the drug-naive monkeys and, more importantly, epileptoid 
behavior in all monkeys. On the basis of the limited therapeutic effects and severe epileptogenic 
properties of SKF 82958, we have concluded that SKF 82958 has less therapeutic potential 
than L-DOPA.
2.2 The therapeutic efficacy o f the dopamine D1 antagonist SKF 83959
Initially it was hypothesized that primarily dopamine D1 receptor agents with high intrinsic 
activity to the dopamine D1 receptor would be therapeutically effective; however, recent studies 
have suggested that some compounds with very low intrinsic activity to the AC-coupled dopamine 
D1 receptor stimulate motor behavior in MPTP-treated primates (Deveney, Waddington, 1995). 
The purported antagonist to rat dopamine D1 receptors, SKF 83959 is the most striking example 
(Gnanalingham et al., 1995a). However, many aspects of the pharmacological profile of SKF 
83959 were unknown; neither its actual intrinsic activity to primate dopamine D1 receptors nor 
its functional interaction with other aminergic receptors had been established. In Chapter 4, 
these questions were addressed: SKF 83959 strongly inhibited the dopamine-induced stimulation 
of AC in primate tissue, indicating that SKF 83959 is not only an antagonist of rat, but also of 
monkey and human dopamine D1 receptors coupled to AC. Moreover SKF 83959 had virtually 
no effect on dopamine transporters and dopamine D2 receptors, but functionally interacted 
with adrenergic transporters and a2 adrenoceptors. We have concluded from this experiment 
that SKF 83959 does not mediate its suggested anti-parkinsonian effects in primates through 
stimulation of AC-coupled dopamine D1 receptors in the striatum. Given the fact that 
noradrenaline appears to only play a subtle, facilitating role on motor behavior (Dickinson et 
al., 1988), it is also unlikely that its interaction with other noradrenergic receptors is solely 
responsible for its behavioral effects.
In Chapter 5 we decided to increase the insight into the clinical potency of SKF 83959 by 
studying its therapeutic and undesired effects after chronic treatment in the validated bilaterally 
MPTP-treated monkey model. This study revealed that the compound had clear therapeutic 
effects, as reflected by an increase in the performance of goal-directed limb movements, and, 
more importantly, the experiment showed that these therapeutic effects of SKF 83959 remain 
stable in time. Although SKF 83959 did induce dyskinesia and dystonia during the first treatment 
day, these side-effects rapidly wore off. Finally, SKF 83959 did not re-initiate epileptoid behavior 
in any of the tested monkeys. We have concluded that SKF 83959 has a unique pharmaco- 
therapeutic profile: it induces stable anti-parkinsonian effects and wearing off dyskinesia. To 
our knowledge there are no such compounds yet available in the clinic, and it is evident that this 
compound needs to be evaluated in patients with PD.
The question then arose which target sites may be involved in the unique behavioural effects 
of SKF 83959. Given the facts that adrenergic receptors in the ACC (see for review Cools,
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1984) and the PFC (Kolachana et al., 1995; Pycock et al., 1980; Wilkinson, 1997) control the 
release of striatal dopamine (Scheel-Kruger, Arnt, 1985) together with our finding that SKF 
83959 functionally interacts with dopamine D1 receptors, a2 adrenoceptors and adrenergic 
transporters in viro  (see Chapter 4) we decided to investigate how SKF 83959 affects these 
target sites in the ACC and/or PFC in Chapter 6. Local injection of the compound into the ACC 
and the PFC elicited behaviors that require the inhibition of dopamine activity at the respective 
levels. Given the fact that reduced prefrontal and accumbal dopamine D1 receptor transmission 
stimulates the release of striatal dopamine, this leads to the intriguing suggestion that SKF 
83959 mediates its anti-parkinsonian effects through an inhibitory action on dopamine activity 
by interacting with these receptors.
3. The therapeutic efficacy of the propargylamine CGP 3466B
Without doubt, the best treatment for PD is a treatment that inhibits the progression of the 
disease. Although several compounds exert protective effects to death of cells in culture, only 
few of those compounds exhibit the properties that are required for obtaining neuroprotection 
in vivo. One of the very few candidates in this respect is CGP 3466B: preliminary studies have 
shown the neuroprotective action of this compound in in vivo models of neurodegenerative 
diseases. We studied the putative protective effects of CGP 3466B in a valid in vivo animal 
model of PD, namely the updated 6-OHDA rat model. The effects of the compound were 
intriguing: it prevented all behavior and morphological deficits produced by 6-OHDA, though 
at different doses. Although 1.4 mg/kg CGP 3466B induced abnormal movements and decreased 
the tyrosine hydroxylase immunoreactivity in the SNc and VTA of sham-lesioned animals, 
suggesting toxic effects at higher doses, lower doses were very effective in preventing the 
behavioral and morphological consequences of 6-OHDA. We have concluded from these data 
that CGP 3466B is one of the few compounds that is able to prevent the behavioral and 
morphological effects of nigral dopaminergic degeneration in vivo. Given these results we are 
currently investigating whether this compound is able to prevent the Parkinson symptoms present 
in the best animal model for PD, the bilaterally MPTP-treated monkey. The first results of this 
study suggest that also in this primate model CGP 3466B is indeed able to prevent the MPTP- 
induced motor disturbances that are so characteristic for PD. The effects of CGP 3466B on 
MPTP-induced degeneration of dopaminergic neurons, as measured by F-DOPA uptake using 
the PET technique are currently under investigation. Given the fact that CGP 3466B is able to 
prevent the behavioral disturbance in two valid animal models of PD, it is suggested that CGP 
3466B is a valuable agent for inhibiting the dopaminergic degeneration in patients with PD.
4. Future prospects for the treatment of PD
L-DOPA has been the therapeutic main stay in PD for more than 25 years, despite its serious 
disadvantages. However, especially in the last decade, our insight into various aspects of the 
disease has rapidly increased and therefore substantial improvements in the treatment of patients 
with PD appear close to reality. Expected developments in the treatments of PD are given 
below.
4.1 Short term prospects
The last decade, response complications have already been fairly reduced by the introduction 
of dopamine D2 receptor agonist treatments. However, further preventing and delaying the 
onset of response fluctuations and dyskinesia would be a major advance in the treatment of PD.
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Today, the insight into the brain areas and receptors involved in the development of these 
undesired effects is rapidly increasing and currently drugs that more specifically interact with 
these sites become available. These developments may offer pharmacological opportunities 
for reducing response complications in short term. The striatal dopamine D1 receptor has long 
been considered as a pharmacological target for symptomatic treatment of PD. However, the 
clinical potency, not only of the benzazepine SKF 82958, but also of other dopamine D1 receptor 
agonists is disappointing: despite the fact that many studies using MPTP-treated primates have 
predicted an important role for dopamine D1 receptor agonists in the treatment of PD, only a 
few agonists are currently being evaluated in patients with PD. This restricted role is not only 
due to the limited therapeutic effects but also due to the epileptogenic effect of some of these 
agonists. Further studies are needed to establish whether this disabling effect is inherent to D1 
receptor stimulation or to the dopamine D1 agonists that have found to be epileptogenic, implying 
that this effect is drug-specific instead of receptor-specific.
In contrast to the limited therapeutic efficacy of the majority of dopamine D1 receptor 
agonists, the striatal dopamine D1 antagonist SKF 83959 exhibits a pharmacotherapeutic profile 
that can be regarded as unique; to our knowledge, there is no compound available that is able to 
induce stable therapeutic effects and wearing off undesired effects. Evidently, such a compound 
requires evaluation as new treatment strategy for PD. Moreover, giving the urgent need for 
symptomatic compounds that lack the development of undesired effects, providing insight into 
the mechanism of action underlying the unique effects of SKF 83959 might finally lead to the 
development of symptomatic treatments that do not induce serious disabling side-effects, which 
would be a real breakthrough in the treatment of PD.
The present study offers some keys to the mechanisms underlying the behavioral effects of 
SKF 83959. Our data show that SKF 83959 does not interact with dopamine receptors in the 
classical way: it does not stimulate striatal dopamine receptors. Moreover it directly or indirectly 
inhibits prefrontal and mesolimbic dopamine function. Given the fact the dopamine activity in 
the latter structures produces diametrically opposite changes in the dopamine activity of the 
striatum, inhibition of dopamine D1 receptors and/or stimulation of adrenoceptors at these 
levels may play a crucial role in the mechanism of action of SKF 83959. This leads to the 
intriguing hypothesis that prefrontal and/or mesolimbic receptors regulating indirectly the 
dopamine activity at the level of the striatum offer a target site for improved therapeutic 
intervention. Evidently, future studies are needed to establish whether the specific manipulation 
of these sites indeed affect the dopamine activity in the striatum as hypothesized and, more 
importantly, elicit the therapeutic effects as produced by SKF 83959 in animal models of PD.
4.2 Long term prospects
The ultimate goal in the treatment of PD is preventing all of the disabling symptoms of this 
disease. This requires not only the development of agents that are able to prevent dopaminergic 
degeneration, but also the diagnosis of PD in an early, preclinical stage of the disease. Diagnosing 
a preclinical stage of PD is possible using neuroimaging techniques; PET and SPECT imaging 
seem able to detect a decline in striatal dopamine function before motor symptoms appear 
(Brooks, 1991; Antoni et al., 1997; Tissingh et al., 1998). However, these techniques do not 
allow the screening of large amounts of people. Several criteria for diagnosing subjects being 
at risk for the development of PD have been proposed including criteria of decreased sense of 
smell (Doty et al., 1995), decreased cognitive shifting aptitude (van Spaendonck et al., 1987) 
and presence of generalized pains. Subjects being categorized in these “risk” groups have to be 
monitored which may increase insight into the reliability of such parameters. The development
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of drugs that interfere with the death of nigral dopamine neurons requires a detailed understanding 
of the pathogenic mechanism underlying PD. Although our insight is not complete, there exists 
already a considerable amount of data concerning the multiple steps involved in apoptotic cell 
death and the biochemical events that can trigger apoptosis in PD. As a result, agents have been 
identified that interfere with the cascade of proposed events that result in degeneration of the 
dopamine system.
In the present study we choose to evaluate the neuroprotective effects of the propargylamine 
CGP 3466B. While an extremely high dose of CGP 3466B induces damaging effects, lower 
doses of this compound were able to prevent the behavioral and morphological consequences 
of 6-OHDA suggesting that it has neuroprotective properties in dopamine neurons in the 
midbrain. Moreover, recent data suggest that CGP 3466B also prevents the MPTP-induced 
parkinsonian symptoms in non-human primates. Thus, the data suggest that, at appropriate 
doses, CGP 3466B may be able to inhibit the progression of dopaminergic degeneration in 
patients with PD.
Although anti-apoptotic compounds may be able to successfully inhibit the neurodegenerative 
process of PD, there are some pitfalls in the developments of such drugs for widespread and 
save use. It is important to realize that drugs blocking apoptosis, block one of the most 
fundamental and widespread biochemical events taking place in the brain. Thus, it cannot be 
excluded that such drugs not only block apoptosis of neurons necessary for normal brain function, 
but also interfere with the controlled and functional breakdown of excessive and perhaps 
damaging cells. The search for possible differences between “pathologic” and “functional” 
apoptosis may be of value for the development of drugs that circumvent the inhibition of 
functional apoptosis. Interfering with the specific events that are likely to be involved in triggering 
the apoptosis of nigral neurons, namely oxidative stress and mitochondrial defects is another 
option. However, the effects of free radical scavengers have so far been disappointing, while 
preventing mitochondrial dysfunction may also induce undesired effects in “healthy” neurons. 
One way of preventing the undesired effects is by introducing neuroprotective compounds 
using gene transfer. Although the research on the use of gene transfer for blocking degeneration 
in the nigrostriatal system has so far been focused on the neurotrophic factors (Isacson, 1995; 
Firm et al., 1999), also transplants of fibroblasts engineered to secrete neuroprotective 
compounds need to be developed.
Given the impressive progress in the development of new treatment strategies for PD it is 
realistic to expect that these developments provide new and improved clinical treatments.
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De ziekte van Parkinson is een progressieve neurodegeneratieve ziekte met als belangrijk­
ste symptomen tremor, hypokinesie en rigiditeit. De dopaminerge neuronen in met name de 
substantia nigra, pars compacta sterven af, hetgeen leidt tot een tekort aan dopamine in het 
caudatus/putamen complex. De dopamine precursor L-DOPA is al sinds de jaren zestig de 
meest voorgeschreven behandeling. Echter, L-DOPA heeft ernstige nadelen: het induceert, na 
langdurige toediening, respons complicaties waaronder dyskinesieën, dystonieën, on-off effec­
ten en wearing off effecten. Daarnaast is L-DOPA niet in staat de progressie van de ziekte af te 
remmen. Dit maakt het ontwikkelen van alternatieven voor de L-DOPA therapie noodzakelijk; 
zowel symptomatische therapieën die minder respons complicaties geven en neuroprotectieve 
therapieën die in staat zijn de progressie van de ziekte af te remmen kunnen de behandeling van 
de ziekte verbeteren. In dit proefschrift wordt getracht het inzicht te vergroten in de werking en 
de effectiviteit van een aantal nieuwe farmacotherapieën voor de ziekte van Parkinson, daarbij 
gebruikmakend van diermodellen voor de ziekte.
Dopamine D1 receptor agonisten zijn gepostuleerd als mogelijke alternatieve symptomati­
sche therapieën voor de ziekte. De therapeutische en ongewenste effecten van een groot aantal 
dopamine D1 agonisten zijn reeds uitgebreid geëvalueerd in het primaten model voor de ziekte, 
de met MPTP behandelde aap. Echter, er bestaat geen unanimiteit over de uitkomst van deze 
studies, hetgeen veroorzaakt wordt door de gelimiteerde predictieve validiteit van een deel van 
deze MPTP modellen. In Hoofdstuk 2 en 3 van dit proefschrift werd de predictieve validiteit 
van twee van deze modellen geëvalueerd middels een nieuwe kwantitatieve gedragsanalyse, 
hetgeen de mogelijkheid biedt een objectief onderscheid te maken tussen therapeutische en 
ongewenste effecten van potentiële anti-parkinson middelen. In Hoofdstuk 2 werd de predictieve 
validiteit van de unilateraal met MPTP behandelde rhesus aap bestudeerd aan de hand van de 
de dopamine D1 agonist SKF 81297 en de dopamine D2 agonist LY 171555. Uit deze studie 
kwam naar voren dat beide agonisten het motorische gedrag stimuleren, echter geen van beide 
stoffen induceert functioneel doelgericht handgebruik, indicerend dat SKF 81297 en LY 171555 
geen therapeutische effectiviteit hebben in dit model. Daarnaast induceerden zowel de dopamine 
D1 als de dopamine D2 agonist dyskinesieën, dystonieën en epileptoïd gedrag. Aangezien de 
effecten van de dopamine D2 receptor agonist niet overeen kwamen met de effecten van 
dopamine D2 receptor agonisten in de kliniek, wordt geconcludeerd dat de unilateraal met 
MPTP behandelde rhesus aap geen geschikt model is voor het bestuderen van de klinische 
effectiviteit van nieuwe farmacotherapieën voor de ziekte van Parkinson. Zowel de unilateraliteit 
van de lesie als de frequente eerdere behandelingen van de apen met L-DOPA, dopamine D2 
receptor agonisten en dopamine D1 receptor agonisten kunnen hieraan ten grondslag liggen. 
De predictieve validiteit van de bilateraal met MPTP behandelde rhesus aap werd bestudeerd 
in Hoofdstuk 3. In dit model werden de chronische effecten van L-DOPA bestudeerd in drug- 
naïve apen, daarbij gebruikmakend van hetzelfde ethogram als in Hoofdstuk 2. Zowel de thera­
peutische als ongewenste effecten van L-DOPA kwamen overeen met de effecten van deze 
therapie in patiënten met de ziekte van Parkinson, waaruit wordt geconcludeerd dat dit dier- 
model een adequaat model is voor het voorspellen van de klinische effectiviteit van nieuwe 
farmacotherapieën voor de ziekte.
Vervolgens werd de therapeutische effectiviteit van stoffen die interacteren met de dopamine 
D1 receptor geëvalueerd in het gevalideerde diermodel, de bilateraal met MPTP behandelde 
rhesus aap. In Hoofdstuk 3 werd de therapeutische effectiviteit van de dopamine D1 receptor 
agonist SKF 82958 geëvalueerd, zowel in L-DOPA voorbehandelde als in drug-naïeve apen. 
Hoewel deze stof een verhoging van de locomotorische activiteit induceerde nam het functio­
nele handgebruik niet toe, hetgeen impliceert dat de therapeutische effectiviteit van deze stof
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gelimiteerd is. Met name gedurende de eerste dagen van toediening induceerde SKF 82958 
dyskinesieën en dystonieën. Daarnaast induceerde de stof epileptoïd gedrag in de meerderheid 
van de apen. In conclusie, SKF 82958 heeft weinig therapeutische effecten en induceert ern­
stige ongewenste effecten in dit gevalideerde diermodel en wordt daarom verwacht minder 
geschikt te zijn voor de behandeling van patiënten met deze ziekte.
Uit recent onderzoek blijkt dat niet alleen volledige receptor agonisten voor de adenylaat 
cyclase gekoppelde dopamine D1 receptor maar ook stoffen met minder intrinsieke activiteit 
voor deze receptor in staat zijn motorisch gedrag te stimuleren in diermodellen voor de ziekte 
van Parkinson. De benzazepine SKF 83959 is daarvan een van de duidelijkste voorbeelden: 
deze stof gedraagt zich als een antagonist op adenylaat cyclase gekoppelde dopamine D1 recep­
toren van de rat, maar stimuleert motorisch gedrag in de met MPTP behandelde aap. Echter de 
vele onbekende aspecten van het farmacologische profiel van SKF 83959 kunnen ten grond­
slag liggen aan de discrepantie tussen de agonistische effecten van deze stof op organismaal 
nivo en zijn antagonistische effecten op celnivo. In Hoofdstuk 4 werd de intrinsieke activiteit 
van SKF 83959 op de dopamine D1 receptor van aap en mens bestudeerd, daarbij gebruik­
makend van gliacellijnen. Daarnaast werd de functionele interactie van SKF 83959 met andere 
catecholaminerge receptoren bestudeerd aan de hand van bindingstudies en superfusie technie­
ken. SKF 83959 had geen effect op de formatie van cAMP en antagoneerde op potente wijze 
de door dopamine geïnduceerde formatie van cAMP, in zowel de humane als de apen gliacellen, 
indicerend dat SKF 83959 niet alleen een antagonist voor de dopamine D1 receptor in de rat is 
maar ook voor dit receptor subtype in aap en mens. De bindingsstudies maakten duidelijk dat 
SKF 83959 de hoogste affiniteit had voor de dopamine D1 receptor and the a2  adrenoceptor 
en matige affiniteit voor de dopamine D2 receptor en de adrenerge transporter. Tenslotte ver­
hoogde SKF 83959 op een concentratie afhankelijke wijze de release van noradrenaline, 
suggererend dat de stof een blokkerend effect heeft op de a 2 adrenoceptor en/of interfereert 
met de adrenerge transporter. Uit deze studie blijkt dat de anti-parkinson effecten van SKF 
83959 in primaten niet worden gemedieerd door striatale dopamine D1 receptoren gekoppeld 
aan adenylaat cyclase op een stimulatoire wijze. Hoewel het noradrenerge systeem een module­
rende effect heeft op motorisch gedrag is het onwaarschijnlijk dat de therapeutische effecten 
van de stof geheel te wijten zijn aan zijn interactie met a 2 adrenoceptoren en/of noradrenerge 
transporters.
Tot nu toe waren de anti-parkinson effecten van SKF 83959 in de MPTP-aap alleen bestu­
deerd na acute administratie. Aangezien ongewenste effecten pas optreden na chronische 
toediening van de dopaminerge farmaca was niet bekend in welke mate SKF 83959 onge­
wenste effecten induceert. In Hoofdstuk 5 werden de therapeutische en ongewenste effecten 
van subchronische toediening van SKF 83959 bestudeerd, daarbij gebruik makend van het 
gevalideerde diermodel voor de ziekte, de bilateraal met MPTP behandelde rhesus aap. SKF 
83959 induceerde therapeutische effecten die niet afnamen in de tijd terwijl de ongewenste 
effecten van SKF 83959 vooral beperkt bleven tot de eerste dag. Daarnaast induceerde de stof 
geen epileptoïde gedragingen. Uit de studie wordt geconcludeerd dat de dopamine D1 antagonist 
SKF 83959 een uniek farmaco-therapeutisch profiel heeft. De stof biedt wellicht een bruikbare 
alternatieve symptomatische therapie. De enorme behoefte aan nieuwe symptomatische met- 
therapieën een profiel als SKF 83959 maakt dat inzicht in het werkingsmechanisme van deze 
stof van groot belang is. Mogelijke aangrijpingspunten voor de veroorzaking van de in vivo 
effecten zijn de adrenerge en dopaminerge receptoren in de nucleus accumbens en de prefrontale 
cortex, aangezien deze een regulerende rol hebben op de release van dopamine op het niveau 
van het striatum en SKF 83959 daarnaast affiniteit heeft voor dit spectrum aan receptoren. Om
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deze redenen werden in Hoofdstuk 6 de gedragsmatige effecten van intra-accumbale en intra- 
prefrontale injectie van SKF 83959 bestudeerd en vergeleken met de effecten van prototypische 
dopamine D1 receptor, a l  adrenoceptor en a2  adrenoceptor agonisten en antagonisten. De 
administratie van SKF 83959 induceerde gedragsmatige effecten die de inhibitie van de dopamine 
functie vereisen: evenals de dopamine D l antagonist SCH 39166 had SKF 83959 geen effect 
op de locomotorische activiteit na lokale toediening in de nucleus accumbens, maar antagoneerde 
de stimulatie van locomotorische activiteit geïnduceerd door SKF 81297. Ook in de prefrontale 
cortex waren de effecten van SKF 83959 vergelijkbaar met de effecten van de dopamine D l 
antagonisten SCH 39166 en SCH 23390: SKF 83959 induceerde een voorkeur voor contra- 
lateraal roteren en blokkeerde de door SKF 81297 geïnduceerde voorkeur voor ipsilateraal 
roteren. Samengevat, SKF 83959 inhibeert de dopaminerge transmissie in de nucleus accumbens 
en de prefrontale cortex, of wel direct, via de inhibitie van dopamine D1 receptoren dan wel 
indirect, via een interactie met a2  adrenoceptoren en / of adrenerge transporters. Het feit dat 
een reductie in de prefrontale en accumbale dopamine D1 receptor transmissie kan leiden tot 
stimulatie van de release van striataal dopamine, geeft aan dat deze receptoren wellicht betrok­
ken zijn bij het anti-parkinson werking van deze stof in diermodellen.
Tenslotte werden in Hoofdstuk 7 de therapeutische effecten van een mogelijk 
neuroprotectieve stof, de propargylamine CGP 3466B, bestudeerd. De effecten van CGP 3466B 
op de gedragsmatige en morfologische consequenties van het neurotoxine 6-OHDA werden 
bestudeerd in een vernieuwd ratten model waarin 6-OHDA bilateraal, in zeer lage doseringen 
lokaal in de substantia nigra werd geïnjecteerd. De hoogste dosering had geen positieve effec­
ten en induceerde daarnaast motorische en morfologische defecten in ongeledeerde ratten. Echter, 
lagere doseringen van deze stof voorkwamen voor een groot deel de reductie in de morfologi­
sche en gedragsmatige defecten geïnduceerd door de 6-OHDA behandeling. In conclusie, CGP 
3466B is in bepaalde doseringen in staat de door 6-OHDA geïnduceerde gedragsmatige en 
morfologische defecten te voorkomen. De studie suggereert dat CGP 3466B een waardevolle 
stof is voor het remmen van het progressieve neurodegeneratieve proces in patiënten met de 
ziekte van Parkinson.
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